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Abstract 
Factor Inhibiting Hypoxia-inducible Factor (FIH) is an asparaginyl hydroxylase 
which regulates the transcription factor Hypoxia-Inducible Factor (HIF), via 
hydroxylation of a conserved asparagine residue of the HIF-alpha subunits (two 
isoforms of which are well established, HIF-1 and HIF-2alpha – HIF-3alpha is 
less well characterized currently). Other targets of FIH have also been reported. 
Little is known about both FIH expression and function. This thesis will 
investigate the expression of FIH in rodents, in cell lines and in renal cancer 
tissue samples. In addition, RNAi technology was used to study FIH function.  
Clear cell renal cell carcinoma (CCRCC) is commonly associated with 
inactivation of tumour suppressor von-Hippel Lindau protein (VHL) and 
constitutive activation of HIF. The main question I have addressed in this thesis 
is whether FIH decreases HIF activation in this setting. To address this I inhibited 
FIH using several approaches. Specifically, using hypoxia, dimethyloxalylglycine 
(DMOG) and RNA interference (RNAi). Each of these increased the expression 
of HIF target genes in two different CCRCC cell lines, RCC10 and RCC4.  
Investigating three different CCRCC cell lines, FIH inhibition decreased numbers 
of RCC4 and RCC10 cells growing in culture, which is likely to be due to an 
increase in expression of pro-apoptotic, FIH-regulated HIF target genes. 
Interestingly, 786-O cells exclusively express the HIF-2alpha isoform. Attenuation 
of FIH in this setting did not affect expression of HIF target genes, nor affect 
growth in culture. To determine if this was due to lack of FIH or may be due to 
lack of HIF-1alpha, I introduced HIF-1alpha via a viral vector. Following this, 
sensitivity to FIH was clearly demonstrated. This implies either specific 
‘protection’ of HIF-2alpha in 786-O or more general FIH selectivity for the HIF-
1alpha isoform. My findings contrast with two reports suggesting that FIH 
expression is suppressed in CCRCC. 
My findings give insight into how FIH asparagine hydroxylation regulates HIF, in 
particular in renal cancer and makes this enzyme a potential target for 
therapeutic inhibition, in the majority of renal cancers. 
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1 Introduction 
To sustain life, mammals have a continual requirement for oxygen. For cells to 
survive and grow, an appropriate level of oxygen must therefore be maintained. If 
levels of oxygen are too low, mitochondrial respiration is compromised and cells 
would be at risk of death. It has been shown that the transcription factor Hypoxia-
inducible factor (HIF) plays a key role in cells and organisms adapting to changes 
in oxygen levels (Maxwell et al., 2001). In low oxygen, HIF target gene levels 
increase, adapting cells and organs to promote survival. There has been 
considerable interest in manipulating the HIF response as a therapeutic strategy. 
For example, increasing HIF activation is potentially attractive to increase tissue 
viability in ischaemia, while decreasing HIF activation may prevent angiogenesis 
in cancer. This thesis is concerned with the enzyme ‘Factor-Inhibiting HIF’ (FIH). 
This introduction will review current knowledge of FIH and the HIF pathway in 
general. 
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1.1 Factor Inhibiting Hypoxia-Inducible Factor (FIH) 
FIH is an asparaginyl β-hydroxylase which belongs to the super-family of 2-
oxoglutarate (2-OG)-dependent and Fe(II)-dependent dioxygenases. FIH 
regulates the function of the HIF transcription complex. It was first identified in a 
yeast two-hybrid screen for proteins that potentially interacted with the C-
terminus of HIF-1alpha (Mahon et al., 2001). At this point it was not appreciated 
that it was an enzyme, or that it modified HIF-alpha subunits. In parallel, it was 
shown that transactivation by HIF-2alpha was regulated by asparaginyl 
hydroxylation (Lando et al., 2002). Following this, these findings were confirmed 
by the demonstration that FIH is an enzyme which hydroxylates the C-terminal 
transactivation domain (CTAD), using oxygen as a co-substrate, preventing HIF-
alpha binding with necessary cofactors, hence preventing HIF transactivation in 
normoxia (Figure 1.1).  
 
 
 
 
 
 
Figure 1.1 CTAD hydroxylation by FIH in normoxia 
In normoxic conditions, hydroxylation of Asn
803
 (HIF-1alpha) prevents the recruitment of co-
factors, inhibiting HIF transactivation (Lisy and Peet, 2008). 
 
 
The CTAD of the HIF-alpha subunits contain a conserved asparagine residue 
(Asn803 in HIF-1alpha and Asn851 in HIF-2alpha) which is targeted by FIH 
CTAD
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hydroxylation (Hewitson et al., 2002). Hydroxylation occurs at the β-carbon of the 
asparagine residue, thus, by way of steric hindrance, preventing the interaction of 
the HIF-alpha CTAD with the cysteine / histidine-rich 1 (CH-1) domain of p300 – 
a co-activator required for the heterodimerization and transcriptional activity of 
HIF – or the closely related cAMP-response element-binding protein (CBP) (Ema 
et al., 1999; Lando et al., 2002). Either CBP or p300 is required for efficient 
transactivation by HIF (Arany et al., 1996). CBP/p300 increase gene expression 
by interacting with transcription factors in three ways; (1) by relaxing chromatin 
structure at the gene promoter region, through their intrinsic histone 
acetyltransferase (HAT) activity, (2) by recruiting basal transcriptional machinery, 
including RNA polymerase II to the promoter and (3) acting as adaptor molecules 
(Goodman and Smolik, 2000).  
Importantly, FIH activity requires oxygen so that the enzyme acts as an ‘oxygen 
sensor’ regulating transactivation by HIF. This complements the action of the 
Prolyl Hydroxylase Domain (PHD) enzymes which also act as oxygen sensors 
and control HIF destruction by hydroxylating conserved prolyl residues (Epstein 
et al., 2001). There are three PHD enzymes in mammals, and they belong to the 
same superfamily of iron and 2-OG dependent dioxygenases as FIH. 
The expression of FIH has been described as mainly cytoplasmic, with some 
nuclear staining as deduced in immunohistological studies, using normal and 
neoplastic human tissue (Soilleux et al., 2005). Using cultured cells, Metzen et al. 
(2003) also found that the intracellular localization of FIH is mainly found in the 
cytoplasm. The expression and intracellular localisation of FIH has been reported 
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not to be influenced by hypoxia (Metzen et al., 2003), however levels have been 
reported to be regulated by proteins such as seven in absentia homolog 1 (siah-
1) (Fukuba et al., 2007; Fukuba et al., 2008) and the protein kinase C-zeta (PKC-
ζ) (Li et al., 2007).   
In principle it seems surprising that FIH is required to regulate HIF-alpha 
transactivation since HIF-alpha is efficiently destroyed in the presence of oxygen, 
a process which involves prolyl hydroxylation (by the PHD enzymes), followed by 
ubiquitination and destruction. An important characteristic of FIH in this regard, 
which was demonstrated by Koivunen et al. (2004) and Stolze et al. (2004), is 
that compared with the PHD enzymes, FIH is better able to function in severe 
hypoxia (Koivunen et al., 2004; Stolze et al., 2004). Koivunen et al. performed in 
vitro kinetic studies and found that the Km value (Michaelis constant; the 
substrate concentration at which the rate of reaction is half its maximum) for 
oxygen for FIH is ~90µM. For the PHDs it was greater than this – between 230 
and 250µM. The lower value for FIH demonstrates that it has a higher affinity for 
oxygen than the PHD enzymes. In other words, when the availability of oxygen is 
low (e.g. <0.5% oxygen) and the PHD enzymes are operating at a much reduced 
rate (through lack of oxygen) - FIH may deactivate HIF that has escaped 
proteosomal degradation.   
Since the PHD enzymes and FIH belong to the same enzyme superfamily, they 
are therefore structurally very similar (Schofield and Zhang, 1999). Inhibitors of 
PHD enzymes and FIH are capable of activating HIF, and a useful prototype is 
N-oxalyl glycine (Jaakkola et al., 2001). These are rapidly being developed to 
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promote EPO production and improve outcomes in ischaemic disease. 
Importantly, despite structural similarities FIH and the PHD enzymes are 
sufficiently divergent that it should be possible to identify small molecules with 
differentiated activity as enzyme inhibitors. Indeed, there is already proof of 
principle of this concept (McDonough et al., 2005). Clearly, in order to 
understand the potential of specific FIH inhibitors, and to determine which 
compounds that inhibit both FIH and PHD enzymes would be preferable, an 
extensive understanding of the function of FIH will be required.  
 
1.1.1 The FIH gene 
The FIH gene is mapped to chromosome 10q24 (locus ID. 55662). It has a 
transcript length of 2,931 base pairs, composed of 8 exons and encodes a 
polypeptide of 349 amino acid residues.  
 
1.1.2 FIH crystal structure 
The crystal structure of FIH has been solved and reveals that it is homodimeric 
(Elkins et al., 2003) (Figure 1.2). Disruption of dimerization, by use of site-
directed mutagenesis, reveals the importance of the dimeric state for its function 
in recognising HIF-alpha subunits as a substrate (Lancaster et al., 2004). The 
dimer interface involves the 2 C-terminal helices of each molecule interlocking 
and is stabilized by hydrophobic interactions. 
FIH contains a Jumonji C (JmjC) domain which is predicted to be involved in 
signal transduction mechanisms and chromatin structure and dynamics. 
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Interestingly, related protein containing JmjC domains have very recently been 
shown to play a major role in histone demethylation (Lu et al., 2008; Saze et al., 
2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A      B 
Figure 1.2 FIH crystal structure 
(A) Protein crystal structure of the FIH monomer (Lee et al., 2003). (B) FIH functions as a 
dimer, which is thought to contribute to substrate recognition. This figure shows the 
interaction of the dimerization domains of two FIH monomers, forming the dimer structure 
(Lancaster et al., 2004). 
 
Consistent with other known structures of this family of hydroxylases, FIH is 
comprised of a β-strand jellyroll core with both Fe(II) and the cosubstrate 2-OG 
bound in the active site (Dann, III et al., 2002). The jellyroll motif is formed from β-
strands 8-11 and 14-17, with an additional four β-strands forming an anti-parallel 
β-sheet that flanks the jellyroll core. β1, β2 and α1 form a sheet-helix-sheet motif 
that is conserved amongst almost all 2-OG dioxygenases. FIH is comprised of 
two separate domains; domain I include residues 1-299 and domain II, residues 
200-349, as described by Lee et al. (2003).  
The structure of FIH and the HIF-alpha CTAD-FIH interface has also been 
characterized by Lee et al. (2003). Residues involved in the coordination of the 
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ferrous ion line the centre of the β-barrel structure. These residues are His199, 
Asp201 and His279 (Figure 1.3).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Mechanism of HIF-alpha asparagine hydroxylation by FIH 
Active site of FIH shown containing Fe(II) co-ordinated by three amino acid residues: His-
199; Asp-201; His-279 (Dann, III et al., 2002). 
 
 
 
The His residues are considered most important for iron binding (Hewitson et al., 
2008). Within this region is an opening for 2-OG, bound by Lys214. Between the 
interconnecting loop of domains I and II, and extending towards the active site, is 
a groove lined with mostly hydrophobic residues. This forms the binding site for 
HIF-alpha. The asparagine residue hydroxylated by FIH sandwiches between the 
FIH residue Tyr102 and the bound ferrous ion, forming hydrogen bonds with the 
side chains of FIH residues Arg238 and Gln239, plus six additional hydrogen bonds 
which stabilize FIH and HIF-1alpha interaction (Elkins et al., 2003). FIH also 
Fe
His-199
His-279
Asp-199
HIF-αAsn803
Dann et al., PNAS 2002
201
 803
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contains a VHL binding site, located at the N-terminal (the NTAD) portion of the 
HIF-alpha binding site; the finding by Lee et al. (2003) being in agreement with 
observations reporting that VHL interacts with HIF-1alpha CTAD only in the 
presence of FIH (Mahon et al., 2001). 
 
1.1.3 FIH regulation 
There is some evidence that FIH levels may be regulated. This includes 
observations that suggest the protein seven in absentia homolog 1 (siah-1) is an 
important negative regulator of FIH, as reported by Fukuba et al. (2007). In 
mammalian HEK293 cells (embryonic kidney cell line) an increase in levels of 
FIH was observed when incubating the cells with the proteosomal inhibitor 
MG132. This result suggested that FIH is degraded by the ubiquitin-proteasome 
system. Immunoprecipitation assays and ubiquitination assays then revealed 
siah-1 interaction and ubiquitination of FIH. Therefore, in normoxic conditions, 
siah-1 appeared to facilitate FIH degradation. Furthermore, an siRNA used to 
attenuate siah-1 increased levels of FIH, in comparison with control, non-specific 
siRNAs (Fukuba et al., 2007).   
Another regulatory mechanism has been described by Li et al. (2007). Their work 
investigates the paradox that HIF is active in VHL defective renal cancer. This 
implies that FIH is not preventing transactivation of HIF target genes. An 
explanation was offered by previous work from this group, published by Datta et 
al.  in 2004, reporting a decrease in functional FIH in CCRCC (Datta et al., 2004). 
Li et al. proposes a molecular mechanism involving PKC-ζ, in CCRCC, which 
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results in repression of transcription of the FIH gene. PKC-ζ is said to 
phosphorylate the Cut-like homeodomain protein (CDP/Cut), which then 
facilitates its binding to the FIH promoter region, thus transcriptionally repressing 
FIH. They reported a CDP/Cut binding site in the FIH promoter and using 
chromatin immunoprecipitation (ChIP), showed CDP binds to the FIH promoter 
region, and that this binding is PKC-ζ-dependent (Li et al., 2007). 
A recent report suggests the auto-hydroxylation of FIH (Chen et al., 2008). 
Normally, FIH couples oxygen activation to the hydroxylation of Asn803 of HIF-
1alpha. However, in the absence of HIF-alpha subunits (i.e. through VHL-
mediated degradation) oxygen activation becomes uncoupled, and this leads to 
self-hydroxylation at Trp296. This reduces the activity of FIH when HIF-alpha is 
lacking, and this possibly acts as a negative feedback mechanism regulating the 
hypoxia sensing by FIH (Chen et al., 2008). 
 
1.1.4 FIH mutation in disease 
Experimental evidence is limited with regards to genetic analysis of FIH in 
disease. Morris et al. (2004) found no evidence of mutation of FIH in sporadic 
renal cancer. They performed mutation analysis of the entire FIH coding 
sequence and intron–exon boundaries in 15 CCRCCs. A missense substitution 
Pro121Ala was detected in seven of 15 CCRCCs. In all cases, the Pro121Ala 
substitution was also present in the germline. None of the tumours harbouring the 
Pro121Ala variant demonstrated loss of heterozygosity. The Pro121Ala variant 
was also detected in nine of twenty normal control samples. As a result their 
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conclusion was that there was no evidence to suggest that somatic mutations 
occur in the FIH gene in sporadic CCRCCs (Morris et al., 2004). 
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1.2 FIH mode of action on HIF-alpha subunits 
FIH requires iron, 2-OG, molecular oxygen and ascorbate to catalyse the 
hydroxylation of a conserved asparagine residue in HIF-alpha (Hewitson et al., 
2002).  
Evidence that only two FIH-based residues (His199 and His279) are required for 
metal binding have recently been reported by Hewitson et al. (2008) (Hewitson et 
al., 2008). Three variants (Asp201Ala, Asp201Glu and Asp201Gly) of the iron 
binding Asp201 residue were made and analyzed. FIH-Asp201Ala and FIH-
Asp201Glu did not catalyse Asn hydroxylation but in the presence of a reducing 
agent showed enhanced 2-OG turnover compared with wildtype FIH. Turnover of 
2-OG by FIH-Asp201Ala was significantly stimulated by adding HIF-1alpha786-826 
peptide. Asp201Gly, on the other hand, also turned over 2-OG but it also 
catalysed asparaginyl hydroxylation. 
Interaction assays have been used to show that FIH binds to the CTAD of HIF-
1alpha in a region that does not contain an asparagine residue that is readily 
hydroxylated (Mahon et al., 2001). Instead, the asparagine residue hydroxylated 
by FIH is located around 20-30 residues away towards the C-terminal relative to 
the putative FIH binding region. Therefore, in order to hydroxylate the asparagine 
residue efficiently, FIH has to bind to a region that is adjacent to the asparagine 
motif. Lando et al. in 2003 described a region found in both HIF-1alpha and HIF-
2alpha which may be important for FIH targeting – an Arg-Leu-Leu motif. This 
region was previously shown to be required for suppression of HIF-1alpha CTAD 
in normoxic conditions (O'Rourke et al., 1999). Crystallographic data has shown 
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the existence of two distinct FIH-CTAD interaction sites. One contains the 
hydroxylation site (CTAD795-806) and the other at CTAD813-822, shows weaker 
binding according to kinetic studies. Mutation studies, Val802 to Ala, showed the 
importance of Val802 for effective catalysis of hydroxylation, but did not 
significantly affect substrate binding (Linke et al., 2004). The substitution to Ala 
caused structural rearrangements around Asn803, consistent with the observation 
that Val802 is important in the reaction catalyzed by FIH. Other residues around 
Asn803 were not found to be as important for catalytic activity.  
FIH is specific for asparagine over aspartic acid. Experimental evidence for this 
includes very low activity being obtained in 2-OG turnover assays, upon mutation 
of Asn803 to Asp803 (Hewitson et al., 2002).  
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1.3 The Prolyl-hydroxylase Domain (PHD) enzymes 
Three prolyl hydroxylases are responsible for prolyl hydroxylation of HIF-alpha 
which leads to destruction in normoxia. The PHD enzymes were first described 
using a forward genetic approach to screening candidate 2-OG dependent 
dioxygenases in C. elegans (Epstein et al., 2001). This approach identified a 
gene called egl9, and worms with defective alleles for egl9 were shown to have 
high levels of HIF protein. The recombinant EGL9 protein was shown to 
hydroxylate an equivalent prolyl residue in vitro, confirming that EGL9 does act 
as a HIF prolyl hydroxylase (Epstein et al., 2001). Three human genes which 
were homologous to egl9 were then identified and termed PHD-1, -2 and -3. The 
enzymes were also identified and described by other groups on the basis of 
similarity to mammalian pro-collagen prolyl-4-hydroxylase, or biochemical 
purification of the HIF hydroxylase activity from rabbit reticulocyte lysate - and 
were named as HIF-PH or EGLN, rather than PHD (Bruick and McKnight, 2001; 
Epstein et al., 2001; Taylor, 2001). 
In normoxic conditions, Pro402 and Pro564 (Masson et al., 2001), in the oxygen-
dependent destruction domain (ODDD) region of HIF-1alpha are hydroxylated by 
the PHD enzymes. For HIF-2alpha, Pro405 and Pro531 are hydroxylated (Haase, 
2006). This leads to the binding of HIF-1alpha to VHL and subsequently results 
in proteosomal degradation (Cockman et al., 2000; Maxwell et al., 1999). Details 
regarding PHD function are highlighted in the next section of this thesis. The 
polypeptides of PHD1, PHD2 and PHD3 consist of 407, 426 and 239 amino acids 
respectively. There is significant (42-60%) sequence homology between the 
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three isoforms (Taylor, 2001). Structural analysis reveals that the PHDs form a 
jelly roll structure composed of eight β-strands. The critical Fe2+-binding residues 
(two His and one Asp) are in a highly conserved motif – His297-X-Asp299-…-His358 
(PHD1) (Bruick and McKnight, 2001; Epstein et al., 2001; Min et al., 2002). The 
crystal structure of the catalytic domain of PHD2 has also been deduced 
(McDonough et al., 2006). McDonough et al. (2006) showed that PHD2 
crystallizes as a homotrimer and contains a double-stranded β-helix core fold 
which is common to the Fe(II)- and 2-OG-dependent dioxygenase family and that 
the residues of which are well conserved in all three human PHD enzymes. 
Studies performed by Berra et al. (2003) have shown that PHD2 appears to be 
the most abundant prolyl hydroxylase, being expressed in most cell types. 
Additionally, suppressing PHD2 alone is sufficient to induce the accumulation of 
HIF-1alpha subunits in normoxia, at least in a number of cell types, leading to 
increased HIF target gene expression (Appelhoff et al., 2004). Evolutionary 
analysis also suggested that PHD2 is the ancestral form of the egln gene family 
(Taylor, 2001). Therefore, PHD2 could be said to be the key hydroxylase 
regulating HIF-alpha, with isoforms PHD1 and PHD3 perhaps playing more 
specialised roles e.g. they may be tissue specific or function under certain 
physiological conditions. For instance, Appelhoff et al. (2004) showed that PHD3 
seems to mainly affect HIF-2alpha, especially under hypoxia where the 
expression of this enzyme is usually greatly increased as it is a HIF target. Both 
PHD2 and PHD3 are induced by hypoxia in most cell types (Aprelikova et al., 
2004; Metzen et al., 2005). As a result, activity of these enzymes is increased in 
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prolonged hypoxia and is possibly responsible for the increased oxygen-
mediated HIF-alpha degradation observed after long periods of hypoxia 
(Pescador et al., 2005). Recently, it has been shown that hypoxia leads to PHD 
over activation and subsequent HIF desensitization, mediated by an increase in 
intracellular oxygen availability due to the inhibition of mitochondrial respiration. 
The result is that cells are prevented from necrosis, which would otherwise result 
in cell lysis and the triggering of the inflammatory pathway (Ginouves et al., 
2008). 
Substrates other than the HIF transcription factor are known for the PHD 
enzymes. For instance, it has been shown by Cummins et al. (2006) that PHD1 
negatively regulates IκB kinase-β (IKKβ), resulting in increased activation of the 
inflammatory-response signaling factor nuclear factor kappa B (NFκB). They had 
found that hypoxia increased both the expression and activity of IKKβ and that it 
contains an evolutionarily conserved Leu-x-x-Leu-Ala-Pro consensus motif for 
hydroxylation by the PHD enzymes; overexpression of PHD1 led to it being 
implicated as the key PHD enzyme regulating IKKβ. Site-directed mutagenesis of 
the proline residue (Pro191Ala) of the putative IKKβ hydroxylation site resulted in 
the loss of hypoxic inducibility. Therefore, their hypothesis was that hypoxia 
releases repression of NFκB activity through decreased PHD-dependent 
hydroxylation of IKKβ, and went on to suggest that this event may then contribute 
to tumor development and progression through amplification of tumorigenic 
signaling pathways (Cummins et al., 2006).  
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1.4  Hypoxia-Inducible Factor (HIF) and its regulation in oxygen 
The transcription factor HIF coordinates cellular responses to a reduction in 
oxygen availability (Jiang et al., 2001; Wang et al., 1995). It was initially identified 
as a hypoxia-inducible DNA-binding activity which could interact with a hypoxia-
response element (HRE) in the 3’ region of the erythropoietin gene (Semenza 
and Wang, 1992). The consensus HRE sequence to which HIF binds is 5’-
RCGTG-3’ (where R is either an A or a G). HIF is a heterodimer consisting of an 
alpha subunit and a beta subunit which are members of the Per-ARNT-Sim 
(PAS) family of basic helix-loop-helix (bHLH) transcription factors. The alpha 
subunit is oxygen sensitive while the beta subunit (also known as aryl-
hydrocarbon receptor nuclear translocator [ARNT] or HIF-beta) is constitutively 
expressed (Schofield and Ratcliffe, 2004). Regulation is primarily through post-
translational modification of the alpha subunit, as mentioned in previous sections. 
Three HIF-alpha and three HIF beta family members have been identified (HIF-
1alpha, HIF-2alpha and HIF-3alpha: and HIF-1beta, HIF-2beta and HIF-3beta). 
HIF-1alpha underpins the majority of the transcriptional response to hypoxia in 
most cell types, while the role of HIF-2alpha is more specialised. At present, the 
function of HIF-3alpha is less clear. The HIF-alpha subunits dimerize exclusively 
with HIF-beta family members, whereas the HIF-beta subunits can dimerize with 
other non-HIF transcription factors (Kang et al., 2006).  
The HIF-1alpha and HIF-2alpha subunits are highly homologous and each of 
them contains two transactivation domains. These are termed the N-terminal 
transactivation domain (NTAD) and the C-terminal transactivation domain 
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(CTAD). In hypoxia, the CTAD recruits co-activators and activates transcription. 
The NTAD overlaps with the oxygen-dependent destruction domain (ODDD), 
which mediates destruction in the presence of oxygen.  
 
 
Figure 1.4 The regulation of HIF-1 and HIF-2alpha subunits by oxygen 
Figure taken from Molecular Medicine©. 
 
As already mentioned, regulation of HIF transactivation is through oxygen-
dependent modifications of HIF-1alpha and HIF-2alpha (Figure 1.4). The alpha 
subunits are hydroxylated at two conserved prolyl and one conserved 
asparaginyl residue. The conserved prolyl residues are present at the 
NTAD/ODDD (Pro402 and Pro564 of HIF-1alpha) and the asparaginyl residue is 
present in the CTAD (Asn803 in HIF-1alpha). Hydroxylation can only occur in the 
presence of oxygen and the enzymes which mediate it are PHD1, PHD2 and 
PHD3 (EGLN2, EGLN1 and EGLN3 or HIF-PH1, HIF-PH2 and HIF-PH3 
respectively) for prolyl hydroxylation and FIH for asparaginyl hydroxylation. The 
reaction rate of the four enzymes depends on the availability of oxygen as a co-
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substrate and they act as the “oxygen sensors” of the system. Prolyl 
hydroxylation in the presence of oxygen leads to proteosomal degradation of HIF 
by enabling an interaction with the VHL tumour suppressor protein (Maxwell et 
al., 1999). Prolyl hydroxylation creates a high affinity VHL binding site. Together 
with Elongin B, Elongin C and Rbx1, VHL forms an E3 ubiquitin ligase complex 
which efficiently targets HIF for proteosomal degradation (Iwai, 1999). In 
contrast, hydroxylation via FIH of Asn803 prevents binding of co-factor p300/CBP 
(required for HIF transactivation) presumably through steric hindrance 
(Freedman et al., 2002; Lee et al., 2003; McNeill et al., 2002). As oxygen levels 
fall, HIF-alpha is progressively protected from these regulatory hydroxylation 
events. Expression of genes which adapt cells to low oxygen availability is then 
increased through HIF-alpha complexing with HIF-beta and p300/CBP, which 
activates gene expression via hypoxic response elements (HREs) that are 
present in the regulatory regions of HIF target genes (Wenger et al., 2005). HIF 
facilitates adaptation to oxygen deprivation by regulating expression of genes the 
products of which are involved in (for example) glucose transport, energy 
metabolism, angiogenesis, apoptosis, cell proliferation, iron metabolism and red 
blood cell production (erythropoiesis). Examples of these hypoxia-sensitive 
genes are erythropoietin (EPO), which is involved in red blood cell production by 
suppressing apoptosis of erythroid precursers in the bone marrow (Jelkmann, 
1992), vascular endothelial growth factor (VEGF), which stimulates 
angiogenesis, and glucose transporter 1 (GLUT-1). Heme oxygenase 1 (HO-1) is 
another HIF target gene which has been shown to have a protective effect 
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against ischaemic injury (Dawn and Bolli, 2005). It is likely that several hundred 
genes are directly regulated by HIF, and it is clear that the repertoire is cell- and 
context- dependent. I have summarised HIF target genes identified to date in 
Tables 1-7, together with some information concerning the approach used to 
show that they are modulated by HIF.  As can be seen, the HIF system has 
pleiotropic downstream effects, consistent with the biological importance of 
appropriate responses to changes in oxygenation. The list of potential HIF target 
genes is ever increasing. For example, a very recent HIF target gene discovered 
is N-Myc downstream-regulated gene 2 (NDRG2) (Wang et al., 2008). Several 
tumour cell lines exhibited NDGR2 upregulation in hypoxia. Additionally, three 
HREs were detected in the NDGR2 promoter region and shown to bind to HIF. 
Using luciferase reporter contructs, truncation of these three HRE binding sites 
resulted in 80.9% loss of luciferase activity when compared with the wildtype 
NDGR2 promoter. Although its function is not yet fully understood, it is known to 
be regulated in the stress response of certain cells (Yao et al., 2008). Wang et al. 
further showed that this gene was required for hypoxia-induced apoptosis in the 
human lung cancer cell line A549 (Wang et al., 2008). Another HIF target gene is 
Bcl-2/E1B 19 kDa interacting protein (BNIP3); a pro-apoptotic member of the Bcl-
2 family and expressed in hypoxic regions of various tumours, including breast, 
lung and cervix (Mellor and Harris, 2007). It has been shown that during hypoxia, 
BNIP3 expression is increased in many cell types and forced overexpression of 
BNIP3 can induce cell death (Guo et al., 2001; Imazu et al., 1999; Vande et al., 
2000).  
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Both HIF-1alpha and HIF-2alpha have been found to have distinct functions 
which only partially overlap. For instance, glycolytic genes seem to be mainly 
regulated by HIF-1alpha (Hu et al., 2003). HIF-2alpha seems to be the main 
regulator of genes such as VEGF and EPO, when both HIF-1alpha and HIF-
2alpha are expressed in the tissue/cells concerned (Morita et al., 2003; 
Warnecke et al., 2004). The mechanism by which HIF-alpha subunits having 
selective effects on downstream genes is not currently well understood, but may 
be the result of tissue-specific interactions with other nuclear factors, differential 
interactions with transcriptional co-factors or a reflection of tissue and cell type-
dependent differences in the ratios of HIF-alpha protein levels (Haase, 2006).  
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1.5 Non-oxygen dependent modes of HIF-alpha regulation 
Evidence has been accumulating with regards to additional HIF regulation aside 
from proteolytic regulation and CTAD inactivation.  
One such pathway which appears to be important involves the phosphatidyl-
inositol 3-kinase (PI3K)/Akt/mTOR cascade (Stiehl et al., 2002). This was shown 
to mediate the stimulation of the HIF system through extracellular growth factors 
such as insulin and insulin-like growth factor-1 (IGF-1) and involved enhanced 
translation of HIF-alpha (Fukuda et al., 2002; Laughner et al., 2001).  
Post-translational modifications of HIF-alpha which may be important include 
phosphorylation, originally suggested by its slow mobility in SDS-polyacrylamide 
gel electrophoresis – which could be reversed by treatment with phosphatases 
(Richard et al., 1999). However, no phospho-specific acceptor site has yet been 
clearly shown to be important in physiological regulation of HIF-1alpha. HIF 
activation therefore may not be modulated by phosphorylation of HIF-alpha 
subunits. In fact, Sang et al. in 2003 showed that mitogen activated protein 
kinase (MAPK), which was thought to be responsible for the phosphorylation of 
HIF-1alpha, actually exerts its effects on HIF activity by phosphorylating the co-
substrate of HIF-alpha, namely p300 (Sang et al., 2003).  
Another example of post-translational modification of HIF-1alpha is the 
acetylation of Lys532 by ARD1, an N-acetyltransferase (Jeong et al., 2002). 
Acetylation was considered to destabilise HIF-1alpha in normoxia. The 
expression of ARD1 was reduced in hypoxia, consistent with a role in the 
regulation of HIF in normoxic conditions. However, the exact mechanism by 
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which stability of HIF-1alpha is reduced by ARD1 was not known. Interestingly, 
more recent data suggests that although there is interaction between HIF-alpha 
and ARD1, ARD1 did not induce acetylation and destabilization of HIF-alpha 
(Arnesen et al., 2005). The connection between these two proteins is therefore 
not yet clear.  
Thus, in contrast to the roles of prolyl and asparaginyl hydroxylation, the role of 
other post-translational modifications of HIF-alpha subunits are much less clear. 
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1.6 Knockout mouse models for HIF-1 and HIF-2alpha 
One of the most powerful ways to understand the biological role of a gene and its 
protein product is to delete it, or modify it, in a whole mammal. Such studies are 
usually performed in the mouse, since techniques for targeted genetic 
modification of embryonic stem cells in this species exist. 
The role of HIF-1alpha and HIF-2alpha in embryonic development and in post-
natal physiology has been studied by various groups, with the use of knockout 
mice, which have clearly established the biological importance of this pathway. 
Homozygous hif1alpha-/- mice were shown to have severe defects in their 
embryonic development. Major malformations of the heart and vasculature were 
noted, which led to embryonic death at mid-gestation (Ryan et al., 1998; 
Semenza et al., 1999). A complete loss of HIF-1alpha resulted in myocardial 
hyperplasia, developmental arrest and considerable cell death within the cephalic 
mesenchyme (which related to defects in neural tube closure). Therefore, HIF-
1alpha is important for embryonic morphogenesis and vascularisation. Vascular 
defects observed in hif1alpha-/- were initially presumed to be as a result of 
downregualted VEGF levels, due to the absence of HIF-1alpha expression. 
Interestingly, elevated levels of VEGF were demonstrated in hif1alpha-/- embryos 
(Kotch et al., 1999), showing that the situation is more complex than initially 
thought.  
Since HIF-1alpha is required for the mouse embryo to develop successfully it is 
not possible to study the role of HIF-1alpha postnatally using a standard 
knockout approach. This can be circumvented using conditional knockouts, in 
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which a genetic modification is made in the presence of an enzyme (usually cre 
recombinase). Studies of a conditional HIF-1alpha knockout restricted to myeloid 
cells showed that HIF-1alpha was essential for normal function of these cells in 
vitro and inflammation responses in vivo (Cramer et al., 2003). Cramer et al. 
showed that inflammatory responses mediated by myeloid cells were decreased 
in HIF-1alpha deficient cells, suggesting a role for HIF-1alpha in regulating 
glycolysis and energy metabolism in this setting. HIF-1alpha was shown to be 
required for infiltration, oedema formation and tissue destruction caused by 
granulocytes and macrophages in the inflammatory response. Pfander et al. in 
2003 also showed that conditional inactivation of the hif1alpha gene in 
chondrocytes led to mice being smaller, in comparison with wildtype mice with 
HIF-1alpha intact. They also soon died after birth. The knockout mice had 
tracheal and skeletal abnormalities with considerable chondrocyte death, 
suggesting HIF-1alpha may also be required for chondrocyte growth and survival 
(Pfander et al., 2003). These, and other similar experiments, show that HIF-
1alpha is essential for normal functioning of a range of different cell types. 
Hif2alpha-/- knockout mice show variable defects in development, including in 
their cardiovascular and respiratory systems (Compernolle et al., 2002; Tian et 
al., 1998). Tian et al. showed that hif2alpha-/- knockout mice had reduced levels 
of catecholamine (required for normal cardiovascular function in embryonic and 
neonatal development), which led to slower heart beat and foetal death (caused 
by circulatory failure). This indicated an important role for HIF-2alpha in the 
regulation of catecholamine homeostasis and protection from lethal heart failure. 
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In another knockout experiment, Campernolle et al. (2002) showed that HIF-
2alpha was also important for development of the respiratory system 
(Compernolle et al., 2002). Neonatal homozygous mice exhibited severe 
respiratory failure and died soon after birth, as a result of collapsed lungs. In this 
case, the expression of VEGF was shown to have been reduced in the alveolar 
cells, leading to impaired lung maturation. Therefore both HIF-2alpha and VEGF 
are required for normal lung maturation. There is increased expression of HIF-
2alpha with gestation in normal lungs in type II pneumocytes, which correlated 
with VEGF expression. VEGF was decreased in these cells in the knockouts, 
implying that VEGF is these cells is regulated by HIF-2alpha (Ema et al., 1997). 
High energy demand tissue has also been shown to develop pathological 
abnormalities in  hif2alpha-/- knockout mice (Ding et al., 2005; Scortegagna et al., 
2003). Abnormalities have been reported in the eye, skeletal muscle, heart, 
testis, liver and bone marrow; organs that are likely to be sensitive to high 
oxidative stress. 
Another approach for dissecting the role of HIF in biology is to examine the effect 
of heterozygosity for a null allele of a HIF-alpha subunit. These mice do not show 
any obvious abnormalities under baseline conditions, but do show differences 
when exposed to hypoxia. Such differences imply a critical role for the normal 
amount of HIF-alpha in determining specific pathophysiological responses. For 
example, heterozygous hif1alpha+/- and hif2alpha+/- knockout mice revealed 
impaired or complete loss of development of pulmonary hypertension and right 
ventricular hypertrophy when exposed to chronic hypoxia (Brusselmans et al., 
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2003; Yu et al., 1999). Hif1alpha+/- mice displayed a delayed increase in 
erythrocyte levels when responding to hypoxia, in comparison with wildtype mice. 
This was not the case, however, in hif2alpha+/- knockout mice. Under prolonged 
hypoxia, hif1alpha+/- lost more weight than did the wildtype mice. In contrast, 
hif2alpha+/- mice lost a minimal amount of weight and survived longer than 
wildtype (Brusselmans et al., 2003; Yu et al., 1999).  
Observations made from studying knockout mice have therefore suggested that 
the two HIF-alpha subunits (HIF-1alpha and HIF-2alpha) have distinct roles, are 
non-redundant, and important in many aspects of mammalian biology. 
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1.7 Cross-talk of HIF with other transcription factors 
As described previously, heterodimerization of HIF-alpha with HIF-beta results in 
the formation of a transcription complex, which mediates the hypoxic response. 
However, the HIF-alpha subunit also regulates processes via protein-protein 
interactions with other factors. These include p53 (a tumour suppressor protein) 
(Ravi et al., 2000) and c-Myc (a protooncogene) (Koshiji et al., 2004). p53 was 
found to promote the Mdm2-mediated ubiquitination and degradation of HIF-
1alpha, whereas HIF-1alpha counteracted c-Myc, which derepresses p21, a 
cyclin-dependent kinase inhibitor that controls a cell’s cycle checkpoint.  
A more recent example is HIF-1alpha ability to associate with the intracellular 
domain (ICD) of the Notch receptor – a protein involved in maintaining cells in an 
undifferentiated state (Gustafsson et al., 2005). Association of HIF-1alpha with 
the ICD increased Notch signalling, leading to upregulation of Notch target genes 
such as Hairy/E(spl)-related with YRPW motif  (Hey), hairy and enhancer of split 
(Hes) and neurogenin (Ngn).   
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1.8 HIF expression in the normal kidney 
The main focus of this thesis is the expression of FIH and the biological role of 
FIH in regulating HIF, with particular emphasis on FIH in the context of renal 
cancer. Here, I review some of the literature regarding HIF expression in the 
normal kidney. 
The expression of HIF has been studied in the context of nephrogenesis, where 
HIF-alpha subunits exhibited a cell type and stage specific expression pattern 
(Bernhardt et al., 2006). Support for the idea that HIF has a regulatory role in the 
developing kidney was provided by the correlation of its expression with that of 
important angiogenic factors such as VEGF. 
For the HIF-1alpha subunit, expression was predominantly found in the cortical 
and medullary collecting ducts, glomerular cells and S-shaped bodies. 
Expression of HIF-2alpha was detected in podocytes and cortical and medullary 
endothelial and interstitial cells (Freeburg et al., 2003). Since S-shaped bodies 
only express HIF-1alpha and that mature glomeruli expressed HIF-2alpha, it has 
been proposed that there may be a distinct role for both these alpha subunits in 
glomerular development. However, the role of individual HIF transcription factors 
in renal development is not yet fully defined, although experiments involving the 
use of conditional knockout mice are pending and should provide further insight. 
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1.9 HIF and disease 
Hypoxia potentially plays a central role in the pathology of a number of diseases, 
including cancer and ischaemia. As a result, it has been suggested that it could 
be an attractive target for therapeutic manipulation (Bazan et al., 2002; Brahimi-
Horn and Pouyssegur, 2007; Park et al., 2004; Wilhide and Jones, 2006). For 
instance, use of rapamycin and histone deacetylase (HDAC) inhibitors as 
combinational therapy, showed antiangiogenic and antitumour activity through a 
decrease in HIF-1alpha expression as well as inhibition of downstream signalling 
in the mTOR pathway (Verheul et al., 2008). Conversely, stimulation of HIF 
activity may be of benefit where neo-angiogenesis is required, e.g. ischaemia 
(Giaccia et al., 2003) (Figure 1.5). This could be achieved by small molecule 
inhibitors of the HIF hydroxylases, which could augment the HIF response in 
normoxia or moderate hypoxia. An example of augmenting the HIF response is 
hypoxic preconditioning, which is discussed in the next section.  
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Figure 1.5 HIF and disease 
 
Caution is required however, for two reasons. First, activating the HIF response 
has many downstream consequences. Decreasing HIF activation in cancer may 
have a range of beneficial effects (e.g. decreasing angiogenesis) but can also 
have pro-tumour effects (Carmeliet et al., 1998). Similarly, in ischaemia, HIF 
activation may have both desirable and undesirable consequences. Second, 
there is evidence suggesting that there are other substrates of the hydroxylases, 
aside from HIF, and there are many structurally similar enzymes (Schofield and 
Zhang, 1999). Consequently, existing small molecules are predicted to have 
other effects besides activating HIF. Further study would be required, as well as 
development of more specific inhibitors if there is to be therapeutic potential, i.e. 
DMOG will inhibit collagen prolyl hydroxylases as well as HIF prolyl and 
asparaginyl hydroxylases. 
heart
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1.9.1 Ischaemia 
Reduced tissue oxygenation is a key feature in many diseases. Myocardial 
infarction and stroke occur when there is inadequate blood flow (ischaemia) to 
part of the heart or brain. In these settings, oxygen delivery to cells is insufficient. 
Particularly sensitive to ischaemic damage are the kidney, the brain and the 
heart. The effects of HIF activation are anticipated to improve cellular survival 
and tissue adaptation when oxygen levels are reduced.  
Interestingly, “preconditioning” by a moderate ischaemic exposure is a powerful 
way of protecting tissues from the deleterious effects of subsequent ischaemia 
(Eckle et al., 2008). Certain genes which have been implicated in ischaemic 
preconditioning are HIF targets, suggesting that HIF activation could mediate 
some of these effects. Supporting this, hypoxic exposure can also be used to 
precondition, and this has been shown to be substantially mediated by HIF. 
Insight into how HIF is regulated by oxygen has revealed ways to activate the 
pathway in the presence of oxygen (Safran and Kaelin, Jr., 2003). Specifically, 
inhibiting the enzymes that hydroxylate HIF provides a route by which small 
molecules can be used to increase HIF activation, and this is viewed as an 
exciting possibility in ischaemic conditions.  
Recent immunohistochemical studies have shown that the HIF system is 
activated in acute myocardial ischaemia in rats and in humans (Jurgensen et al., 
2004; Lee et al., 2000). In another study, treatment with a polypeptide, PR39, 
was shown to stabilise HIF (HIF-1 alpha to be specific) and to increase 
vascularity along the infarct border zone after acute myocardial infarction in mice 
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(Li et al., 2000). Interestingly there is also some genetic evidence in humans that 
an increased hypoxic induction of the HIF target VEGF in isolated mononuclear 
cells correlates with more extensive collateral vessels following myocardial 
infarction (Schultz et al., 1999).  
The idea that enhancing the HIF response could be of benefit in ischaemic 
disease is supported by studies in rodents from Bernhardt et al. (2006) and Hill et 
al. (2008) (Bernhardt et al., 2006; Hill et al., 2008), involving HIF hydroxylase 
inhibitors in a rat model of renal ischaemia. In the case of Hill et al., HIF 
heterozygotes increased susceptibility to ischaemia-reperfusion injury. Since the 
requirement of oxygen for the PHD enzymes is greater than that required for FIH 
(Stolze et al., 2004), inhibition of FIH is potentially of greater or, at least, additive 
benefit, compared with PHD inhibition in hypoxia/ischaemia.  Effective Inhibition 
of asparaginyl hydroxylation may also be easier to achieve since there is only 
one asparaginyl hydroxylase (FIH). This is in contrast to the prolyl hydroxylases, 
of which there are three which are structurally very similar. 
 
1.9.2 Cancer 
The opposite approach – inhibiting HIF activation - may be attractive in cancers. 
As cancer cells grow, they become displaced from sources of blood and 
therefore nutrients and oxygen. Oxygen can diffuse up to 150µm from functional 
blood vessels. In the case of tumours, rapid growth often results in areas which 
exceed this distance (THOMLINSON and GRAY, 1955).  Additionally, tumours 
also exhibit an immature vasculature, which provides an inefficient blood supply.  
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As a result, the microenvironment of cancer is often hypoxic. HIF is activated in 
these regions and this could potentially promote the survival of cancerous tissue 
via increased expression of HIF target genes, as well as increasing angiogenesis 
(by increasing VEGF expression). There is extensive genetic evidence for this in 
experimental cancers, going back to Maxwell et al. in 1997 (Maxwell et al., 1997). 
Indeed, HIF-2alpha has recently been implicated in tumour aggressiveness in 
neuroblastomas (Holmquist-Mengelbier et al., 2006). They had found that in 
neuroblastoma specimens, HIF-2alpha but not HIF-1alpha was strongly 
expressed in well-vascularized areas. Also, suppressing HIF-2alpha reduced the 
growth of neuroblastoma tumors in athymic mice. Increased HIF-2alpha protein 
levels were also correlated with advanced clinical stage and high VEGF 
expression, predicting poor prognosis in clinical neuroblastomas. A caveat to 
inhibiting HIF-alpha subunits as a therapeutic strategy is it has also been 
reported that the overexpression of HIF-1alpha may actually reduce tumour 
growth (Volm and Koomagi, 2000), presumably through upregulation of a subset 
of HIF-1alpha regulated genes that are pro-apoptotic. One such HIF target is 
BNIP3 (Sowter et al., 2001). This is in contrast to HIF-2alpha genes, 
overexpression of which contributed to tumour growth when using the renal 
cancer cell line 786-O (Raval et al., 2005). This clearly implied contrasting 
properties of both the HIF-alpha subunits in terms of renal cancer growth. In fact, 
Raval et al. also found a reciprocal relationship between HIF-1alpha and HIF-
2alpha; attenuating the HIF-2alpha subunit enhanced levels of HIF-1alpha. This 
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may prove a factor for development of a therapeutic strategy for renal cancer and 
is the main focus of this thesis. 
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1.10 VHL loss in clear cell renal cell carcinomas (CCRCC) 
One of the main aims of this thesis is to investigate the potential role of FIH in 
CCRCC. CCRCC’s account for ~2% of all cancers that occur in adults and 
causes, worldwide, 100,000 deaths per year (Parkin et al., 2005). CCRCC often 
presents late during the course of the disease and approximately 30% of patients 
have metastatic disease. The term ‘clear cell’ is based on the microscopic 
appearance and is the commonest form of kidney cancer. CCRCC accounts for 
80% of these types of renal tumours (Motzer et al., 1996). The 5 year survival 
rates for patients presenting with metastatic disease is poor, at less than 10% 
(Motzer et al., 1996). Treatment options include nephrectomy, radiation, 
immunotherapy and chemotherapy – all of which provide limited success as a 
cure. Approximately 80% of CCRCCs show inactivation of the VHL tumour 
suppressor gene by mutation, deletion or hypermethyltion (Gnarra, 1998). This 
results in constitutive activation of HIF. VHL conforms to Knudson’s two-hit model 
of tumour suppressor gene action and was originally identified as the gene 
underlying the autosomal dominant condition von-Hippel Lindau disease. It is the 
loss or defects in the VHL suppressor gene, as revealed by various genetic 
studies, which underlies CCRCC. Components of the syndrome were recognized 
by Eugene von Hippel in 1904 and Arvid Lindau in 1927. The VHL gene was 
identified by a positional cloning approach in 1993 (Latif et al., 1993). For tumour 
formation to occur in VHL disease, both alleles must be inactivated. Loss of the 
first allele usually occurs as an inherited germline mutation. Tumours may then 
potentially develop when somatic mutation or methylation inactivates the second 
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copy. Other disorders that can result from VHL loss are haemangioblastomas of 
the retina and CNS, endolymphatic sac tumours, tumours of pancreatic islet 
cells, papillary cystadenomas of the epididymis (males) or broad ligament 
(females) and benign cysts affecting multiple organs (Kondo and Kaelin, Jr., 
2001).  
In VHL defective CCRCC cells, re-expression of VHL suppresses tumour growth 
(Iliopoulos et al., 1995). Subsequent work showed that VHL was required for HIF 
destruction in the presence of oxygen (Maxwell et al., 1999). It acts as the 
recognition component of a ubiquitin E3 ligase which specifically captures HIF-
alpha subunits that have been hydroxylated by the PHD enzymes. Importantly, 
although VHL has other functions, active HIF-2alpha appears to be both 
necessary and sufficient for growth of VHL defective CCRCC cells as xenografts 
(Kaelin, Jr., 2004; Kaelin, Jr., 2007). 
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1.11 Methods of activating HIF 
In cell lines in which VHL is active (i.e. the non-renal cancer cells used in this 
project), it is necessary to stabilize HIF if functional studies of FIH on HIF activity 
can be investigated, independent of PHD activity. The following are methods 
commonly used to stabilize and activate the HIF transcription factor. 
 
1.11.1 Dimethyloxalylglycine (DMOG) 
DMOG is a cell permeable ester of N-oxalylglycine, an analogue of 2-OG which 
can be used to inhibit 2-OG-dependent dioxygenases such as the PHD and FIH 
enzymes, as described by Jaakkola et al. in 2001. This allows accumulation of 
HIF-alpha subunits which are stable and active.  DMOG also inhibits other 2-OG 
dependent dioxygenases and is therefore considered unspecific.  However, a 
recent report by Elvidge et al. (2006) found that most of the effects of DMOG, in 
terms of gene expression, were mediated by HIF (Elvidge et al., 2006).  
 
1.11.2 Hypoxia 
Hydroxylation of prolyl residues within HIF-alpha subunits is necessary for the 
recognition of HIF by VHL, and oxygen is an essential co-substrate of this 
reaction.  Therefore, exposing cells to low oxygen can be used to prevent this 
and stabilize HIF. This is the main physiological route by which HIF is activated in 
vivo; in vitro, HIF activation is progressive in cell culture for 20% oxygen to 0.5% 
oxygen. The main caveat associated with the use of low oxygen for HIF 
activation is that HIF independent processes may also be affected e.g. other 
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enzymes may also require oxygen to function.  However, it is interesting to note 
that the genetic manipulation of HIF suggests that many effects of hypoxia are 
mediated by HIF.  
 
1.11.3 Cobalt chloride (CoCl2) / Desferrioxamine (DFO) 
The PHD enzymes use iron and 2-OG as cofactors (Jaakkola et al., 2001). CoCl2 
will substitute the Fe2+ ion (for the cobalt ion, Co2+) resulting in an inactive 
enzyme and DFO is an iron chelator. Both can be used in culture and therefore 
activate HIF.  However, treatment with an iron chelator is also likely to impair 
other cellular reactions which use iron. Results should therefore be interpreted 
with care, as this is not a specific method of HIF activation. For instance, the iron 
regulatory proteins IRP1 and IRP2 also require Fe2+ for their function of iron 
uptake and distribution (Iwai et al., 1998) and would likely be affected.  
 
It is important to mention that DMOG, CoCl2 and DFO will affect both FIH and the 
PHD enzymes. 
 
1.11.4 Constitutively active HIF 
The forced expression of HIF isoforms is also possible.  Constitutively active HIF-
alpha can be prepared by mutation of the two prolyl residues which are 
hydroxylated in normoxia, allowing recognition by VHL (e.g. HIF-1alpha - Pro402 
and Pro564; HIF-2alpha - Pro405 and Pro531).  Mutation of these proline residues 
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results in exogenously expressed HIF-alpha subunits resistant to VHL-mediated 
degradation.  
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1.12 Other substrates of FIH besides HIF 
Although this thesis focuses on the role of FIH in regulating HIF transactivation, 
potential substrates for asparaginyl hydroxylation by FIH have been identified 
besides HIF. These include ankyrin repeat motifs containing the asparagine 
residue hydroxylated by FIH (Coleman et al., 2007; Ferguson, III et al., 2007). 
Well characterized substrates are ankyrin repeat and SOCS box protein 4 
(ASB4); a protein thought to mediate ubiquitination of various target proteins, as 
well as the ICD of the Notch receptor (involved in maintaining cells in an 
undifferentiated state). Two conserved Asn residues in Notch ICD (Asn1945 and 
Asn2012) have been identified as being hydroxylated by FIH using mass 
spectroscopy (Zheng et al., 2008). Using a thioredoxin-histidine6 (Trx-H6)-tagged 
Notch ICD, FIH-dependent hydroxylation was tested in a 2-OG decarboxylation 
assay. The full length mNotch ICD and a shorter form which spanned the seven 
ankyrin repeats, ANK 1-7, displayed robust activity (in vitro), whereas a truncated 
version containing the ‘RAM’ domain of Notch ICD alone did not. The Asn 
residues were therefore found to be important for Notch-mediated transcriptional 
activation, as alanine substitution of Asn1945 had a major impact on gene 
activation and mutation of both Asn1945 and Asn2012 abolished activity almost 
completely (Zheng et al., 2008). Figure 1.6 shows the structure of the Notch 
receptor, highlighting the Asn residues hydroxylated by FIH (Coleman et al., 
2007). 
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   A           B 
 
Figure 1.6 The Notch receptor 
(A) Cartoon representation of the Notch receptor. Binding of the ligand (Delta) promotes two 
proteolytic processing events (Notch cleavage just outside the membrane and extracellular 
Notch and ligand endocytosed into the ligand expressing cell); as a result of proteolysis, the 
intracellular domain can enter the nucleus to engage other DNA-binding proteins and 
regulate gene expression. (B) Crystal structure (ribbon) showing conserved Asn residues 
(ball and stick) hydroxylated by FIH, within the ICD of Notch. 
 
 
Other targets identified recently and also possessing ankyrin repeat motifs are 
the IkappaB family of proteins, providing further evidence that FIH-dependent 
asparaginyl hydroxylation is not restricted to HIF-alpha (Cockman et al., 2006). 
Potential alternative FIH substrates were investigated using a human testis cDNA 
library, screened by yeast two-hybrid, using FIH as bait.  
ICD
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Aims and hypothesis of thesis 
This project seeks to understand the role of FIH in its function to inhibit the HIF 
transcription factor, with particular emphasis on CCRCC cells. 
 
The major hypotheses underlying this thesis are; 
1. FIH is an important modulator of HIF activation 
2. Inhibiting FIH could be a therapeutic strategy in hypoxia and CCRCC 
 
The major aims of this thesis are; 
1. To determine the expression profile of FIH in various cell lines, in rat organ 
tissue samples and in human renal carcinoma samples 
2. To test whether expression of FIH is regulated by oxygen 
3. To determine whether, and to what extent, FIH regulates HIF activity in 
CCRCC cells  
4. To determine what would be the downstream effects of FIH inhibition in 
CCRCC cells 
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2 Materials and Methods 
2.1 Animals  
6-8 week old, male 200-300g Wistar rats were used for the experiments involving 
animals (supplied by Harlan Olac Ltd) and kept in a pathogen free environment.  
Rats were sacrificed and the organs removed by Dr. Peter Hill with the relevant 
ethical permission and according to institutional guidelines. Tissue hypoxia was 
induced in a subset of rats. This was achieved by exposing rats to 0.1% carbon 
monoxide (CO) gas mixed with air (BOC) for 24 hours. This induces functional 
anaemia because is has a higher affinity for haemoglobin than oxygen does. A 
set of rats were used for RNA analysis. A second set of rats were also used 
where both protein and RNA was analysed, using western blotting and 
ribonuclease protection assay (RPA) respectively. In this second set of animals, 
hypoxia was induced by exposing rats to low oxygen (7%) for a period of 24 
hours. Tissue was rapidly removed for RNA and protein extraction for analysis of 
FIH distribution and expected upregulation of HIF target gene GLUT-1.  
Organs (pituitary gland, spleen, lung, pancreas, skin, small gut, large gut, liver, 
kidney, thymus, stomach, testis and bone marrow) for RNA extraction were 
placed in solution D (4M guanidinium thiocyanate, 25nM sodium citrate [pH7], 
0.1M 2-mercaptoethanol, 0.5% sarcosyl) and homogenised. Organs for protein 
analysis were placed in urea/lysis buffer (8M urea, to which was added 10% v/v 
glycerol, 5% v/v 20% sodium dodecyl sulphate [SDS], 0.5% 1M [DTT], 2% 0.5M 
Tris [pH6.8]) and homogenised.  
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2.2 RNA extraction from tissue samples 
RNA was extracted using a method described by Chomczynski and Sacchi 
(Chomczynski and Sacchi, 1987) and was performed on ice. Tissue was placed 
in freshly made solution D. 1ml of solution D was used for every 100mg of tissue. 
After homogenization, 1 volume of 5:1 phenol chloroform and 0.1 volume 3M 
sodium acetate (pH4) was added and vortex mixed thoroughly. Samples were 
centrifuged at 12,000g for 1 hour at 4°C. The aqueous phase was carefully 
aspirated and added to 1 volume of ice cold Isopropanol, then placed at -20°C for 
a minimum of 2 hours in order to precipitate the RNA. To obtain the RNA pellet, 
samples were centrifuged at 12,000g for 40mins at 4°C and the Isopropanol 
removed carefully. The RNA pellet was dissolved in 500µl solution D and 
transferred to a 1.5ml eppendorf tube.  2 volumes of Isopropanol were added. 
RNA was once again precipitated at -20°C (for 1 hour). Samples were 
centrifuged at 15,000g for 20mins at 4°C in order to pellet the RNA. The 
supernatant was aspirated carefully and the pellet allowed to air dry for 10mins. 
The pellet was dissolved in formamide hybridization buffer (80% formamide, 
400nM sodium chloride, 40mM Pipes pH6.4, 1mM EDTA). The RNA 
concentration was determined by spectrophotometry. 
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2.2.1 Ribonuclease protection assay (RPA) 
Linearized DNA templates including FIH (nucleotides 599-736 and accession 
number AF395830) and U6 small nuclear RNA (nucleotides 1-107 and accession 
number X01366) were transcribed with T7 and SP6 polymerase respectively. 
The transcription reactions included [32P] UTP, thus producing a radio-labelled 
riboprobe specific to fih messenger RNA (mRNA) and another specific to 
U6snRNA. 
 
Linearization of the template - A concentration of 0.3µg/µl of plasmid was used 
together with 150Units of restriction enzyme, 20µl of 10x restriction buffer and 
20µl 10x BSA. The total volume was 200µl. This was then digested for 6 hours. A 
3µl aliquot was electrophoresed on a 1% agarose gel to confirm complete 
linearization.  
The DNA was then extracted using phenol/chloroform/isoamylalcohol, an equal 
amount (200µl) being added to the sample. This was then vortexed for around 30 
seconds, stored on ice for 15mins, centrifuged at 12,000g and 4°C for 5mins and 
then the upper aqueous phase placed into new Eppendorf tubes (~180µl). An 
equal volume of chloroform was added (180µl), vortexed and centrifuged at 
12,000g and 4°C for 5mins. The supernatant was then transferred into a new 
Eppendorf. DNA was precipitated by adding 1/10th volume RNase-free 3M 
sodium acetate (18µl), 2.5 volume 100% ethanol, vortexing and then leaving at -
20°C for 30mins. The DNA was then pelleted by centrifuge, 12,000g at 4°C for 
20mins. The pellet was then washed using 400µl of 70% ethanol, followed by 
Chapter 2 – Materials and Methods 
 73 
centrifugation at 14,000g and 4°C for 10mins. 30µl of RNase-free water was 
used to resuspend the pellet after air-drying for 10mins. The concentration was 
then verified using a 1% agarose gel and 1µl of the DNA to confirm that the 
concentration was ~1µg/µl. 
 
The generation of transcripts with SP6 and T7 – The polymerase SP6 (Roche 
Cat no. 810274) was used for production of the FIH riboprobe and T7 (Roche Cat 
no. 881767) for the control U6 SnRNA riboprobe.  
A separate U6 mix was also prepared, as the U6 riboprobe was labelled in the 
presence of non-radioactive UTP. This results in a specific activity of the U6 
probe which is ~40-fold lower, due to the addition of the unlabelled UTP in the 
reaction mix. Reactions were prepared as follow: 
 
Cold mix: 0.9µl NTP mix, 1.2µl H2O, 1.2µl 10x transcription buffer, 0.6µl DTT 
Hot mix: 1.875µl H2O, 0.625µl 100µM cold UTP, 2.5µl [
32P]UTP 
U6 Mix: 2.5µl hot mix (from above), 2.5µl 2mM UTP 
 
For each riboprobe the following was mixed: 3.25µl cold mix, 5µl hot mix (for 
control, 5µl of the toad probe was used instead), 0.8µl RNase Inhibitor (Roche 
Cat no. 799017), 1µl DNA template, 1µl SP6 (for FIH) or T7 (for U6). 
The probes were incubated for 90mins at 40°C in a water bath). 
Following incubation, 2µl of RNase-free DNase I (Pharmacia Cat no. 27-0514) 
was added and the samples then incubated for 30mins
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The reaction was stopped by addition of 57µl of buffer 10mM Tris-HCl (pH7.5), 
5mM EDTA, 0.1% SDS, making a final volume of 70µl.  
To precipitate the labelled riboprobes, the samples were first purified using a spin 
column (Roche Cat no. 1814427), according to manufacturer’s instructions. 7µl of 
sodium acetate, 2µl 10mg/µl tRNA and 180µl 100% ethanol were added and then 
the samples were snap frozen on solid CO2 for ~30mins and slowly thawed at -
20°C for >30mins. Centrifugation at 12,000g at 4°C for 15mins produced visible 
pellets for both riboprobes. The pellets were then resuspended in 100µl of 80% 
formamide hybridisation buffer. A β-scintillation counter was used to assess 
labelling efficiency of both the FIH and U6 riboprobes. 
 
Probe hybridisation and RNase digestion of unprotected species - 100µg of 
the RNA from each tissue was dissolved in hybridisation buffer and hybridised 
with the FIH antisense riboprobe, which was produced as above. 1µg was 
hybridised in parallel with the U6snRNA control probe. Samples were denatured 
at 95°C for 20mins then hybridized in a waterbath at 60°C overnight. Non-
hybridised probe was digested using RNase A (4mg/ml) and RNase T1 
(200mg/ml) at 25°C for 30mins. To prepare the RNase mixture, 133µl of RNase 
T1 was centrifuged at 1,000g for 5mins, the supernatant was aspirated and the 
pellet was dissolved in 1ml RNase A (4mg/ml). In order to digest the RNase 
enzymes, proteinase K (1 mg/ml in RNase buffer [10mM Tris- Cl pH7.5, 5mM 
EDTA, 300mM NaCl]) with 200µl of 20% SDS, was added to the samples which 
were then incubated at 37°C for 30mins. Protected, double stranded RNA was 
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extracted using phenol:chloroform followed by chloroform. RNA precipitation was 
achieved using 2.5 volume of ethanol and 2µl 10mg/µl tRNA. These were added 
to the samples which were then kept on dry ice for ~45mins (until frozen) then 
thawed for 1 hour at -20°C. The samples were then centrifuged at 12,000g for 
30mins at 4°C. The ethanol was aspirated and the pellet air-dried for 15mins at 
(room temperature) RT. The pellet was dissolved in 5µl of running buffer (80% 
formamide, 1X TBE, ~0.1% bromophenol blue and ~0.1% xylene cyanol), by 
heating for 20mins at 95°C with intermittent vortex mixing. 
 
Electrophoresis and detection - Samples were loaded on a pre-warmed 8% 
polyacrylamide gel. Multi-digested pBR322 DNA (radio-labelled) was used as a 
size marker. Electrophoresis was performed in 1X TBE at 55W for approximately 
2 hours. The gel was then fixed (10% acetic acid, 10% methanol), transferred 
onto Whatman paper, wrapped in saran wrap, dried under a vacuum at 80°C for 
1 hour and finally exposed to radiography film at -80°C overnight. 
 
2.3 Cell culture  
Cells were incubated at 37°C in humidified air with 5% CO2. Renal cancer 
RCC10, RCC4 and 786-O cells, cervical cancer HeLa cells and Phoenix cells 
(viral packaging cells) were cultured in RPMI culture media containing 10% foetal 
bovine serum (FBS), 1% penicillin/streptomycin (p/s) and 1% glutamine (glu). Rat 
cardiac myocyte cells, H9C2 and human foreskin fibroblasts were cultured in 
DMEM, also containing 10% FBS, 1% p/s and 1% glu. Human microvascular 
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endothelial cells (HMEC) were grown on pre-coated plates with 1% gelatine, in a 
specially prepared medium containing the following - MCDB-131 media (GIBCO), 
1% p/s, glu, heparin 10 U/ml, 15% FBS and epidermal growth factor (Peprotech) 
at 10ng/ml. 
To expose the cells to hypoxia, the media of the cells was replaced with fresh 
media and then the plates were placed in a specialised workstation (BioTrace), 
set at either 1% or 5% O2 and 37
°C. A 2-OG analogue, DMOG (500µM), was also 
used to inhibit FIH. This was added to the culture medium and cells were then 
harvested after 16 hours for analysis. 
 
2.3.1 RNA extraction from cells 
Cells in a P60 dish were washed with cold phosphate buffered saline (PBS) twice 
then trypsinized using 1ml trypsin and transferred to a 1.5ml eppendorf tube. The 
supernatant was removed after spinning down the cells to form a pellet and 500µl 
of RNA-Bee reagent was then added and vortexed thoroughly. A total of 10% of 
the volume of chloroform was added to the tube, vortexed and placed on ice for 
15mins. After this, samples were centrifuged at 12,000g for 15mins at a 
temperature of 4°C. The RNA containing aqueous phase was carefully aspirated 
(~200µl) and added to an equal volume of cold Isopropanol. Samples were 
centrifuged again, for 10mins at 12,000g and 4°C. The resulting pellet was 
washed twice with 75% ethanol. Pellets were dissolved in 25µl of RNase-free 
water (Ambion Inc.).  
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After measuring absorbance at 260nm, RNA quantity was calculated using the 
following equation: 
Concentration (µg/µl) = (Dilution factor [100] X Constant [40] X A260) / 1000 
 
A (A260/A280) ratio of 1.7-2.0 was deemed appropriate quality to continue to use 
for the reverse transcription analysis. RNA samples were also run on an RNase-
free 1% agarose gel with 0.5µg/ml ethidium bromide added. A clearly visible 18S 
and 28S ribosomal RNA band for each of the sample indicated appropriate RNA 
integrity. 
 
2.3.2 Reverse transcription 
The production of cDNA from RNA extracted from cells was performed using a 
reverse transcription kit (Roche) and performed according to the manufacturer’s 
instructions. 2µg of RNA was used in the reverse transcription assay.  
 
Program: 
 
Heated lid 110˚C 
25˚C  10mins 
42˚C  1hr 
95˚C  5mins 
4˚C  Store 
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2.3.3 Reverse Transcription - Polymerase Chain Reaction (RT-PCR) 
RT-PCR was performed using SYBR Green detection methods (HeLa, 786-O, 
RCC10, RCC4) or Taqman™ probes (H9C2). Nucleotide sequences of primers 
used for analysis of cDNA encoding FIH, GLUT-1, VEGF, PHD3, BNIP3, 18s and 
β–actin mRNA are listed below: 
 
β-ACTIN: F-5’ CCCAGAGCAAGAGAGG R-5’ GTCCAGACGCAGGATG  
GLUT-1: F-5’ TGGCATGGCGGGTTGT R-5’ CCAGGGTAGCTGCTCCAGC  
VEGF: F-5’ TGCCAAGTGGTCCCAG R-5’ GTGAGGTTTGATCCGC  
PHD3: F-5’ GATGCTGAAGAAAGGGC R-5’ CTGGCAAAGAGAGTATCTG  
BNIP3: F-5’ GATATGGGATTGGTCAAGTCGG R-5’ CGCTCGTGTTCCTCATGCT  
FIH: F-5’ AAAATGTGGTTGGTTACGAAACAG R-5’ GACTCTATGTGATGCCACCAGTACA 
18s: F-5’ CGCCGCTAGAGGTGAAATTC R-5’ TTGGCAAATGCTTTCGCTC 
 
Taqman probes (for rat H9C2 cells) were supplied by Applied Biosystems. 
Details are: Vegf assay ID Rn00582935_m1, glut-1 assay ID Rn00593670_m1, 
bnip3 assay ID Rn00821447_g1, hprt assay ID Rn01318745_g1. 
The expression of each target mRNA relative to β–actin (Hprt for H9C2 cells) 
mRNA was calculated based on the threshold cycle (Ct) as R = 2-∆ (∆Ct), where 
∆Ct = Cttarget – Ctβ-actin and ∆ (∆Ct) = ∆Ctexperimental – ∆Ctcontrol. 
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2.4 Preparation of protein extracts 
A list of solutions used for protein analysis procedures can be found in the 
appendix section at the end of this thesis. 
 
2.4.1 Cell extracts 
Cell extracts for immunoblotting were generated by urea/SDS lysis. Cell 
monolayers grown on culture dishes were removed from the incubator and 
chilled by the addition of a large volume of ice-cold PBS for 30secs, on a bed of 
crushed ice. Residual PBS was then removed.  Cells were harvested by scraping 
into 200µl of urea/SDS lysis buffer.  Lysates were sonicated for 15secs (Soniprep 
150, Sanyo, USA) and briefly centrifuged at 12,000g for ~1min and kept on ice.  
Extracts were assayed for protein concentration (see below) and aliquots were 
stored at -80oC. 
 
2.4.2 Protein extracts from tissue 
Renal cancer and paired normal tissue kidney samples which had been collected 
from the operating theatre (with informed consent), snap frozen and stored at -
80oC were kindly provided by Mr. R. Barod (Imperial College, London). Frozen 
tissue (~100–200mg) was placed into a tube containing Urea/SDS to which an 
EDTA-free protease inhibitor tablet (Roche) had been added.  Protein lysates 
were then prepared by homogenising the tissue (homogenisor; IKA, UK).  
Following homogenisation, samples were centrifuged (12,000g, 5mins and 4oC) 
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and supernatants aliquoted into fresh eppendorf tubes, which were then stored at 
-80oC. 
 
2.4.3 Determination of protein concentration 
A commercial BCATM Protein Assay (Pierce, USA) was used to estimate protein 
concentration. The protein concentration of cell extracts was determined by 
comparing the colour absorbance values of test extracts to the colour values 
derived from a standard curve of BSA (which were analyzed in parallel). 200µl of 
BCA Working Reagent (50 parts of BCATM Reagent A mixed with 1 part of 
BCATM Reagent B) was added to 25µl of sample (consisting of 3.5µl of BSA 
standard, plus 3.5µl of SDS/urea lysis buffer and 18µl of dH2O or 3.5µl of cell 
extract, plus 21.5µl of dH2O) in a 96 well microplate plate. The plate was then 
covered, gently mixed on a plate shaker for 30secs and then incubated at 37oC 
for 20mins.  Once the plate had cooled to RT, the absorbance was read at 
550nm on a plate reader (Anthos HT-II, Anthos Labtec Instruments, Austria).   
 
2.4.4 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE) 
Electrophoretic separation of proteins was performed using the Mini-Protean 
system (BioRad).  Resolving gels were prepared using 30% acrylamide:bis-
acrylamide (37.5:1) mix and TrisCl/SDS (pH8.8) buffer (350mM Tris-Cl, and 0.1% 
SDS) to the desired specification eg. 6% gels (HIF-1α, HIF-2α) 10% gels (FIH, 
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CAIX, GLUT-1 and α-tubulin) or 12% gels (BNIP3) (see below [Table 8] for 
formulations used for gel preparation, and Table 9 for a summary of gel 
requirements for specific proteins).  For stacking gels, the acrylamide 
concentration was 3.9% in Tris/SDS (pH6.8) buffer (125 mM Tris-Cl (pH6.8), and 
0.1% SDS).  Gels were polymerised by the addition of ammonium persulphate 
(APS) to 0.05% and N,N,N’,N’-tetramethylethylenediamine (TEMED) to 0.07%.  
Typically, protein extracts at 2µg/µl were mixed with 4x SDS loading buffer and 
heated at 95oC for 2min, followed by brief centrifugation at 12,000g for ~30sec, 
before loading 12µl of protein sample (~18-20µg) onto a polyacrylamide mini-gel.  
Gel electrophoresis was performed at a constant 100V in electrophoresis buffer.  
Coloured molecular weight standards (ProSieve Colour protein markers, 
Cambrex, USA) were also run on every SDS-PAGE gel to monitor 
electrophoresis, and were used to calibrate the mobility and hence apparent 
mass (kDa) of proteins of interest. 
Stacking Gel  
• 0.65 mL 30%Acrylamide/0.8% Bis-acrylamide 
• 1.25 mL 4 x TrisCl/SDS (pH 6.8) 
• 3.05 mL dH2O 
• 6.7 µL TEMED 
• 33 µL 10% APS 
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% Gel 30% Acrylamide/0.8% Bis 4 x Tris-Cl/SDS  
(pH 8.8) 
dH2O 10% APS TEMED 
 
6 2ml 2.5ml 5.5ml 47µl 9.4µl 
10 3.3ml 2.5ml 4.2ml 47µl 9.4µl 
12 4ml 2.5ml 3.5ml 47µl 9.4µl 
Table 8 Volume of reagents required for making the appropriate resolving 
gel for a given target protein 
 
 
Protein Relative 
molecular 
weight 
(kDa) 
Antibody 
clone 
Antibody source Antibody 
dilution 
Secondary 
antibody used 
%  
acrylamide 
in gel 
HIF-1alpha 120 54 Transduction 
laboratories 
1:500 Goat polyclonal 
anti-mouse 
HRP 
6 
HIF-2alpha 118 Ep109b CRUK 1:500 Goat polyclonal 
anti-mouse 
HRP 
6 
FIH 40 - Novus 1:1000 Goat polyclonal 
anti-rabbit HRP 
10 
BNIP3 22 - AbCam 1:1000 Goat polyclonal 
anti-mouse 
HRP  
12 
CAIX 54/58 M75 Dr Pastorekova, 
(Institute of 
Virology, Bratislava) 
1:1000 Goat polyclonal 
anti-mouse 
HRP 
10 
GLUT-1 ~45 GT12A Alpha Diagnostics 1:1000 Goat polyclonal 
anti-rabbit HRP  
10 
Pk-tag n/a - Serotec 1:500 Goat polyclonal 
anti-rabbit HRP 
n/a 
α-tubulin 55 TAT-1 CRUK 1:250 Goat polyclonal 
anti-mouse 
HRP 
10 
 
Table 9 Details of primary antibodies used to detect proteins of interest 
during this project 
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Resolved proteins were transferred to PVDF membranes (Immobilon,
 Millipore, 
USA) by tank transfer (Mini-Transblot Apparatus; BioRad). The transfer cassette 
comprising pre-equilibrated gel and PVDF membrane was sandwiched between 
chromatography paper (Whatman, UK) and Scotch-Brite pads.   The cassette 
was then placed in a transfer tank, immersed in transfer buffer, and 
electrophoresed at a constant 25V overnight at 4oC, followed by 1 hr at 100V. 
For immunodetection, membranes were transferred to blocking solution for 1 
hour on a rocking platform (Platform Rocker STR6, Bibby, UK) at ~25rpm at RT, 
to prevent non-specific antibody binding.  Primary antibodies were diluted in 
blocking solution to the dilution specified in Table 9 and applied to the membrane 
for 1 hour at RT.  After three washes of 5mins with PBST solution on a rocking 
platform set at ~40rpm at RT, membranes were incubated with secondary 
antibodies conjugated to horseradish peroxidise (HRP) (Dako) for 1 hour (diluted 
1:2000 in blocking solution), followed by at least five washes of 5mins on a 
rocking platform set at ~40rpm.  
Bound HRP activity was visualized by enhanced chemiluminescence (ECL [for α-
tubulin, GLUT-1]), or the higher sensitivity ECLplus (FIH, CAIX, Pk-tag, HIF-
1alpha, HIF-2alpha, BNIP3) Amersham Pharmacia Biotech) using Kodak MXB 
film (GRI autoradiography film, Blue sensitive, GRI, UK). 
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2.5 RNA Interference  
Sequences for siRNA targeting FIH and HIF-1alpha were generated using Target 
Finder from Ambion Bioscience’s website and the oligonucleotides were 
purchased from Eurogentec. A BLAST search was performed to ensure 
specificity for the target concerned. Nucleotide sequences are: 
 
FIH HUMAN#1:  F-5’ AUG AGG AGC CUG UGG UGC UdTdT 3’  
                      R-5’ A GCA CCA CAG GCU CCU CAU dTdT 3’ 
 
FIH HUMAN #2:  F-5’ GAU GCU UGG AGA GGC CUU GdTdT 3’ 
                                R-5’ C AAG GCC UCU CCA AGC AUC dTdT 3’ 
 
HIF-1α HUMAN:  F-5’ CUG AUG ACC AGC AAC UUG AdTdT 3’ 
                                 R-5’ U CAA GUU GCU GGU CAU CAG dTdT 3’ 
 
HIF-2α HUMAN:  F-5’ CAG CAU CUU UGA UAG CAG UdTdT 3’ 
                     R-5’ A CUG CUA UCA AAG AUG CUG dTdT 3’ 
 
Firefly Luciferase:       F-5’ CGU ACG CGG AAU ACU UCG AdTdT 3’ 
 R-5’ U CGA AGU AUU CCG CGU ACG dTdT 3’ 
 
1µM siGLO® was used for optimization of RNAi procedures and were transfected 
as described for siRNAs. For cells at 40-50% confluency in p60 cell culture 
dishes, 50nM of siRNA was transfected using a 1/300 dilution of LipofectAMINE 
2000 (Invitrogen). The siRNA concentrations were adjusted using optiMEM. 
From 100µM siRNA stock (FIH, HIF-1alpha, HIF-2alpha), 2µl of siRNA was 
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added to 498µl optiMEM. In parallel, 12µl of LipofectAMINE 2000 was added to 
488µl optiMEM. After 5mins incubation, the 500µl of the siRNA mix was added to 
the 500µl Lipofectamine mix, gently pipetting up and down. This 1ml transfection 
mix was then incubated for 20mins. In this time, media was removed from the 
cells that are to be transfected, washed twice with cold PBS and replaced with 
3ml of serum- and antibiotic-free media. 1ml of the relevant transfection mix was 
then added slowly, drop-by-drop, to each of the plates, while gently shaking. The 
total volume of the media covering the cells is 4ml, making 50nM total siRNA 
concentration. The cells were then incubated at 37°C in humidified air containing 
20% O2, 5% CO2 for 4 hours. 4 hours after transfection, the cells were overlaid 
with 1ml each of culture media containing FBS, p/s and glu. Gene expression 
was then assayed by RT-PCR (mRNA) or western blot (protein). 
 
2.5.1 Short-hairpin RNA (shRNA) vector for FIH 
The following shRNA oligonucleotide sequences were annealed then ligated to a 
pSUPER.puro vector (~4kb) from pSUPER RNAi System™ (Cat no. VEC-PBS-
0008). The hairpin sequence is shown in red: 
 
F-5’ GATCCCCGATGCTTGGAGAGGCCTTGTTCAAGAGACAAGGCCTCTCCAA 
GCATCTTTTTGGAAA 
 
R-5’ AGCTTTTCCAAAAAGATGCTTGGAGAGGCCTTGTCTCTTGAACAAGGCC 
TCTCCAAGCATCGGG 
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The oligonucleotides were dissolved in sterile, nuclease-free H2O to a 
concentration of 3mg/ml. The annealing reaction consisted of 1µl of each oligo 
(forward and reverse) with 48µl annealing buffer (100mM NaCl and 50mM Hepes 
pH7.4). The mixture was incubated at 90°C for 4mins, then at 70°C for 10mins. 
The annealed oligonucleotides were then step-cooled as follows: 37°C for 15-
20mins, then to 10°C or RT before use.  
The pSUPER vector was provided as a circular vector of size 4353bp and 
containing a ubiquitous H1 promoter sequence. 1µl of 0.5mg/ml pSUPER vector 
was linearized sequentially by adding 1µl of Xho1 and incubating for 60mins at 
37°C, and then adding 1µl of BglII and continuing the reaction for 2 hours. The 
reaction was heat inactivated by raising the temperature to 80°C for 20mins. For 
the ligation, 2µl of the annealed oligos were added to 1µl of T4 DNA ligase 
buffer. 1µl of the vector was then added together with 5µl nuclease-free H2O and 
1µl T4 DNA ligase. This was incubated overnight at RT. A negative control, 
containing vector only was also included. Prior to transformation, plasmids were 
treated with BglII to reduce the level of background, as recommended by the 
manufacturer of the vector. This was performed by addition of 1µl of BglII to the 
plasmid and incubating at 37°C for 30mins. 
Ligation reactions were transformed into chemically-competent E. coli (DH5α), 
which were prepared by Tapan Bhattacharyya (Imperial College, Hammersmith 
Hospital). Bacteria were grown overnight and positive clones were picked and 
grown in ampicilin broth. Plasmid DNA was extracted using a Qiagen kit, 
according to the manufacturer’s instructions. To check for the presence of 
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positive clones (vector with oligonucleotide insert), a digestion was performed 
with EcoRI and HindIII. A positive clone cut with both these restriction enzymes 
produced a band of 281bp on a 1% agarose gel. DNA sequencing was also 
performed (MRC CSC Genomics Core Laboratory) to confirm the presence of the 
insert within the recombinant pSUPER vector.  
 
2.6 pCMV-R-FIH-Pk synthesis for FIH overexpression 
The ~5kb vector, pCMV-R, was ligated to a human FIH cDNA sequence, in order 
to overexpress it in renal clear carcinoma RCC10 cells. A Pk-tag was added to 
the FIH sequence using PCR (Gly-Lys-Pro-Ile-Pro-Asn-Pro-Leu-Leu-Gly-Leu-
Asp-Ser-Thr). 10ng of the epitope tagged FIH cDNA was used in the ligation 
reaction. To check for positive clones, several digestion reactions using 
restriction enzymes were performed. The initial digest was performed using AseI 
and XhoI. An additional digest using PstI was performed as there is a restriction 
site for this in the FIH sequence. Bands were analysed on a 1% agarose gel to 
confirm successful ligation. 
 
2.7 Infection of RCC10 (for shFIH and pCMV-R-FIH-Pk) 
Transfection of the viral packaging Phoenix cells - LipofectAMINE 2000 was 
used to transfect 25µg of the plasmid DNA into a ~90% confluent P90 culture 
dish. RPMI, containing 10% FBS and 1% glu but no antibiotics, was then added 
to the mixture (10ml total volume). This was placed over the Phoenix cells and 
incubated for 20 hours at 37°C and 5% CO2. Following this, the medium was 
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removed and replaced with fresh complete medium. The cells were then placed 
into another incubator set at 33°C and 5% CO2 for 16 hours. 
 
Infecting RCC10 with the virus supernatant - The RCC10 cells were at 30% 
confluency at the time of infection. Supernatant from the Phoenix cells was 
placed into a 50ml tube and fresh, complete medium was added to the cells. 
Phoenix cells were then incubated at 33°C and 5% CO2  for 24 hours, to be used 
for a second round of infection.  
The supernatant was centrifuged in order to separate any cells and then passed 
through a 0.45 micron sterile filter. This was topped up with 2ml of fresh RPMI 
containing 4µl of polybrene (hexadimethrine bromide which increases infection 
efficiency) to make up the volume to 10ml. Medium from the RCC10 was then 
replaced with this new virus-containing medium and plates were incubated for 12 
hours at 37°C and 5% CO2. This infection was stopped by replacing the infection 
medium with RPMI (with 10% FBS, 1% p/s and 1% glu) and cells were incubated 
for 10 hours at 37°C and 5% CO2. Infection was then repeated a second time.  
 
Selection - For the shRNA and control (pSUPER.puro without insert) selection 
was performed over 5 days using puromycin at 1.5µg/ml, 48 hours after the 
second infection. G418 selection was used for pCMV-R-FIH-Pk and its control 
(pCMV-R empty) at 1.5µg/ml for 5 days. 
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2.8 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) 
assay 
MTT assays were performed with the use of 24 well cell culture plates seeded 
with 3000 cells from treated pools. Multiple plates were set up so that colorimetric 
measurements could be performed at designated time intervals after initial 
seeding. All cells were kept in the same incubator at 37°C. 0.2mg/ml of MTT was 
added to the cells and these were then incubated at 37°C for 4 hours. Once the 
formazan crystals were formed by the viable cells (via reduction of the yellow 
MTT in the mitochondria into purple formazan crystals), 100µl of Isopropanol-
Triton (0.1%) was added in order to dissolve them (~30mins at RT). A 
colorimetric measurement was then performed, measuring absorbance at a 
wavelength of 550nm, after transfer into 96 well plates. 
 
2.9 Fluorescence-activated cell sorting (FACS) 
Cells were investigated for apoptosis using a flow cytometer instrument (BD™ 
Biosciences, LSRII) and annexin-V staining. The cells at a later stage of 
apoptosis were detected by use of propidium iodide (PI) staining.  
Treated cells were released from P60 culture plates using cold PBS to first wash 
the cells (twice) then adding 1ml of trypsin and incubating the cells for 5mins in 
humidified air containing 20% O2, 5% CO2 at 37°C. The cells were then 
transferred into sterile 15ml Falcon tubes, after addition of 5ml RPMI media 
containing 10% FBS, 1% p/s and 1% glu and then centrifuged at 1250g for 
10mins at 4°C. The medium was removed and the cell pellet was suspended in 
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1ml annexin-V binding buffer (10mM Hepes/NaOH pH 7.4, 140mM NaCl, 2.5mM 
CaCl2). A volume of 100µl of the solution (~1x10
5 cells) for each of the treated 
cells was transferred to 5ml tubes. 5µl of fluorescein isothiocyanate (FITC)-
labelled annexin-V (BD-Biosciences) was added and then incubated in the dark 
for 20mins at RT. 400µl of binding buffer was added to the samples before 
analysis using flow cytometry (within 1 hour). After this initial reading for annexin-
V, 1µl PI was added and a second reading was taken immediately. As a positive 
control, apoptosis was induced using the telomerase I inhibitor, camptothecin, at 
25µM concentration. 
Data was analysed using Flowjo Flow Cytometry Analysis Software© (Treestar).  
 
2.10 Cell Death Assay (Roche) 
Cell death assays were used to quantify cytoplasmic histone-associated DNA 
fragments (as markers of apoptosis). A Cell Death Detection ELISA kit was 
obtained from Roche Applied Science. Lysates were produced from siRNA-
transfected cells following trypsinization, pelleting, washing twice with cold PBS 
and then adding 200µl of fresh lysis buffer. Cell death assays were then 
performed according to the manufacturer’s instructions.  
 
2.11 Statistical analysis 
All data expressed as the mean of the individual experiments ± the standard 
error (SE) of the mean. Differences were considered significant at p < 0.05, using 
a Student’s T-Test. An ANOVA was also used to evaluate differences between 
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data sets where indicated. The level of statistical significance is indicated by the 
use of asterisks: * p < 0.05, ** p < 0.01, *** p < 0.001.  
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3 Characterization of FIH - distribution and expression 
3.1 Introduction 
The expression of FIH remains relatively unexplored. Immunohistological studies 
by Soilleux et al. (2005) showed widespread expression in the epithelial cells of 
various tissues, including the oesophagus, stomach, liver, salivary gland ducts 
and renal tubules. They had also reported that FIH staining was increased in 
neoplasia in comparison with the corresponding normal tissues investigated 
(Soilleux et al., 2005). 
As a first step to understand in which tissues and cell types FIH may play a 
significant role, I set out to determine which organs in the rat express FIH at the 
mRNA and protein level. Since feedback inhibition is commonly a feature of 
biological control systems, and also of the HIF system, I also examined whether 
hypoxia increased FIH expression. Current knowledge is lacking on this subject 
with regards to FIH expression. Therefore, it may well be the case that FIH is 
also affected by oxygen tension. For instance, as mentioned previously in this 
thesis, both PHD2 and PHD3 are themselves HIF target genes (Aprelikova et al., 
2004; Metzen et al., 2005). In the case of PHD2, Metzen et al. (2005) discovered 
a functional HRE in its promoter region (Metzen et al., 2005). By electrophoretic 
mobility-shift assay, they had demonstrated binding of HIF-1alpha to a putative 
HIF-1-binding site. The downstream promoter was active and was also found to 
be induced by hypoxia. Using a Northern blot, human osteosarcoma (U2OS) and 
ovarian carcinoma (OVCAR3) cells were subjected to normoxic (20% O2) or 
hypoxic (1% O2) incubation for 4 hours. They found in a hypoxic setting, PHD2 
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levels were clearly increased. Exposing rodents to hypoxia, FIH expression 
levels were compared with levels in wildtype rodents, at both mRNA and protein 
level. 
Since reports have suggested the transcriptional repression of FIH in renal 
cancer (Datta et al., 2004; Li et al., 2007), I investigated the expression of FIH in 
renal cancer samples, compared with the corresponding normal kidney sample, 
using western blotting and RT-PCR. CCRCC cell lines were also investigated for 
the expression of FIH at protein level using western blotting. 
To investigate just how widespread FIH expression may be, I used a variety of 
cells and cell lines in order to immunoblot for FIH protein.  
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Results 
3.1.1 FIH distribution in the rat: RNA expression results 
Two male Wistar rats were used in the initial experiment to investigate the level 
and distribution of fih mRNA in twelve different organs and to test whether FIH 
levels are affected by hypoxia. A ribonuclease protection assay (RPA) was used 
for this investigation. Extracted RNA was quantified using spectrophotometry and 
an agarose gel (1%) confirmed negligible degradation for all samples. 
The principle of this assay is to detect specific RNA transcripts, using an in vitro 
transcribed radio-labelled anti-sense riboprobe. The riboprobe will bind to the 
mRNA transcript due to complementarity, thus protecting it from RNase activity, 
which may then be used to isolate the targeted species. The choice of probe 
length determines optimal sensitivity and was therefore carefully considered. 
Previous experience in the laboratory has found that the generation of 100-200bp 
of protected species is optimal. For my RPA, I therefore generated a 137bp 
riboprobe. 
For the determination of fih mRNA expression in the rat, an initial RPA was 
performed to confirm the quantitative nature of the assay (Figure 3.1). The assay 
was also used to determine the optimum amount of RNA to load onto the gel for 
fih mRNA detection. Protection of the fih mRNA by the fih probe is highly specific, 
as RNase digestion will cleave the RNA duplexes even if there is a single 
mismatched base.  
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Figure 3.1 RPA Optimisation 
RPA results using varying amounts of rat liver total RNA (extracted from normoxic and 
hypoxic rat). 25-200µg of RNA was hybridised in parallel and with either 1µl or 2µl (not 
shown) of probe. For 1µl probe added, duplicate hybridisations were performed in normoxic 
and hypoxic liver tissue samples. After RNase digestion, the protected probe was analysed 
on an 8% polyacrylamide gel. The protected fih probe appears at ~137 base pairs. As 
expected, the amount of signal is proportional to the amount of total RNA showing that the 
amount of fih mRNA is within the linear range of the assay. The amount of probe hybridized 
to the RNA was equal for all samples loaded. The empty lane (E) serves as an important 
control, in which no RNA is hybridized with the radioactive antisense probe, and no signal 
should be present. U6sn signal was used as a loading control and was equal for all samples 
(not shown). 
 
 
RNA extracted from rat liver was used to evaluate the amount of RNA to use in 
the assay. Figure 3.1 shows that the signal is within the linear range of the assay 
since increasing the target RNA results in a proportionate increase in signal. Use 
of 1µl of riboprobe was also found to be sufficient to produce a viable signal. 
Using these results, it was decided that 100ug of RNA was sufficient to give a 
signal. The signal in the assay would be proportional to the amount of fih mRNA 
present in the particular organ that the total RNA would be extracted from. 
Thirteen organs were extracted from the male Wistar rats. These were: pituitary 
gland, spleen, lung, pancreas, skin, small gut, large gut, liver, kidney, thymus, 
stomach, testis and bone marrow. Two rats were used for this experiment – one 
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as a control (normoxic, N) and the other exposed to low oxygen over 24 hours 
(hypoxic, H) as described in the methods and materials chapter.  
 
 
 
 
 
 
 
Figure 3.2 Fih mRNA expression in the rat 
Two independently performed RPAs (A and B) showing fih mRNA signal at the expected 
protected length of ~137 base pairs for (A) spleen, lung, small intestine, heart and (B) liver, 
large intestine, testis and stomach in normoxia (N) and hypoxia (H). 100µg total RNA was 
used for each organ. The E lane (no RNA) controls for non-specific protection. U6sn signal, 
used as a loading control, was equal for all lanes (not shown). Expression of fih mRNA does 
not appear to alter in hypoxia, except for liver, small gut, heart and stomach. However, this 
was not reproducible in subsequent RPAs. Testis did consistently show the lowest 
expression of fih mRNA. Conversely, lung, heart and liver showed the highest level of fih 
mRNA expression overall. 
 
 
Fih mRNA was found to be expressed in all of the organs tested. This was true 
for organs in normoxia and hypoxia. A representative gel is shown (Figure 3.2). 
The level of fih mRNA was noted to be higher in the heart, lung and liver and 
lower in the testis. There was no clear evidence of consistent increases in 
expression of fih mRNA in hypoxia. For instance, repeating the RPA with the 
same organs from different rodents produced inconsistent data when comparing 
normoxic and hypoxic fih mRNA levels. Further work using cell lines, shown in 
later chapters, are consistent with FIH not being regulated in hypoxia. This 
contrasts with the prolyl hydroxylases phd2 and phd3 (Appelhoff et al., 2004; 
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Aprelikova et al., 2004; Metzen et al., 2005), which are highly upregulated in 
hypoxia. However, it should be made clear that FIH levels in cell lines will likely 
give less insight to what actually happens in vivo, with regards to FIH regulation 
by oxygen. 
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3.1.2 FIH distribution in the rat: protein expression results 
Protein lystates were made using lysis buffer and the concentrations were then 
measured using BCA™ quantification assay, for each of the organs tested 
following homogenization.  
Organs were extracted from the same Wistar rats as those used for the RPA. 
Equal amounts (20µg) of lysate were resolved using 10% polyacrylamide SDS-
PAGE gels and analysed using immunoblotting. Figures 3.3 and 3.4 are from 
representative western blots. Similarly to fih mRNA, FIH was also expressed in 
all of the organs at the protein level, in both normoxia and hypoxia.  
 
 
 
 
 
 
A    B  
 
 
 
 
               C 
Figure 3.3 FIH protein expression in the rat 
(A) and (B) show FIH levels in rat organs, comparing normoxic with hypoxic tissue samples. 
(C) shows FIH levels in the kidney and thymus. Coomassie blue (40% methanol, 10% acetic 
acid) staining showed equal loading (not shown) for (C). Another band with lower mobility 
than FIH is also consistently present in the thymus. This may be due to a cross-reading 
protein on a differentially spliced FIH transcript.  
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In most tissues this affinity purified polyclonal antibody (Novus) consistently gave 
a band at the anticipated molecular weight of ~40kDa. That this band represents 
FIH was demonstrated by the fact that it was specifically suppressed by an FIH 
siRNA which I had designed in a subsequent experiment, as well as a pre-
designed siRNA targeting FIH and also an FIH targeting shRNA (shown in 
chapters 4 and 6). As with mRNA levels, there appeared to be little evidence of 
FIH protein levels being influenced by hypoxia. However, in the thymus, there 
appeared to be lower protein expression of FIH in hypoxia compared with 
normoxia (Figure 3.3C). Other organs showed little or no difference between 
normoxic and hypoxic levels.  In the thymus, a second band with lower mobility 
was also consistently present. This may be non-specific binding of the antibody, 
or post-translational modification of the protein, which is so far unreported for 
FIH. However, this was not investigated further. 
To verify that hypoxia was indeed induced, I blotted for a well established HIF 
target gene and marker of hypoxia (Koukourakis et al., 2006), namely glucose 
transporter 1 (GLUT-1) and confirmed an increase in protein levels in the hypoxic 
rat heart sample (Figure 3.4), when comparing with the normoxic control sample. 
This would be expected in a hypoxic setting. 
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Figure 3.4 Upregulation of GLUT-1 in rat heart 
Representative blot showing GLUT-1 protein levels in rat heart in normoxic (N) and hypoxic 
(H) tissue. A total of 20µg of protein was loaded. GLUT-1 protein upregulation in rat heart 
confirms hypoxia was induced as levels appear to be upregulated in hypoxia (lane 2 shows 
more GLUT-1 protein than the first lane). Alpha-tubulin confirms equal loading for samples. 
 
 
From the results shown here, it appears FIH is widely expressed in the rat, 
similarly to the PHD enzymes. However, in contrast to PHD2 and PHD3, it does 
not appear that FIH is regulated by oxygen tension, based on a limited number of 
observations made here. 
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3.1.3 FIH is expressed in renal cancer and renal cancer cell lines 
HIF is active in many CCRCC cell lines. Certain genes which are upregulated in 
hypoxia are expressed at a high level in CCRCC (Jiang et al., 2003). This was 
shown to be corrected by re-expressing VHL, which suppressed expression of 
these transcripts. Although other effects (e.g. of VHL on mRNA stability) are 
likely to contribute, it is now established that this is mainly because of the 
requirement of VHL for destruction of HIF (Maxwell et al., 1999). This is caused 
by a VHL mutation, therefore preventing its destruction in normoxia following 
prolyl hydroxylation by the PHD enzymes. This implies that FIH is either not 
expressed or that a proportion of HIF is resistant to FIH. Three CCRCC cell lines 
were used to investigate FIH expression at the protein level, using 
immunoblotting (Figure 3.5). These were RCC10, RCC4 and 786-O cell lines. 
 
 
 
 
 
 
 
Figure 3.5 FIH protein levels in clear cell renal carcinoma cell lines 
FIH protein levels in clear cell renal carcinoma cell lines in normoxia (N) and 1% oxygen (H). 
A total of 20µg of lysate was loaded for each cell line. The positive control is lysate taken 
from rat heart. There does not seem to be any regulation of FIH by oxygen, as levels are 
equal for all cell lines in normoxic or hypoxic conditions.  
 
 
R
C
C
1
0
7
8
6
-0
R
C
C
4
+
v
e
 c
o
n
tr
o
l
FIH
N H N HN H N
R
C
C
1
0
7
8
6
-0
R
C
C
4
+
v
e
 c
o
n
tr
o
l
α-tubulin
R
C
C
1
0
7
8
6
-0
R
C
C
4
+
v
e
 c
o
n
tr
o
l
R
C
C
1
0
7
8
6
-0
R
C
C
4
+
v
e
 c
o
n
tr
o
l
Chapter 3 - Results 
 103 
Fully confluent cells were washed then lysed. 20µg of protein was loaded to a 
10% SDS-PAGE gel. Immunoblotting was performed using the same FIH 
polyclonal antibody that was used in the tissue distribution experiment in the rat. 
The presence of FIH protein in renal cancer cells raises the question whether it 
regulates HIF, which forms the basis of Chapter 5 of this thesis. 
To investigate expression in cancerous tissue, renal cancer samples were 
obtained with informed consent from patients by nephrectomy (donated by Mr. 
Ravi Barod, Maxwell Group), snap frozen using liquid nitrogen and protein and 
mRNA then isolated. The quantification of FIH protein and mRNA was performed 
using western blots and RT-PCR respectively (Figure 3.6 and 3.7A). As a 
control, a non-cancerous portion of tissue was also analysed and GLUT-1 mRNA 
measured. Tumours that are VHL -ve will show upregulated levels of GLUT-1 
(Figure 3.7B). 
 
 
 
 
 
 
 
Figure 3.6 FIH in renal cancer samples 
Representative blot showing FIH protein levels in tumours (T), comparing with levels in 
control, non-cancerous region of normal kidney (Co). Equal amounts of total lysate were 
loaded for each sample (20µg). Differences in FIH protein between tumour and control 
regions were negligible.  
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From the experiments, FIH is expressed in renal cancer and normal kidney 
tissue. There is no evidence of significant or consistent FIH downregulation in 
renal cancer. This is in contrast with two recent publications concerning FIH in 
786-O CCRCC cells, which describes FIH as not functioning in renal cancer 
(Datta et al., 2004), because it is being transcriptionally repressed by 
phosphorylated Cut protein binding to the FIH promoter region and thus 
preventing its transcription. 
 
 
 
 
 
 
 
 
Figure 3.7 FIH mRNA in renal cancer samples 
(A) FIH mRNA levels in tumours and corresponding control regions. RT-PCR results show 
comparable FIH levels in tumour and control samples for each patient sample. ±SE, n=10 
(B) GLUT-1 mRNA levels are upregulated in the tumours, as is expected in VHL negative 
tumour samples. Significance is shown against control. ±SE, n=5 
 
 
My data shows FIH mRNA levels are in fact slightly increased in CCRCC, 
compared with normal kidney, although this was not statistically significant.  As 
expected, upregulation of GLUT-1 mRNA, a well characterized HIF target gene, 
was evident in these tumours. This suggests that although FIH is present, HIF is 
transcriptionally active in the tumour when compared with the control region. 
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These results suggest that rather than the downregulation of FIH allowing HIF-
alpha subunits to be active in renal cancer, HIF-alpha seems to escape the 
inhibitory effects of asparaginyl hydroxylation by some other mechanism. This led 
me to investigate FIH function in the context of renal cancer, and subsequent 
chapters deal with this part of my investigation. 
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3.1.4 Cells expressing FIH protein 
Immunoblot analysis of whole cell extracts revealed FIH to be widely expressed 
and at similar levels across a wide range of cell types. The cells used included 
HeLa (human, cervical cancer), H9C2 (rat, cardiac myocytes), HMEC-1 (human, 
microvascular endothelial), THP-1 (human monocyte) and MCF-7 (human, breast 
cancer).  
Of particular interest are HMEC-1 and H9C2 cells, due to their relevance in 
ischaemic heart disease. Since the requirement for oxygen for FIH function is 
lower than that of the PHD enzymes, FIH is potentially an attractive therapeutic 
target for inhibition in ischaemic disease. Inhibiting FIH may have the effect of 
increasing potentially beneficial HIF target genes (e.g. VEGF, GLUT-1, EPO etc), 
which may then in turn help prevent or reduce ischaemic injury, for example, in 
the heart (cardiac ischaemia), brain (stroke) or kidneys (acute renal failure). 
Effective Inhibition of asparaginyl hydroxylation may also be easier to achieve 
since there is only one asparaginyl hydroxylase (FIH). This is in contrast to the 
prolyl hydroxylases, of which there are three and are all closely homologous. The 
idea that enhancing the HIF response could be of benefit in ischaemic disease is 
supported by a studies involving HIF hydroxylase inhibitors in a rat models of 
renal ischaemia (Bernhardt et al., 2006; Hill et al., 2008; Rosenberger et al., 
2008). Interestingly there is also some genetic evidence in humans that an 
increased hypoxic induction of the HIF target VEGF in isolated mononuclear cells 
correlates with more extensive collateral vessels following myocardial infarction 
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(Schultz et al., 1999). The effects of HIF activation are therefore anticipated to 
improve cellular survival and tissue adaptation when oxygen levels are reduced.  
Since levels of HIF prolyl hydroxylases are modulated by hypoxia through the 
action of HIF (Berra et al., 2003; Del et al., 2003; Marxsen et al., 2004), I tested 
whether FIH protein levels are altered by hypoxia in cell lines. Whole cell extracts 
were prepared following parallel normoxic and hypoxic (0.1% oxygen) 
incubations for 16 hours (HIF target genes such as GLUT-1 and PHD3 are at 
their peak level at this time, according to previous experience). A western blot 
was used and FIH was found to be expressed in all of the cells that were 
investigated (Figure 3.8). 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 FIH expression in several cell lines 
FIH protein levels in six non-renal cancer cell lines. FIH was expressed all six cell lines 
analyzed. The positive control is tissue lysate taken from rat heart. A coomassie stain 
confirmed equal loading of lysates. 
 
 
These results show that the expression of FIH is characteristic of the cells that 
were investigated, and that the expression of FIH is independent of their VHL 
status. Interestingly, HMEC cells consistently showed lower levels of FIH 
expression, compared with FIH expression observed in the other cells 
investigated.  
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3.2 Conclusion 
FIH appears to be expressed in all tissues examined in the rat, both at the mRNA 
and protein level. It is therefore widely expressed in cells. Some organs, such as 
heart, lungs and liver in limited experiments showed higher levels of expression 
at the mRNA level. Additionally, this was comparable with FIH protein levels in 
heart and lung. There appears to be little difference in FIH mRNA expression 
when comparing normoxia and hypoxia, and therefore levels are unlikely to be 
influenced or regulated by oxygen. The expression of FIH at protein level also 
confirmed that it seems not to be regulated in hypoxia, in a limited number of 
observations.  
Renal cancer samples, as well as renal cancer cell lines also show evidence for 
FIH expression. Lysates from renal cancer samples showed comparable levels of 
FIH protein to that of control (normal kidney) tissue. I have not found any 
evidence to suggest the transcriptional regulation of FIH in this setting in three 
cell lines.  
Further evidence for FIH being widely expressed is provided by cell lines and 
cultures, all of which show expression of FIH at the protein level. 
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4 RNA Interference (RNAi) of FIH 
4.1 Introduction 
RNAi is a mechanism that suppresses gene expression (Figure 4.1) by hindering 
transcription of specific genes (Fire et al., 1998; Hammond et al., 2000). The 
RNAi pathway forms a natural defence from RNA from viruses and transposons, 
as well as playing a role in regulation and maintenance of the genome (e.g. 
micro-RNA [miRNA]) (Pillai et al., 2007).  
 
 
 
 
 
  
 
 
 
 
 
 
Figure 4.1 RNAi mechanism 
(Image courtesy of Cenix Bioscience GmbH) 
 
 
Small interfering RNA strands (siRNA) have, by design, complementary 
nucleotide sequences to the target strand. RNAi pathway proteins are guided by 
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siRNAs to the target mRNA, which is then cleaved and is therefore not translated 
into protein. Endogenously expressed miRNAs work in the same way. The RNAi 
pathway is initiated by the enzyme dicer (Jaskiewicz and Filipowicz, 2008; Kim et 
al., 2006). Dicer cleaves long dsRNA molecules into shorter 20-25bp fragments. 
One of the strands for each fragment (the ‘guide’ strand) is then incorporated into 
the RNA-induced silencing complex (RISC) which then pairs with complementary 
sequences (Preall and Sontheimer, 2005). The result is post-transcriptional gene 
silencing, as the catalytic component of RISC, known as argonaute, induces 
cleavage of the target mRNA. 
The robust effect of RNAi on gene expression makes it a valuable tool in 
research. For this reason, I sought to develop siRNAs targeting FIH in a variety 
of cell lines. Suppression of FIH would be useful in evaluating its function. 
 
 
 
 
 
 
 
 
Chapter 4 - Results 
 112 
4.2 Results 
4.2.1 siRNA design 
For siRNAs to be optimal for silencing a specific target gene, certain criteria are 
relevant in terms of sequence design. For example, the percentage of a 
particular nucleotide in the sense or antisense strand of siRNA, the presence or 
absence of a specific nucleotide at a certain internal position or the stability of the 
siRNA antisense strand. In order to design FIH siRNAs, I used a program 
available from the Ambion Inc. website, namely Target Finder 
(http://www.ambion.com/techlib/misc/siRNA_finder.html). The tool employs 
siRNA design guidelines first described by Tuschl and colleagues (Elbashir et al., 
2001). 
Two siRNA sequences, targeting human FIH, were generated using Ambion’s 
Target Finder algorithm. Both sequences were then BLAST searched against the 
relevant genome (i.e. human, rat) in order to confirm specificity for FIH. 
Experiments with both siRNAs were then used to validate possible phenotypes 
resulting from FIH attenuation, as two non-overlapping siRNA sequences will not 
have the same sequence-related off-target effects. An interferon-response (one 
type of off-target effect potentially caused by dsRNA) can be induced with siRNA; 
this was controlled by using an irrelevant siRNA. 
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4.2.2 Optimization of RNAi against FIH in cell lines 
Initial RNAi experiments were first performed on HeLa cells, a cervical cancer 
cell line. This was to establish whether the siRNA sequences would attenuate 
FIH. I assessed delivery of siRNAs into these cells, using 1µM siGLO® and 
immunofluorsence, and tested attenuation at the protein level using western 
blotting. siGLO® localisation in the nucleus indicates successful uptake of siRNA. 
Figure 4.2 shows successful siRNA delivery in HeLa cells, following transfection 
with siRNA siFIH #1 at a concentration of 50nM. 
 
 
 
 
 
 
 
 
 
Figure 4.2 RNAi optimisation 
siGLO® (1µM) was used to visualize the uptake of siRNA in HeLa cells. As part of 
optimization of this experiment, cells were transfected at two densities (30% and 50%) and 
were left for 48hours before immunofluorescence. The left hand panels show cell density. 
The right hand panels show results from immunofluorescent microscopy. siRNAs can be 
seen as brightly coloured ‘nuclei’. 
 
 
siGLO® is a transfection indicator and localisation into the nucleus confirms 
successful uptake; providing a visual assessment of siRNA transfection success. 
Two cell densities were used in order to test the delivery of siRNAs, as can be 
30 % 
confluence
50 % 
confluence
HeLa
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seen from the left hand panels in Figure 4.2. Cells were incubated with the 
siRNA for 48hours following transfection. At 50% and 30% confluency, cells 
treated with siRNA can be seen in the right hand panels (Figure 4.2), for both 
cell densities used, as brightly coloured ‘nuclei’. In subsequent experiments, I 
used 50nM concentration for my RNAi experiments using cells at 50% 
confluency. This was sufficient for siFIH #1 delivery and 50% confluency 
provided enough cells for further analysis following incubation and harvesting for 
RNA and protein extraction.  
 
 
 
 
 
 
Figure 4.3 FIH attenuation in HeLa cells 
Western blot using a 10% acrylamide SDS-PAGE gel, showing FIH attenuation in HeLa cells 
at protein level, transfected at 50% confluency with 50nM of siRNA targeting FIH (siFIH #1). 
A separate western blot was used to confirm equal loading by blotting for alpha-tubulin. FIH 
has been attenuated when comparing levels with the Firefliy Luciferase siRNA control (LUC) 
and a mock transfection/LipofectAMINE2000 only. Attenuation was evident in normoxia (N) 
and hypoxia (H). 
 
 
Attenuation of FIH was confirmed by use of a western blot. Cells were incubated 
in both normoxic and hypoxic (1% oxygen) conditions for comparison. 
Attenuation of FIH was achieved, both in normoxia and hypoxia (Figure 4.3). The 
antibody used to detect FIH was the same as that in experiments from the 
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previous chapter regarding FIH protein expression in organ samples, tumours 
and cell lines.   
In addition to establishing that this siRNA and transfection protocol is effective for 
knockdown of FIH in HeLa cells, the experiment provides useful validation of the 
polyclonal antibody. This is because it provides direct evidence that the single 
major species recognised by the antibody is FIH. 
For many experimental purposes, utilisation of rodent cells offers advantages 
over human material. For example, primary cardiac myocytes and cardiac 
myocyte cell lines are not available from humans; many aspects of cardiac cell 
biology are therefore examined in rat cardiac myocytes. I wished to use rat 
cardiac myocyte H9C2 cells in order to investigate potential effects on HIF 
targets following siRNA suppression of FIH. I therefore generated another three 
siRNA sequences in order to target rat fih mRNA, using the Target Finder 
algorithm. All three were then tested for FIH attenuation (Figure 4.4).  
 
 
 
 
 
 
 
 
Figure 4.4 Initial western blot analysis of three siRNAs targeting FIH in the rat 
siRNA 1 is showing greater attenuation of FIH levels and was therefore used to silence FIH 
in H9C2 cells in order to investigate potential effects on HIF activity. The indicated controls 
used Firefly luciferase siRNA in each case.  
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FIH #1 showed greater levels of FIH knockdown at protein level, when compared 
with the other two siRNA sequences targeting FIH. I therefore continued the 
experiment (using siFIH #1) to investigate what effect FIH attenuation would 
have on HIF target gene levels using this siRNA sequence in H9C2 cells. 
In these cells, hydroxylation of conserved proline residues in HIF-1alpha, 
catalysed by the PHD enzymes, will lead to proteosomal degradation. Therefore, 
to study the effects of attenuating FIH, I wished to examine conditions in which 
HIF-1alpha would be stabilised. To do this, I performed experiments at different 
oxygen tensions. RNAi was performed as in the HeLa cell line, with cells 
incubated for 2 days in normoxic conditions to allow for silencing to occur. After 
the 2 day period, cells were then placed in standard conditions or a hypoxic 
chamber, at 1% oxygen and 37°C. By using siRNAs against FIH and using Firefly 
luciferase siRNA as a control, it would be possible to study the effects of 
inhibiting FIH and the potential effect this will have on HIF target genes. 
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Figure 4.5 RNAi in H9C2 cells 
Representative western blot using an 10% polyacrylamide gel, showing FIH attenuation in 
H9C2 cells at protein level, transfected at 50% confluency with 50nM of siRNA targeting FIH 
(siFIH #1). FIH levels are attenuated in both normoxic (N) and hypoxic (H) (1% oxygen) 
conditions. 
 
Western blots revealed attenuation of FIH in both normoxia and hypoxia (Figure 
4.5). This had a statistically significant, but modest effect on HIF target gene 
GLUT-1, which was upregulated compared with the control siRNA, but not on the 
pro-apoptotic gene BNIP3, as revealed by RT-PCR (Figure 4.6). 
 
 
 
 
 
 
 
 
Figure 4.6 HIF target genes in H9C2 cells 
RTPCR showing levels of HIF target gene mRNA when attenuating FIH in hypoxia. GLUT-1 
levels increase when attenuating FIH in hypoxia. However, levels of BNIP3 were not 
affected. Significance is shown against the control siRNA (siLUC). ±SE, n=3. 
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A recent report suggested that BNIP3 is not increased by FIH inhibition in a  
human colon carcinoma cell line (Dayan et al., 2006). My results are consistent 
with this report, as it appears BNIP3 mRNA is not increased by FIH manipulation 
in rat cardiac myocyte H9C2 cells (Figure 4.6).  
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4.2.3 RNAi against FIH in primary cell lines 
Primary cells serve as an important model system for gene function analysis, 
target validation, and drug discovery since they are more similar to their in vivo 
counterparts than are immortalized cells. However, delivery of siRNAs into these 
cells has proven to be a challenge (Ovcharenko et al., 2005; Stewart et al., 
2003). The main reason for this is that serum-free media must be used in an 
siRNA transfection assay, to protect against the actions of nucleases on the 
siRNA. Primary cells, however, may lose viability in this serum-free setting. 
Initial RNAi experiments were performed in human fibroblasts using 50nM 
concentration of siRNA, as used in transfections already described (Methods and 
Materials chapter).  This meant using serum-free media for an initial 4 hour 
period, before overlaying the cells with FBS, p/s and glu. This proved to provide 
efficient siRNA delivery into the fibroblasts, without the loss of cell viability.  
Figure 4.7 shows successful attenuation in human fibroblasts, both in normoxic 
and hypoxic (1% O2) conditions. Additionally, attenuating FIH modestly 
increased the protein levels of the HIF target gene GLUT-1, in both normoxic and 
hypoxic conditions, compared with control levels (untreated, mock transfection 
and siLUC). This is consistent with the idea reported by Stolze et al. in 2004, that 
FIH attenuates HIF activity, even in hypoxia. 
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Figure 4.7 Western blot showing levels of FIH and GLUT-1 in a primary cell line 
Human fibroblasts were transfected with 50nM siRNA targeting FIH. The attenuation of FIH 
was tested in normoxic and hypoxic (1% O2) conditions. In both normoxia and hypoxia, there 
is comparable FIH expression at protein level in control samples (untreated [U], mock 
transfection [Mock] and Firefly luciferase siRNA [LUC]). FIH is clearly attenuated in both 
conditions. In hypoxia, levels of HIF target gene GLUT-1 are increased. FIH attenuation 
results in a further increase (although relatively small) in GLUT-1 in hypoxia (compare lane 8 
with 5, 6 and 7).  
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4.3 Conclusion 
The siRNAs generated, targeting both human and rat FIH, show significant levels 
of FIH attenuation, both at protein level and mRNA level, as revealed by western 
blotting and RT-PCR respectively. A concentration of 50nM siRNA provided 
sufficient suppression of FIH in all cell lines tested, as well as primary fibroblasts. 
RNAi against FIH has also provided further validation of the antibody used in the 
previous chapter to investigate FIH expression. Levels of FIH are clearly 
decreased in western blots when immunoblotting lysates made from cells 
transfected with siRNAs targeting FIH.  
Furthermore, attenuation of FIH in H9C2 and fibroblast cells provide some 
evidence of FIH influencing gene expression, as revealed by the resulting 
increases in HIF target gene GLUT-1 mRNA (H9C2) and GLUT-1 protein 
(fibroblasts) levels. 
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5 Distinct regulation of HIF by FIH in renal cancer 
5.1 Introduction 
VHL defective CCRCC cells are an attractive system for studying FIH function 
because the HIF destruction pathway is disabled. In other settings, the effect of 
perturbing FIH function (for example through hypoxia, small molecule antagonists 
or genetic manipulation) may not be evident because the prolyl hydroxylation and 
VHL destruction pathway will operate normally. 
As well as providing a useful tool, there is an important biological question. The 
fact that the HIF pathway is active in VHL defective CCRCC cell lines and clinical 
renal cancer specimens in the presence of oxygen has suggested that FIH either 
does not operate in renal epithelium, or that if it does it might be downregulated 
or inactivated in CCRCC. However, FIH mutations have not been found, and a 
transfected CTAD shows an oxygen dependent interaction with p300 (Morris et 
al., 2004; Yan et al., 2007). FIH mutation analysis was performed by Morris et al. 
(2004) by single stranded conformational polymorphism and direct sequencing of 
PCR products. No evidence of mutation was found in sporadic CCRCC. Yan et 
al. (2007) found that the HIF-2alpha NTAD is capable of activating both artificial 
and naturally occurring HIF-responsive promoters in the absence of the CTAD. 
Previous reports by Datta et al. (2004) and Li J et al. (2007), using 786-O and 
A498 cells, suggested that HIF escapes inactivation by FIH under normoxic 
conditions in CCRCC. They have shown that in 786-O (HIF-1alpha not 
expressed) and A498 (HIF-1alpha mutation and not functional) CCRCC cells, a 
signalling event involving PI3K and PKC-ζ represses the total mRNA level of FIH, 
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thus allowing the association of p300 with HIF-1alpha and HIF-2alpha, leading to 
transcriptional activation.  
Additionally, my own experiment on renal cancer samples, described in Chapter 
3, does show FIH expression in cancerous kidney tissue. Using a western blot 
and RT-PCR, FIH protein and mRNA was expressed, with no evidence of 
downregulation in CCRCC. 
In this chapter I investigate whether FIH is active in renal cancer using several 
different approaches. First, I examined the effect of FIH attenuation using 
hypoxia and DMOG in VHL defective CCRCC cell lines RCC10 and RCC4 cells. 
These manoeuvres suggested that FIH does operate in these two cell lines, but 
will have other effects besides inhibiting FIH. To address this, I went on to 
perform experiments with FIH specific siRNAs in RCC10, RCC4 and 786-O.  
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5.2 Results 
5.2.1 Inhibition of FIH by hypoxia and DMOG increases HIF activity 
Since FIH requires oxygen for the enzyme reaction, it would be predicted that 
hypoxia would inhibit FIH in CCRCC cell lines (RCC10 and RCC4). RT-PCR was 
used to probe levels of HIF target genes. Levels of HIF target genes provided 
information on the level of HIF activity following FIH attenuation. 
FIH has greater oxygen binding affinity than the PHD enzymes (Koivunen et al., 
2004) and known to function even in severe hypoxia (~0.2% oxygen) (Stolze et 
al., 2004), so I exposed renal cancer cells to a very low oxygen level of 0.1%, in 
order block FIH activity further, as well as 1% oxygen. As Figure 5.1 reveals, I 
found increased mRNA levels of four validated HIF-alpha target genes GLUT-1, 
PHD3, VEGF and BNIP3 in RCC10 cells at 0.1% and 1% oxygen. This would be 
consistent with FIH attenuation decreasing HIF transactivation in the presence of 
oxygen in this CCRCC.  
 
 
 
 
 
 
 
Figure 5.1 HIF target gene levels in RCC10 cells 
Levels of HIF target gene mRNA in RCC10 cell line after exposure to hypoxia for 16hours. 
Severe hypoxia (0.1% oxygen) clearly upregulates HIF targets genes. Statistical significance 
(*) is against the normoxic control. ±SE, n=3. 
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To determine if this can be applied in a different renal cancer cell background, I 
performed the same experiment in the RCC4 cell line (Figure 5.2). 
 
 
 
 
 
 
 
 
Figure 5.2 HIF target gene levels in RCC4 cells 
Levels of HIF target gene mRNA in RCC4 cell line after exposure to hypoxia for 16hours. 
Severe hypoxia (0.1% oxygen) clearly upregulates HIF targets in both cell lines. ±SE, n=3. 
 
Results obtained from experiments performed in the RCC4 cell line were 
consistent with that from RCC10, with upregulation of four HIF-alpha target 
genes in hypoxia, and in general a greater effect of 0.1% oxygen than 1% 
oxygen. 
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5.2.2 Inhibition of FIH by DMOG increases HIF activity 
2-OG is required as a substrate for FIH and PHD1-3 activity. N-oxalyl glycine 
inhibits the enzymes by competing with 2-OG. DMOG is an esterified form of N-
oxalyl glycine which penetrates cells effectively (Epstein et al., 2001).  
I have used DMOG as a pharmacological probe to antagonise FIH activity. It 
should be borne in mind that this will inhibit the action of the PHD enzymes and 
other 2-OG-dependent dioxygenases. However, this is less of an issue in VHL 
defective renal carcinoma cells, in which HIF destruction is disabled downstream 
of prolyl hydroxylation. Nevertheless, transactivation by the NTAD has been 
reported to be influenced by prolyl hydroxylation, so effects of DMOG on HIF 
target genes in VHL-defective CCRCC may not be entirely mediated by FIH. 
Interestingly, although it might be predicted that DMOG would have effects on 
other enzymes which use 2-OG, in array studies the effects correlate rather 
remarkably with those due to HIF activation (Hagg and Wennstrom, 2005).  
To test the concept of FIH function in CCRCC further, I treated RCC10 cells with 
DMOG, a hydroxylase inhibitor. A concentration of 500µM was used.  
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Figure 5.3 Levels of HIF target gene mRNA in RCC10 cells 
Levels of HIF target gene mRNA in RCC10 cells after exposure to DMOG for 16hours. 
DMOG (500µM concentration) upregulates HIF target genes. Significance (*) shown against 
the untreated control. ±SE, n=3. 
 
 
Figure 5.3 shows the effect of DMOG on levels of HIF targets in RCC10 cells. 
Once again, I tested whether this can be applied in another renal cancer cell 
background (RCC4 cells). Figure 5.4 below shows that, as with the RCC10 cell 
line, DMOG increases levels of the four HIF target genes analyzed. 
 
 
 
 
 
 
 
 
Figure 5.4  Levels of HIF target gene mRNA in RCC4 cells 
Levels of HIF target gene mRNA in RCC4 cells after exposure to DMOG for 16hours. As with 
the RCC10 cell line, DMOG (500µM concentration) upregulates HIF target genes in RCC4 – 
with the exception of BNIP3 (ns). ±SE, n=3. 
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Since prolyl hydroxylation is not able to promote HIF degradation due to VHL 
mutation, we have presumed that any further increase on HIF activation will be 
due to the attenuation of the FIH asparaginyl hydroxylation by DMOG. Indeed, 
Figures 5.3 and 5.4 show that treatment of CCRCC cells with DMOG further 
increases HIF activation. 
A caveat is that neither hypoxia nor DMOG are specific methods of 
downregulating FIH. The PHD enzymes would also be inhibited by both these 
methods and this experiment is based on the assumption that prolyl 
hydroxylation has no effect on HIF transactivity. 
For this reason short-interfering RNA (siRNA) was used to target FIH specifically. 
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5.2.3 FIH attenuation using RNA interference (RNAi) in renal cancer 
cells 
To test whether FIH does function in renal cancer cells, I developed RNA 
interference (RNAi), as described in chapter 4, to specifically inhibit FIH. If the 
hypothesis that FIH does not function in renal cancer is correct, attenuation of 
FIH would not influence expression of HIF targets.  
Following successful attenuation of FIH and showing upregulation of a HIF target 
gene as a result in the previous chapter (in H9C2 cells), using the same methods 
I sought to suppress FIH expression in renal cancer cell lines. RCC10 cells were 
initially used to test the siRNAs targeting human FIH.  Two concentrations of 
siRNA were used; 25nM and 50nM, and westerns blots showed attenuation at 
the protein level (Figure 5.5).  
 
 
 
 
 
Figure 5.5 Attenuation of FIH in renal cancer cell line RCC10 
Western blot showing attenuation of FIH in renal cancer cell line RCC10. 50nM and 25nM 
concentrations of siRNA were compared. Both concentrations attenuated FIH at protein 
level.  
 
 
A concentration of 50nM provided sufficient attenuation of FIH. I then transfected 
RCC10 cells with both siRNAs generated for human FIH, at a concentration of 
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50nM.  Attenuation of FIH was investigated at mRNA and protein level using RT-
PCR and western blotting respectively.  
 
 
 
 
 
 
 
 
Figure 5.6 Attenuation of FIH mRNA in RCC10 cells 
RT-PCR confirms attenuation of FIH at mRNA level in RCC10 cells. siFIH #2 produces 
greater knockdown compared with siFIH #1. ±SE, n=3. 
 
 
Figure 5.6 reveals successful attenuation of FIH at the mRNA level in RCC10 
cells, for both the siRNA sequences targeting FIH and a western blot showed 
attenuation at the protein level (Figure 5.7). 
 
 
 
 
 
Figure 5.7 Attenuation of FIH protein in RCC10 cells 
Western blot showing attenuation of FIH in  RCC10 cells. 50nM concentration of siRNA were 
used for both siRNAs. FIH is attenuated when comparing with the control siRNA (siLUC) and 
mock transfection (LipofectAMINE2000 only).  
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I then used RCC4 cells to perform the same RNAi experiment. Once again, FIH 
was attenuated at mRNA level using both siRNAs (Figure 5.8). Additionally, at 
mRNA level, siFIH #2 produced a better knockdown of FIH than did siFIH #1 as 
seen in the RCC10 cell line. 
 
 
 
 
 
 
 
 
Figure 5.8 Attenuation of FIH mRNA in RCC4 cells 
RT-PCR confirms attenuation of FIH at mRNA level in RCC4 cells. siFIH #2 produces 
greater knockdown compared with siFIH #1. These results are similar to those obtained in 
RCC10 cells. ±SE, n=3. 
 
 
A western blot also confirmed the attenuation of FIH protein in RCC4 (Figure 
5.9). 
 
 
 
 
 
Figure 5.9 Attenuation of FIH protein in RCC4 cells 
Western blot showing attenuation of FIH in RCC4 cells. As with RCC10 cells, 50nM 
concentration of siRNA were used for both siRNAs. FIH is attenuated when comparing with 
the control siRNA (siLUC) and mock transfection (LipofectAMINE2000 only).  
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Both siRNAs successfully attenuated FIH, both at protein and mRNA level. From 
the data, siFIH #2 was used for future experiments since there was greater 
attenuation of FIH with this particular sequence. siFIH #1 was therefore used to 
confirm any potential phenotypes resulting from FIH attenuation with siFIH #2. 
My previous data using hypoxia and DMOG suggested that FIH may decrease 
HIF activity in RCC10 and RCC4. To examine this directly I now used siRNA to 
knockdown FIH specifically. I performed RT-PCR on cDNA generated from RNA 
extracted from both RCC10 and RCC4 cells transfected with siFIH #2. I probed 
for HIF target genes GLUT-1 (metabolism), PHD3 (HIF regulation), VEGF 
(angiogenesis) and BNIP3 (apoptosis). HIF target gene levels were significantly 
increased upon FIH attenuation (Figure 5.10). 
 
 
 
 
 
 
 
 
Figure 5.10 HIF target genes following FIH attenuation 
RT-PCR showing levels of HIF target genes when attenuating FIH, in comparison with 
control siRNA, in RCC10 and RCC4 cells. Attenuating FIH increased levels of HIF target 
gene mRNA in RCC10 and RCC4 cells, with the exception of BNIP3 in RCC4. Results show 
FIH indeed functions in both clear cell renal carcinoma cell lines. ±SE, n=3. 
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An increase in HIF targets was evident in both cell lines (with the exception of 
pro-apoptotic gene BNIP3 in RCC4). The results implied that FIH may indeed 
function to inhibit HIF in renal cancer. In order to verify this finding at the protein 
level, lysates from RCC10 cells were blotted for HIF target GLUT-1 (Figure 
5.11). 
 
 
 
 
 
 
Figure 5.11 Upregulation of GLUT-1 protein following FIH attenuation 
Western blot showing attenuation of FIH resulting in a significant increase in HIF target 
GLUT-1. Lanes 1 and 2 should be compared with controls LUC, negative/scrambled 
sequence NEG (Ambion), a mock transfection and lysate from untreated RCC10 cells (U). 
Both siRNAs resulted in an increase in the level of GLUT-1 protein, implying FIH is functional 
in this renal cancer cell line. As an additional control, attenuating HIF-1alpha decreased 
GLUT-1 levels confirming it as a HIF target.  
 
 
The results show clear evidence for FIH functioning in these two CCRCC cell 
lines. As can be seen, results were reproducible at the protein level with siFIH #1 
(Figure 5.11).  
By using two different non-overlapping siRNA sequences independently, I have 
observed a significant reduction of FIH at mRNA and protein level in RCC10 and 
RCC4. In addition, I have reproducibly observed further increases in HIF-alpha 
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target gene mRNA levels as well as GLUT-1 protein levels, confirming that FIH is 
active in renal cancer.  
An important consideration however is that FIH may also exert a non-enzymatic 
influence on HIF activity. This is because FIH binding to the CTAD of HIF-alpha 
could in theory directly compete with p300/CBP binding. However, a mutant form 
of FIH (inactive due to Asp201 to Asn mutation at the catalytic site of FIH) did not 
suppress HIF activity (Stolze et al., 2004).  
Next, I performed the same RNAi experiment in 786-O cells (Figure 5.12). The 
786-O cell line exclusively expresses the HIF-2alpha isoform, with HIF-1alpha 
not being detectable at protein level. Previous reports (e.g. Datta et al. in 2004) 
have used 786-O cells and went on to suggest that FIH does not function in 
CCRCC. 
 
 
 
 
 
 
 
   A     B 
Figure 5.12 RNAi in 786-O cells 
(A) RT-PCR showing FIH attenuation in 786-O cells. ~75% knockdown of FIH mRNA was 
achieved with siFIH #2 when comparing with levels in the control pool transfected with 
siLUC. (B) Levels of HIF target genes in 786-O when attenuating FIH with siRNA. In contrast 
to RCC10 and RCC4 cells, inhibiting FIH does not upregulate HIF target gene levels in this 
cell line. In fact, for GLUT-1 mRNA, there appears to be a decrease in levels when 
attenuating FIH. ±SE, n=3. 
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The siRNA attenuated FIH (Figure 5.12A) and using RT-PCR I once again 
probed for HIF target genes in this cell background. FIH did not appear to be 
decreasing HIF activation, since I found that FIH siRNA has no significant effect 
on HIF target gene expression in 786-O cells (Figure 5.12B). This contrasted 
with my findings in RCC10 and RCC4 cells.  
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5.2.4 Overexpression of FIH has little effect on HIF transactivation of 
HIF target genes 
In both RCC10 and RCC4 cells there is striking evidence of HIF activation 
compared with stable transfectants with VHL (Krieg et al., 2000; Maxwell et al., 
1999). One possible explanation for this could be that the amount of FIH 
expressed in RCC10 and RCC4 is insufficient to suppress HIF completely. 
Although my experiments have shown that FIH is decreasing the effect of HIF in 
RCC10 and RCC4 cells, it is clear that this inhibition is incomplete. To test this, I 
then decided to overexpress FIH in RCC10 cells in order to investigate whether 
this would attenuate HIF activity further.  
I ligated a full length FIH cDNA into a retroviral vector (pCMV) and used this to 
express FIH in RCC10 cells. A Pk-tag was incorporated with the FIH sequence to 
enable detection of exogenous FIH (Figure 5.13). The Pk-tag encodes the 
sequence Gly-Lys-Pro-Ile-Pro-Asn-Pro-Leu-Leu-Gly-Leu-Asp-Ser-Thr from P and 
V proteins on the paramyxovirus of simian virus 5 (Dunn et al., 1999). There are 
excellent monoclonal antibodies to the Pk epitope allowing secure detection of 
recombinant proteins expressing the epitope.   
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Figure 5.13 FIH dimer structure 
Diagram showing the FIH dimer crystal structure and the position of the Pk-tag (Pk structure 
is not shown) used to detect expression of exogenous FIH in RCC10 cells transfected with 
the pCMVR-FIHPk plasmid. Monomers are shown in red and yellow (Mol A and Mol B). 
Adapted from a figure by Lee et al., 2003.  
 
 
10ng of the insert was used in the ligation reaction. The insert:vector ratio was 
1:3 and the reaction was incubated overnight at 16°C. Ligation reactions were 
transformed into chemically-competent E. coli (DH5α). Bacteria were grown 
overnight and positive clones were picked and grown in an ampicilin broth for an 
additional cycle. Several colonies were then picked and a mini-prep was 
performed using a Qiagen kit, according to the manufacturer’s instructions. To 
check for positive clones, several digestion reactions using restriction enzymes 
were performed. The initial digest was performed using AseI and XhoI. An 
additional digest using PstI was performed as this is within the FIH cloning 
region. Bands were analysed on a 2% agarose gel to confirm successful ligation 
(data not shown). The pCMVR-FIHPk plasmid was then transfected into the viral 
packaging Phoenix cell line (25µg of plasmid DNA was used). The supernatant 
Pk-tag at C-terminus
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from this cell line, containing the viruses that will transfer the FIH cDNA, was then 
used to infect RCC10 cells. G418/neomycin selection (1.5µg/ml) to select for 
cells expressing exogenous FIH was added to culture media for 2 weeks before 
harvesting for protein and mRNA for further analysis. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.14 Western blot reveals expression of exogenous FIH 
Western blot reveals expression of exogenous FIH, tagged with the Pk epitope, in cells 
transfected with the pCMVR-FIHPk plasmid. The mobility of the band detected using a Pk 
antibody was the same as that for FIH (~40.7kDa). As expected, this is not detected in the 
empty vector control (pCMVR). Levels of FIH are also increased, in comparison with the 
empty vector transfection. 
 
 
Western blots revealed a band, when using antibodies to the Pk-tag, with similar 
mobility to FIH in a 10% polyacrylamide gel (~40.7kDa), as well as an increase in 
FIH levels (Figure 5.14).  
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Furthermore, analysis of mRNA levels using RT-PCR confirmed a ~6-fold 
increase in FIH mRNA when compared with levels in RCC10 cells infected with 
the empty vector (negative control) (Figure 5.15). 
 
 
 
 
 
 
 
Figure 5.15 Increase in FIH mRNA levels from cells infected with pCMVR-FIHPk 
RT-PCR showing a ~6-fold increase in FIH mRNA levels from cells infected with pCMVR-
FIHPk, compared with the empty vector control transfection (pCMVR). ±SE, n=2. 
 
 
 
 
 
 
 
 
Figure 5.16 HIF target gene levels following FIH overexpression 
RT-PCR showing HIF target gene levels following FIH overexpression. The overexpression 
of FIH did not block HIF activity. Only a moderate reduction in HIF activity was seen in cells 
transfected with the pCMVR-FIHPk plasmid. ±SE, n=3. 
 
The ~6-fold increase in FIH mRNA only produced a moderate reduction of three 
HIF target genes – namely GLUT-1, VEGF and PHD3 (Figure 5.16), at the 
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mRNA level, none of which were statistically significant. No reduction in GLUT-1 
protein was evident (data not shown). These effects are much less than the 
effect of expressing VHL, which results in a ~3.5-fold reduction in VEGF and ~5-
10-fold reduction in PHD3, according to a recent report (Esteban et al., 2006). 
An attractive explanation for these results would be that FIH is only inhibiting one 
isoform of HIF-alpha (i.e. HIF-1alpha). Overexpressing FIH therefore would 
diminish HIF activity incompletely due to the continuing activity of the second 
HIF-alpha isoform. This may also explain (1) the sub-maximal inhibition FIH 
exerts on HIF activity in renal cancer and (2) the lack of response from HIF target 
genes when attenuating FIH in 786-O cells, which exclusively express the HIF-
2alpha isoform.  
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5.2.5 FIH attenuation in 786-O cells expressing HIF-1alpha increases 
HIF transactivity 
Attenuating FIH in 786-O cells did not affect HIF target gene expression (Figure 
5.12, pg. 135). Although is has been previously suggested that FIH is not present 
in these cells, my results are consistent with an alternative possibility. This is that 
HIF-2alpha is protected from the inhibitory effects of FIH asparaginyl 
hydroxylation in this setting. To test this, I expressed HIF-1alpha in 786-O cells 
and performed RNAi against FIH. This would potentially show that (1) FIH is 
functional in this cell line and (2) provide further evidence of preferential inhibition 
of the HIF-1alpha isoform. To express HIF-alpha I used a retroviral vector, 
pBMNz, kindly provided by Dr. R. Raval and Prof. P. J. Ratcliffe. 
Western blot analysis revealed exclusive expression of the HIF-2alpha isoform in 
a pool of parental 786-O cells expressing an empty vector (pBMNz) (Figure 
5.17A). 
 
 
 
 
 
   A         B 
Figure 5.17 HIF-1 expression in 786-O cells 
(A) Western blot showing expression of HIF-1alpha in a pool of 786-O cells transfected with 
the pBMNz-HIF1α plasmid. Blots also show the attenuation of FIH in both pools using siFIH 
#2. (B) FIH attenuation in two pools of 786-O cells at mRNA level. FIH has been silenced in 
both the empty vector control pool (expressing HIF-2alpha only) and the pBMNz-HIF1α pool 
(expressing HIF-1alpha and HIF-2alpha). ±SE, n=3. 
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Expression of cloned HIF-1alpha in a separate pool of 786-O cells (stable 
transfectants pBMNz-HIF-1alpha) was also confirmed by western blot (Figure 
5.17A). I next blotted for CAIX, as this is a HIF-1alpha specific target gene in this 
cell background (Raval et al., 2005). CAIX blots confirmed expression of this HIF-
1alpha specific target exclusively in the stable transfectant pBMNz-HIF-1alpha 
pool (Figure 5.18).  
 
 
 
 
 
 
 
 
Figure 5.18 Western blot showing CAIX expression 
CAIX is exclusively a HIF-1alpha target gene. Expression is therefore only expected in the 
786-O cells in which HIF-1alpha has been introduced via a viral vector (pBMNz-HIF1α). 
Where FIH is attenuated, a further increase in this HIF target is evident. 
 
 
The siRNA targeting FIH attenuated FIH in both pools of 786-O cells (pBMNz 
and pBMNz-HIF-1alpha), at mRNA and protein level (Figure 5.17A and B).  
In the pBMNz transfected pool, in which there is exclusive expression of HIF-
2alpha, attenuation of FIH did not affect HIF transactivation when observing HIF 
target gene levels, in comparison with the siLUC control.   
 
siLUC siFIH
CAIX
siRNA
p
B
M
N
z
p
B
M
N
z
H
IF
1
α
p
B
M
N
z
p
B
M
N
z
H
IF
1
α
α-tubulin
p
B
M
N
z
p
B
M
N
z
H
IF
1
α
p
B
M
N
z
p
B
M
N
z
H
IF
1
α
Chapter 5 - Results 
 144 
However, in pBMNz-HIF-1alpha, FIH attenuation augmented HIF target gene 
levels of PHD3, VEGF and the pro-apoptotic gene BNIP3 (Figure 5.19) and 
increased expression of CAIX protein (Figure 5.18). These results imply that FIH 
may only function to inhibit the HIF-1alpha isoform in this setting, explaining the 
incomplete inhibition of HIF activity in renal cancer despite the presence of FIH. It 
is notable that HIF-2alpha can function when lacking the CTAD, according to 
reports (Yan et al., 2007); this is the region of HIF-alpha where the Asn residue 
hydroxylated by FIH is found. This is consistent with the data shown here. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.19 Increase in HIF activity is HIF-1alpha dependent 
RT-PCR results show that an increase in HIF target gene levels/HIF activity using siFIH #2 
(PHD3 [top]), VEGF [left], BNIP3 [right]), following attenuation of FIH in 786-O cells, is HIF-
1alpha dependent. Results are reproducible using two siRNAs with non-overlapping 
sequences targeting FIH data not shown). ±SE, n=3. 
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These results show that functional FIH is present in 786-O cells, but that the HIF-
2alpha normally present is resistant to its action. Three explanations could be 
considered; (1) HIF-2alpha is inherently resistant to the effect of FIH, and this 
may apply in all cell types, (2) HIF-2alpha is subject to a post-translational 
modification (e.g. phosphorylation) in 786-O cells, which protects it from FIH or 
(3) HIF-2alpha is mutated in 786-O cells, and the mutant protein is resistant to 
FIH. 
To test whether the HIF-2alpha subunit is mutated in 786-O cells (and hence 
active in the presence of FIH), I expressed exogenous HIF-2alpha via a viral 
vector into the cell line to determine the functional effect, by comparing the 
transactivation potential with wild type HIF-2alpha. This would determine whether 
overexpression of HIF-2alpha by retroviral gene transfer also produces sensitivity 
to FIH siRNA, which would strongly support a cis mutation in HIF-2alpha. In 
parallel, I introduced HIF-1alpha into the 786-O cells as a repeat of the previous 
experiment, and also performed an empty vector transfection. Phoenix cells were 
transfected with 25µg of the relevant plasmid DNA and resulting supernatant was 
then used to infect 786-O cells.  
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Figure 5.20 is a western blot showing the expression of both HIF-1alpha and 
HIF-2alpha in infected 786-O cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.20 HIF-alpha expression in 786-O pools 
A western blot showing expression of exogenous HIF-2alpha in 786-O cells. 786-O cells 
express the HIF-2alpha isoform exclusively, and levels are greater when infected with the 
pBMNzHIF2 plasmid (left hand panels). Additionally, HIF-1alpha was also introduced via the 
pBMNzHIF1 plasmid in a separate pool of 786-O cells (right hand panels). A signal is visible 
at ~120kDa only in the pBMNzHIF1 transfected pool and the RCC10 lysate (positive control). 
 
From Figure 5.20 it can also be seen that HIF-2alpha levels are increased in 
786-O pools transfected with pBMNzHIF2 (left hand panels). HIF-1alpha is only 
expressed in 786-O pools transfected with pBMNzHIF1. Additionally, it does also 
appear that the expression of exogenous HIF-1alpha has increased HIF-2alpha 
levels (left hand panels, compare pBMNz levels with pBMNzHIF1). This may be 
the result of HIF-1alpha sequestering VHL away from HIF-2alpha. However, this 
observation was not investigated further.  
RNAi was performed to target FIH in both 786-O pools and the effect on HIF 
target genes were compared with FIH attenuation in the empty vector transfected  
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Figure 5.21 Attenuation of FIH in 786-O pools 
RT-PCR showing attenuation of FIH mRNA in all three 786-O stable transfectant pools. n=2, 
±SE. 
 
control. An RT-PCR was used to confirm suppression of FIH at mRNA level 
(Figure 5.21).  For each 786-O pool, there is clear attenuation of FIH mRNA 
when comparing levels with the control siRNA. I then probed for the HIF target 
gene BNIP3 (Figure 5.22). 
 
 
 
 
 
 
 
 
 
 
Figure 5.22 HIF-1alpha-dependent increase in BNIP-3 
BNIP3 mRNA upregulation following attenuation of FIH appears to be principally HIF-1alpha-
dependent. However, overexpressing HIF-2alpha had a very small effect – attenuating FIH in 
this setting produced a modest but statistically significant increase in HIF-2alpha 
transactivity. n=2, ±SE. 
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Attenuating FIH had a much greater effect on levels of BNIP3 mRNA in the HIF-
1alpha pool of 786-O cells, compared with the very modest increase in the 786-
O/HIF2 pool. This is consistent with previous data that I have shown in this 
thesis, describing HIF-2alpha as more resistant to FIH inhibition than HIF-1alpha 
and also suggests that a mutation specific to HIF-alpha subunits in 786-O cells is 
unlikely. 
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5.3 Conclusion 
Exposing CCRCC cells RCC10 and RCC4 to hypoxia (0.1% and 1% oxygen) for 
16 hours increased levels of HIF target genes at mRNA level. In low oxygen, FIH 
activity will decrease and allow for increased HIF transcriptional activity due to 
the lack of co-substrate. Both the RCC10 and RCC4 cell lines are VHL defective 
(Alberghini et al., 2005), therefore any effect on HIF activity in hypoxia is likely to 
be due to decreased FIH activity, since it cannot be due to decreased VHL-
mediated destruction. DMOG at 500µM concentration also increased HIF activity. 
DMOG is an analogue of the co-substrate 2-OG and exposing RCC10 and RCC4 
cells to this (for 16 hours) will inhibit the hydroxylation of the conserved 
asparagine residue of HIF-alpha by FIH. HIF activity increased on exposure to 
DMOG, consistent with the possibility that FIH is functioning in both cell lines and 
inhibits HIF activity. However, both of these methods used to inhibit FIH will also 
have non-specific effects. For instance, both hypoxia and DMOG will also inhibit 
the activity of the three PHD enzymes.  
The usual route by which PHD activity regulates HIF is by providing the signal for 
VHL-mediated destruction. While this is not the case in these VHL-defective 
cells, it remains possible that PHDs regulate VHL-independent destruction of 
HIF-alpha and/or alter the transactivation activity of the NTAD. There is published 
data to support the latter possibility (Yan et al., 2007). Yan et al. (2007) 
suggested that NTAD is necessary for transcriptional activation of HRE-regulated 
genes, when they assayed levels of HIF targets such as VEGF when expressing 
a HIF-2alpha variant with a non-functional NTAD. A caveat they also describe in 
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these experiments is that the NTAD deletion may have affected the folding of the 
CTAD, or its proper orientation once bound to DNA (Yan et al., 2007). 
RNAi against FIH was used as it is a much more direct method to inhibit a 
specific target. With the exception of BNIP3 in RCC4 cells, suppression of FIH 
using RNAi increased levels of HIF target genes in RCC10 and RCC4, at mRNA 
and protein level. This provided strong evidence that FIH does indeed function in 
both these renal cancer cell lines to inhibit HIF activity in normoxia. In contrast, 
the 786-O cell line, which exclusively expresses the HIF-2alpha isoform, does not 
appear to respond to FIH attenuation.  Instead, suppressing FIH has no positive 
effect on HIF target gene mRNA levels. 
Therefore FIH is functioning in CCRCC cells RCC10 and RCC4. However, some 
HIF-alpha subunits clearly escape the inhibitory effect of asparaginyl 
hydroxylation. Also, all HIF-alpha subunits appear to escape inhibition by FIH in 
786-O cells. By introducing exogenous HIF-1alpha, via a viral vector, into 786-O 
cells it is clear FIH does function in this cell line and implies that HIF-2alpha may 
be resistant to FIH. In contrast, exogenous wildtype HIF-2alpha was not inhibited 
by FIH in this cell line.  
The likely conclusion from this is that HIF-2alpha is effectively resistant to FIH. 
Support for this idea comes from the recent publication by Yan et al. (2007), as 
mentioned earlier, which describes the transactivity of HIF-2alpha not requiring 
the CTAD region in order to function and upregulate HIF target gene levels. It 
can therefore be predicted that FIH selectively inhibits HIF-1alpha. Inhibiting FIH 
would therefore increase HIF-1alpha target genes specifically, and this makes 
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FIH a possible target for inhibition in some CCRCC. This is because there is 
good evidence that HIF-1alpha is anti-tumourigenic in the context of CCRCC 
(Metzen et al., 2005; Raval et al., 2005),  and HIF-1alpha expression has already 
been shown to have beneficial effects in lung cancer (Volm and Koomagi, 2000). 
In their study they had examined whether a relationship existed between HIF-
1alpha and proliferation and apoptosis in lung cancer. Using 
immunohistochemistry, they had analyzed HIF-1alpha in formalin-fixed, paraffin-
embedded, non-small cell lung carcinomas, comparing the HIF expression with 
cyclin A protein expression, cell cycle phases, the apoptotic index and the 
expression of caspase 3, Fas and Fas ligand. There was a significant correlation 
between HIF-1alpha expression, apoptosis and pro-apoptotic factors such as 
caspase 3. They also examined whether HIF-1alpha determinations can improve 
the prognostic information concerning a patient's overall survival. Patients with 
HIF-1alpha-positive carcinomas had significantly longer median survival times 
than patients with HIF-1alpha-negative carcinomas (Volm and Koomagi, 2000).  
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6 FIH is a potential therapeutic target for inhibition in clear 
cell renal carcinoma 
6.1 Introduction 
Enhanced HIF activation in cancer has been implicated in tumour growth and 
tumour survival. Carmeliet et al. in 1998 showed that hypoxia reduces 
proliferation and increase apoptosis in wild-type hif-1alpha+/+ embryonic stem 
(ES) cells, but not in hif-1alpha-/- ES cells. They also found that genes regulated 
by hypoxia, involved in controlling the cell cycle, are either HIF-1alpha-dependent 
(p53, p21, Bcl-2) or HIF-1alpha-independent (p27, GADD153), therefore 
suggesting at least two different adaptive responses to being deprived of oxygen 
and nutrients. Importantly, HIF-1alpha was found to reduce hypoxia-induced 
expression of VEGF, preventing the formation of large vessels in ES-derived 
tumours, impairing vascular function, resulting in hypoxic microenvironments 
within the tumour. However, the growth of HIF-1alpha tumours was not 
diminished but in fact accelerated, due to decreased hypoxia-induced apoptosis 
and increased stress-induced proliferation. Furthermore, they had shown that 
apoptosis was comparable in HIF-1alpha+/+ and HIF-1alpha-/- ES cells during 
normoxia. In contrast, during hypoxia, apoptosis increased significantly (~10–30-
fold) in HIF-1alpha+/+ ES cells but unaffected in HIF-1alpha-/- ES cells. Hypoxia 
also induced apoptosis in wild-type Chinese hamster ovary (CHO) C4.5 cells 
(which express HIF-1alpha) but not in HIF-1alpha-deficient CHO Ka13 cells. 
They concluded therefore that HIF-1alpha may be a general mediator of hypoxia 
driven apoptosis (Carmeliet et al., 1998).  
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Transactivation involving the HIF-1alpha subunit therefore potentially includes a 
sub-set of genes that are pro-apoptotic, and overexpression of HIF-1alpha has 
already been shown to reduce growth of lung and renal cancer (Greijer and van 
der, 2004; Volm and Koomagi, 2000). In contrast, a sub-set of HIF-2alpha genes 
have been linked to increased tumour aggression and metastasis, according to 
Yan et al., in 2007.   
A consequence of selective HIF-1alpha activation, through the attenuation of FIH 
for instance, may therefore be tumour suppressive, at least in CCRCC.  
In this chapter, I have compared proliferation of CCRCC cells RCC10, RCC4 and 
786-O when attenuating levels of FIH using RNAi. Initial FIH attenuation 
experiments included development and use of a short-hairpin RNA (shRNA) for 
long-term FIH knockdown. Cell proliferation could then be followed and 
compared with that of cells overexpressing FIH as well as control pools (i.e. 
corresponding empty vectors). Transient attenuation using siRNAs targeting FIH 
was also used on CCRCC cells to follow their growth in culture. Proliferation was 
measured using MTT assays as well as counting cells after treatment with 1% 
trypan blue.  
Potential mechanisms involved in changes in proliferation (i.e. apoptosis through 
increased HIF-1alpha activity) were investigated using a cell death assay 
(Roche) and FACS analysis using annexin-V (early apoptosis) and propidium 
iodide entry (late apoptosis).  
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6.2 Results 
6.2.1 Development of a short-hairpin RNA (shRNA) targeting FIH 
As mentioned in chapter 4, introduction of dsRNA is a powerful tool which can be 
selectively used to suppress gene expression through the RNAi process. The 
reduction in gene expression when using conventional siRNAs is transient; with 
time, gene expression of a specific siRNA target will recover. This therefore 
restricts its application, particularly in experiments which require long incubation 
times where attenuation is necessary throughout the timeframe e.g. cell 
proliferation assays extending for a number of days. In order to investigate the 
effect of FIH attenuation on cell proliferation, I developed an shRNA which would 
provide long-term attenuation of FIH expression and overcomes the limitation set 
by siRNAs.  
A pSUPER.puro RNAi system (VEC-PBS-0008 from Oligoengine™, Seattle) was 
used as a mammalian expression vector that could direct intracellular synthesis 
of siRNA transcripts, using the polymerase III H1-RNA gene promoter.  The ends 
of the transcripts produced using this method would resemble those of 
chemically synthesized siRNAs, as cleavage of the transcript at the termination 
site is after the second uridine (i.e. UU overhangs at the 3’-end).  
The shRNA oligonucleotide sequence was the same as that for siFIH #2, 
targeting human FIH, and extended to a 29-mer (as opposed to the siRNA 
duplex I used, which is a 21-mer). I designed a 29-mer because this length has 
been shown to increase attenuation levels of a given target, at lower molar 
concentration when compared with a 21-mer sequence (Siolas et al., 2005). 
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Figure 6.1 shRNA expression 
The insert, once ligated to the vector, will be expressed as an siRNA transcript containing a 
hair-pin structure (shRNA). The hair-pin is then cleaved (by the enzyme dicer) producing a 
conventional siRNA which may then lead on to gene suppression of a specific target (e.g. 
FIH). One advantage is the long-term attenuation of a target, as the siRNA is constantly 
being expressed. 
 
Figure 6.1 shows the principle behind the expression of an shRNA. 
Forward and reverse oligonucleotides (Sigma Genosys; sequence is given in the 
Methods and Materials section [chapter 2, section 2.6.1]) were resuspended in 
nuclease-free H2O to a concentration of 3µg/µl. The pSUPER vector was 
digested so that ligation of the insert (annealed oligonucleotides) could occur, 
according to the protocol detailed in chapter 2. Several digests of the insert 
containing vector were then performed in order to confirm presence of the 
shRNA sequence in the vector, including an EcoRI + Hind III digest 
recommended by the manufacturer of the vector (not shown).  
pSUPER.puro-FIH
Sequence targeting FIH
Expressed as an shRNA
Dicer cleaves hair-pin (siRNA)
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Figure 6.2 Validation of shRNA insert 
A 1% agarose gel showing several DNA digests for confirmation of the presence of the 
shRNA oligonucleotide sequence with the pSUPER.puro vector. Results confirmed 
successful ligation of the insert to the vector. 
 
 
Figure 6.2 shows several digests that confirm presence of the oligonucleotide 
inserts in pSUPER. The advantage of these additional digests is that they will 
potentially cut within the cloning region (the shRNA sequence). 
The shRNA was used to transfect three independent pools of RCC10 cells. After 
transfection, using the Phoenix viral packaging cell line, pools were treated with 
puromycin at 1.5µg/ml for 5 days, in order to select for cells expressing the 
shRNA vector. A negative selection control (untreated pool of RCC10 cells) was 
also treated with the same concentration of puromycin over the same time 
period.  
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A western blot was used to confirm attenuation of FIH protein for all three pools 
(Figure 6.3).  
 
 
 
Figure 6.3 shRNA attenuation of FIH protein in RCC10 
A western blot reveals attenuation of FIH at protein level in three pools of RCC10 cells 
transfected with an shRNA targeting FIH (pSUPER.puro-FIH). Levels should be compared 
with that of the empty vector control transfection (pSUPER.puro). A coomassie blue stain 
confirmed equal loading of protein lysate. 20µg of lysate was loaded in total. 
 
 
 
An RT-PCR measuring mRNA revealed a ~60% decrease in FIH mRNA when 
compared with the empty vector control pool (Figure 6.4). The attenuation was 
clearly less efficient than with the use of conventional siRNAs. Several attempts 
were made to achieve greater attenuation of FIH (e.g. extending the time period 
pools were exposed to puromycin selection), however attenuation levels of >70% 
at mRNA were not achieved. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4 Attenuation of FIH mRNA levels in RCC10 using shRNA 
An RT-PCR assay comparing FIH mRNA levels in RCC10 pools transfected with an shRNA 
targeting FIH (pSUPER.puro-FIH) and an empty vector control transfection (pSUPER.puro). 
Results show a ~60% knockdown of FIH mRNA in the shRNA transfected pool, when 
comparing levels in the control. ±SE, n=2. 
plasmid:
FIH
pSUPER.puro pSUPER.puro-FIH
pSUPER.puro
pSUPER.puro-FIH
*
0.0
0.5
1.0
1.5
2.0
2.5
R
e
la
ti
v
e
 F
IH
m
R
N
A
 l
e
v
e
ls
R
e
la
ti
v
e
 F
IH
m
R
N
A
 l
e
v
e
ls
Chapter 6 - Results 
 159 
RT-PCR analysis showed no effect on HIF target genes BNIP3, GLUT-1 or 
PHD3 mRNA when suppressing FIH using this shRNA (data not shown). This 
may be because there is a threshold effect, and is consistent with the lack of 
effect of overexpressing FIH. 
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6.2.2 The proliferation status of renal cancer cells when manipulating 
levels of FIH 
Having generated pools of RCC10 cells which overexpress and underexpress 
FIH, I next examined their proliferation. Figures 6.5 and 6.6 shows an MTT 
assay used to measure the proliferation of pools of RCC10 cells both 
overexpressing and under expressing FIH. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5 FIH overexpression and proliferation of RCC10 cells 
An MTT assay was performed to measure proliferation of pools of RCC10 cells 
overexpressing FIH (pCMVR-FIHPk) together with the corresponding empty vector control 
(pCMVR). Absorbance at 550nm is proportional to the number of viable cells. Results 
indicate overexpression of FIH does not appear to affect the rate of growth of these pools in 
culture. The reduction in proliferation after 48 hours may be explained by the possible 
depletion of nutrients in the cell media. ±SE, n=2. 
 
 
In the previous chapter, it was clear that overexpressing FIH did not affect levels 
of HIF target genes (Figure 5.11, pg. 134). Perhaps consistent with this, the 
proliferation of RCC10 is unaffected by FIH overexpression (Figure 6.5). 
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Figure 6.6 FIH suppression and proliferation of RCC10 cells 
An MTT assay was also performed to measure proliferation of pools of RCC10 cells under-
expressing FIH (pSUPER.puro-FIH), together with the corresponding empty vector control 
(pSUPER.puro). Results indicate that suppression of FIH does not to affect the rate of 
growth of these pools in culture. Once again, the reduction in proliferation after 48 hours may 
be explained by the depletion of nutrients in the cell media. ±SE, n=2. 
 
Additionally, although attenuation of FIH was achieved, both at protein and 
mRNA level, a ~60% knockdown did not increase HIF target gene levels. 
Potentially as a result, the proliferation of RCC10 pools was not affected when 
manipulating FIH, as seen in Figures 6.5 and 6.6. Although it appears as though 
attenuating FIH increases growth of RCC10 cells in culture (compare with the 
proliferation rate of untreated cells) (Figure 6.6), the corresponding empty vector 
control (pSUPER.puro) for the shRNA also showed a potential increase in the 
rate of proliferation. This is therefore an unspecific effect of the vector and/or 
transfection and selection procedures. 
Since attenuating FIH using an siRNA achieves greater reduction in FIH mRNA 
levels (>70% knockdown at mRNA level), I decided to investigate the effect of 
silencing FIH using transient knockdown (siRNA targeting FIH) on proliferation of 
renal cancer cell lines RCC10, RCC4 and 786-O. As shown in previous chapters, 
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siRNAs targeting FIH significantly increase levels of HIF target genes. This would 
include the HIF-1alpha target genes described as pro-apoptotic (e.g. BNIP3), in 
RCC10 cells. The experimental design is shown in Figure 6.7 below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7 Experimental design for proliferation studies in CCRCC 
 
 
 
 
 
 
 
 
 
 
Cells split into P60 dishes
before transfection
Transfection with 50nM siRNA 
(siFIH and siLUC)
24hr
Cells split
For MTT assay: 3000 cells/well
For cell counting: 20,000 cells/well
24hr
Fresh Media addedTime zero
Day 1 – Day 3: MTT, cell counts, RNA extraction (from counted cells) for RT-
PCR analysis, FACS analysis (apoptosis), cell death assay
24hr
24hr
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6.2.3 Attenuating FIH cells induces apoptosis and affects the 
proliferation status CCRCC cells expressing HIF-1alpha 
My hypothesis is that FIH could favour tumour growth in CCRCC, by suppressing 
HIF-dependent apoptosis through inhibition of HIF-1alpha. To test this I 
examined the effect of FIH siRNA on RCC10, RCC4 and 786-O. I observed a 
robust decrease in the number of cells in cultures exposed to FIH siRNA (50nM 
of siFIH #2). I followed cell proliferation in the three renal cancer cell lines after 
silencing FIH and found that cell proliferation was significantly reduced in RCC10 
and RCC4 cells, but not in 786-O cells.  
A time-course RNAi experiment was first performed and showed FIH attenuation 
over 6 days. Levels of FIH protein appeared to recover substantially by day 6 
(Figure 6.8).  
 
 
 
 
 
 
 
 
Figure 6.8 Time course of RNAi effects 
A western blot showing attenuation of FIH protein levels over 6 days using an siRNA in 
RCC10 cells (siFIH #2). Over 3 days, there was clear suppression of FIH protein, with levels 
recovering to some extent at day 6. The proliferation of renal cancer cells was therefore 
measured over a 3 day period, while FIH levels were attenuated. 
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I therefore followed the growth of the CCRCC cell lines over a 3 day period, 
following FIH attenuation with siFIH #2, during which FIH levels were 
substantially reduced. RT-PCR revealed successful attenuation of FIH for the 
three cell lines (Figure 6.9) over this time. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.9 Attenuation of FIH mRNA for three CCRCC cell lines 
Attenuation of FIH mRNA for three CCRCC cell lines used to investigate potential effects of 
FIH attenuation on cell proliferation. There is robust suppression of FIH mRNA for all three 
cell lines over the 3 days. ±SE, n=3. 
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Following attenuation of FIH with siFIH #2, cells were incubated with trypan blue 
(in order to exclude dead cells) and the number of cells was counted for each of 
the 3 days. A reduction in cell number was evident in RCC10 and RCC4 cells, 
but not in the 786-O cell line over this time (Figure 6.10). A possible reason may 
well be inducement of apoptosis in cells expressing the HIF-1alpha isoform. If 
FIH is indeed preferentially inhibiting HIF-1alpha (as discussed in the previous 
chapter), attenuating FIH may increase levels of pro-apoptotic HIF target genes. 
This would result in reduced cell proliferation. However, this would not be the 
case in 786-O cells, due to the lack of the HIF-1alpha isoform.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.10 Cell numbers after FIH knockdown 
Cells were counted after treatment with trypan blue (1%) and numbers of cells are 
represented here as a histogram. In both RCC10 and RCC4 cells, there is a robust decrease 
in the number of cells in culture when attenuating FIH. However, this is in contrast to 786-O 
cells, which exclusively expresses the HIF-2alpha isoform. ±SE, n=3. 
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Using MTT assays I could follow the number of cells in a different way 
(Mosmann, 1983). The yellow chromogen MTT is reduced in the mitochondria to 
water-insoluble purple formazan crystals. The formazan crystals were then 
dissolved using 100µl of Isopropanol-Triton (0.1%). Absorbance was then 
measured at a wavelength of 550nm using an Ascent spectrophotometer. A MTT 
assay measures the activity of mitochondria so might give different results from 
counting the number of cells. This is especially the case with manipulating the 
HIF pathway, since activation is recognised to alter the number and enzyme 
composition of mitochondria (Simon, 2006). However, with the renal cancer cells 
used here, the rate of MTT reduction (and therefore increased absorbance at 
550nm due to formazan production) gave similar results compared with counting 
the number of cells in culture.  
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Figure 6.11 MTT assay of CCRCC cell lines after FIH attenuation 
An MTT assay revealed a reduction in cell numbers for RCC10 and RCC4 cells when 
attenuating FIH, in comparison with the control (siLUC) over 3 days. This was in contrast to 
786-O cells, where there is no change in cell number when comparing FIH attenuation with 
the same control siRNA. Significance of differences was evaluated by ANOVA. ±SE, n=3. 
 
The results from the MTT assay reveal a reduction in both the RCC10 and RCC4 
cell lines (Figure 6.11). Once again, this was not true for the 786-O cell line. The 
data shown here are consistent with the results obtained in Figure 6.9 when 
counting the cells, confirming a reduction in cell number when inhibiting FIH in 
two different CCRCC cell lines. 
Changes in cell density are shown in Figure 6.12; RCC10 and RCC4 cells were 
once again transfected with 50nM concentration of siFIH #2 and corresponding 
control siRNA, siLUC. These experiments were performed in duplicate. Cells 
were incubated for a period of 48 hours with the siRNA mixture before analysis. 
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.    RCC10    RCC4 
siLUC    
  siFIH    
Figure 6.12 Cell morphology following FIH attenuation 
Representative pictures of RCC10 and RCC4 cells transfected with siFIH #2 and siLUC. 
Transfections were performed to investigate potential morphological changes and changes in 
cell density when attenuating FIH. Two separate pools of cells were transfected with either 
siLUC (top panels) or siFIH #2 (bottom panels). Cells transfected with the siFIH #2 siRNA 
were less densely packed in comparison with cells transfected with the control siLUC siRNA. 
The morphology between siFIH #2 pools and siLUC, although is different, may be secondary 
to the reduced cell density. 
 
 
Cells transfected with siLUC are tightly packed at almost 100% confluence. In 
contrast, cells transfected with siFIH #2 are not confluent. Inhibition of FIH in the 
786-O cell line did not display any changes to confluency or any morphological 
changes and is consistent with data already shown.  
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6.2.4 FACS analysis to investigate for apoptosis  
I focused my next set of experiments on investigating the mechanism(s) by which 
FIH inhibition was reducing the number of CCRCC cells. Data in chapter 5 shows 
an increase in the pro-apoptotic gene BNIP3 in RCC10. I anticipated that FIH 
knockdown may induce apoptosis in RCC10, which would result in labeling with 
annexin-V and propidium iodide uptake (PI) in cells treated with siRNA for FIH, 
compared with cells treated with siLUC. Expression of the phospholipid 
phosphatidylserine, at the cell surface, occurs in apoptotic cells (for recognition 
by macrophages). It has been shown that annexin-V, an anticoagulant, 
preferentially binds to negatively charged phospholipids such as 
phosphatidylserine (Andree et al., 1990). As a result, annexin-V may be used in 
flow cytometric analysis (FACS) in order to detect apoptotic cells (Koopman et 
al., 1994). This occurs at the early stages of apoptosis. Apoptosis may also be 
assessed by measuring plasma membrane integrity using PI (Riccardi and 
Nicoletti, 2006; Span et al., 2002). Apoptotic cells are characterized by DNA 
fragmentation and as a result, loss of nuclear DNA content (Zhang and Xu, 2000; 
Zhivotosky and Orrenius, 2001). PI is capable of binding and labeling DNA, 
which is then detected by FACS analysis. Plasma membrane integrity loss will 
allow the uptake of PI, while intact plasma membranes will exclude it (Riccardi 
and Nicoletti, 2006). A caveat to its use is that PI cannot distinguish between 
apoptotic and necrotic cell death. However, in combination with counting the 
number of cells, use of cell death assay and MTT assay used in this thesis, PI 
uptake can be used to estimate likelihood of apoptosis occurring in this cell line. 
Chapter 6 - Results 
 170 
Therefore, I used FACS analysis of annexin-V binding and PI uptake. 
Fluorescein-conjugated annexin-V binding and PI uptake (detected by flow 
cytometry) were used as criteria for distinguishing early apoptotic and late 
apoptotic cells.  
I found a dramatic increase (~11% to ~48% positive for annexin-V) in the level of 
apoptotic cells in the RCC10 cell line when attenuating FIH using siFIH #2 and 
comparing with the control siLUC transfection (Figure 6.13). This was observed 
in two independently performed RNAi experiments on RCC10 cells (n=2). 
 
 
 
 
 
 
 
 
 
Figure 6.13 FACS analysis using annexin-V and PI in RCC10 cells 
There is a clear and significant shift towards apoptosis in RCC10 cells when comparing siFIH 
#2 transfected cells with those transfected with the siLUC control. n=2 
 
 
RCC10 cells transfected with the siLUC control siRNA do show early apoptosis 
(positive for annexin-V). This may be due to trypsinization of these adherent cells 
before treatment with annexin-V and PI dyes. However, there is a much greater 
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shift towards apoptosis when transfecting RCC10 cells with siFIH #2. PI uptake is 
also increased in cells transfected with siFIH #2, possibly demonstrating a loss in 
membrane integrity. 
 
. 
 
 
 
 
 
 
 
 
 
 
Figure 6.14 FACS analysis using annexin-V and PI in 786-O cells 
The result shows less apoptosis in comparison with that seen in RCC10 cells transfected 
with siFIH #2. n=2 
 
 
786-O cells (Figure 6.14) were also positive for annexin-V and PI uptake (n=2), 
but to a far lesser extent to that observed in RCC10. The apoptosis observed in 
786-O may be the result of a HIF-independent apoptotic pathway, as other 
substrates for FIH have recently been discovered, including the ICD of the Notch 
receptor and the IkappaB family of inhibitory proteins, as mentioned in previous 
chapters. 
The expectation was that cells only expressing the HIF-1alpha isoform would 
become apoptotic when suppressing FIH. One major limitation of FACS analysis 
for apoptosis is the use of trypsinization, which can disrupt cell membranes 
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leading to high false positives, including in controls (as was observed here). 
Another is that the early apoptotic phase is rapid and can often be missed. This 
may then show cells as either live or necrotic. I therefore followed up this 
experiment with the use of a cell death assay (Roche), and performed the assay 
using all three CCRCC cell lines. 
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6.2.5 Apoptosis in CCRCC cells, following FIH attenuation, is likely to 
be HIF-1alpha-dependent 
The cell death assay system provides a useful standardised method to quantify 
cytoplasmic histone-associated DNA fragments, which are a marker of apoptosis. 
Comparing effects of FIH inhibition on VHL defective (-ve) RCC10, RCC4 and 
786-O cells, I investigated how apoptosis correlated with the presence of HIF-
1alpha and my previous assays of HIF-dependent gene expression. Additionally, 
since substrates other than HIF have recently been elucidated for FIH, RNAi 
against FIH in VHL +ve RCC10 cells were also performed to examine whether 
induction of apoptosis relies on the presence of active HIF, which is at a high 
level in VHL –ve RCC cell lines but is suppressed in VHL +ve cells.  
Figure 6.15 shows increased cell death in VHL –ve RCC10 and RCC4 cells 
when attenuating FIH, consistent with my previous cell proliferation data. 
However, this increase was not observed in 786-O cells or in VHL + ve RCC10 
cells, when comparing with the siLUC controls. 
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Figure 6.15 Cell death in the presence of HIF-1alpha 
A cell death assay (Roche) used to quantify cytoplasmic histone-associated DNA fragments. 
Increased cell death occurs in the presence of HIF-1alpha (RCC10 and RCC4 HIF1a) but not 
in cells expressing HIF-2alpha exclusively (786-O) or cells expressing basal HIF-alpha levels 
(RCC10 VHL +ve). n=2, ±SE.  
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6.2.6 Apoptosis in renal cancer cells is not associated with p53 
activation 
I next focused on levels of the tumour suppressor protein p53 in RCC10 cells 
transfected with siFIH #2 versus RCC10 cells transfected with control siRNA 
(siLUC). p53 is expressed and rarely mutated CCRCC cells, including RCC10 
(Stickle et al., 2005). p53 becomes activated in response to a number of stress 
types, which include DNA damage (induced by either UV, IR or chemical agents), 
oxidative stress, osmotic shock, ribonucleotide depletion and deregulated 
oncogene expression. The half-life of the p53 protein increases, leading to 
accumulation of p53 in stressed cells. This upregulation of p53 may then induce 
apoptosis (Harms and Chen, 2005; Maltzman and Czyzyk, 1984). 
 
 
 
 
 
 
 
 
 
 
Figure 6.16 p53 and PARP in RCC10 cells transfected with siFIH #2 
p53 and PARP levels, in RCC10 cells transfected with siFIH #2 and siLUC control, 
represented in a western blot. A control pool of untreated RCC10 cells were also included 
(U). Neither evidence of PARP cleavage nor elevated levels of p53 were found. 
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Figure 6.16 shows levels of p53 protein, as well as Poly (ADP-ribose) 
polymerase (PARP), a DNA repair protein which is cleaved by caspase 3 during 
apoptosis (Boulares et al., 1999).  
p53 levels, when attenuating FIH in RCC10 cells, were not elevated. Additionally, 
PARP protein was not found to have been cleaved. This suggests that apoptosis 
in RCC10 cells, induced by FIH suppression is both p53-independent and does 
not involve PARP cleavage by caspase 3. 
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6.3 Conclusion 
There are important therapeutic implications regarding FIH and selective 
hydroxylation of the HIF isoforms. Specific upregulation of potentially pro-
apoptotic HIF-1alpha target genes could reduce the growth of renal cancers, 
where HIF-1alpha is expressed. Several reports have already suggested positive 
outcomes with regards to HIF-1alpha upregulation and its therapeutic potential 
for renal and lung cancer. Here, we show that FIH inhibition could increase levels 
of pro-apoptotic genes (e.g. BNIP3) associated with HIF-1alpha and reduce the 
numbers of renal cancer cells in culture, possibly through HIF-1alpha-specific 
activation. An increase in BNIP3 (induced by exposure to hypoxia) has been 
reported as being sufficient to induce apoptosis in HeLa cells and that this was 
found to be independent of p53 activation and caspase 3 and caspase 9 activity 
(Guo et al., 2001). Indeed, my own data did not show any differences in p53 
levels when attenuating FIH and cleavage of the DNA repair protein PARP, 
known to be cleaved by caspase 3 in apoptotic cells, was not evident (Figure 
6.16). 
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7 Discussion 
The crystal structure of FIH, as well as its interaction with HIF has been widely 
studied (Dann, III et al., 2002; Lee et al., 2003). However, little else was known 
about this hydroxylase enzyme. For instance, expression levels, distribution in an 
organism, its potential regulation by oxygen and characterisation of function on 
individual HIF-alpha subunits were still relatively unknown. During this thesis, I 
have investigated the expression and distribution of FIH as well as the role FIH 
plays in inhibiting HIF activity, in particular in CCRCC. 
 
Chapter 3 shows that, as with the PHD enzymes, there is widespread expression 
of FIH, both at mRNA and protein level. Levels are not regulated by oxygen, in 
contrast to PHD2 and PHD3. Reports have previously suggested the 
transcriptional repression of FIH in renal cancer, based on studies performed on 
two cell lines where HIF-1alpha is either not expressed or is mutated (Li et al., 
2007). However, using three different CCRCC cell lines, I found no evidence of 
transcriptional repression of FIH mRNA in renal cancer. My results show that 
levels of FIH mRNA and protein are comparable with that found in control, non-
cancerous kidney tissue samples. Additionally, I have found that FIH does 
function in renal cancer using the CCRCC cell lines RCC10 and RCC4 (Chapter 
5). A possible mechanism to explain this is that FIH selectively inhibits the HIF-
1alpha isoform. As a result, FIH manipulation using siRNA has no effect on HIF 
activity in 786-O cells, unless HIF-1alpha is introduced via a viral vector. 
Additionally, forced expression of FIH, in RCC10 cells, also had no effect on HIF 
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activity and is likely due to the continuing activity of the HIF-2alpha isoform, 
which I have found to be more resistant to the inhibitory effects of FIH.  
Since a sub-set of HIF-1alpha target genes have been described as pro-
apoptotic (Wang et al., 2008), Chapter 6 investigates whether suppressing FIH 
could induce apoptosis of CCRCC cell lines RCC10 and RCC4, but not in 786-O 
cells, by specifically upregulating HIF-1 target genes. Apoptosis was found to be 
dependent on the presence of HIF-1alpha, according to the data provided by cell 
death assay, MTT assay and counting cells in culture. FACS analysis confirmed 
apoptosis in RCC10 cells.  
 
As part of future work, an additional experiment to confirm HIF-1alpha-mediated 
apoptosis would be the attenuation of FIH in the 786-O/HIF-1alpha pool. It would 
be anticipated that suppressing FIH in this setting could induce apoptosis (as 
seen in the RCC10 and RCC4 CCRCC cell lines), contrasting the lack of 
apoptosis in the 786-O cell line.  This could be shown by counting numbers of 
cells in culture as well as the use of FACS analysis for annexin-V and PI and cell 
death assay. Future work could also extend to in vivo models. This could be 
achieved by use of xenograft assay. Stable shRNA (suppression) and FIH 
plasmid (overexpression) transfected CCRCC cell lines can be injected in to the 
flanks of nude mice and the growth of resulting tumours investigated (by mass 
and/or dimension). If the suppression of FIH does indeed induce apoptosis in 
vivo (as was the case in vitro), tumours resulting from cells transfected with FIH 
shRNA would be smaller, since there would be an upregulation in HIF-1alpha 
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pro-apoptotic genes such as BNIP3.  Additionally, elucidation of the pathways 
involved in apoptosis of CCRCC cell lines by FIH attenuation could also be 
investigated. The experimental design would include investigating whether 
apoptosis initiation was intrinsic or extrinsic. The intrinsic pathway is initiated 
through the release of mitochondrial signalling factors. In contrast, the extrinsic 
pathway is initiated through the stimulation of transmembrane proteins such as 
Fas (Csipo et al., 1998).  
Finally, in addition to measuring levels of HIF target genes, the function of FIH 
(for instance, in varying oxygen tensions) could also be measured directly though 
a reporter gene e.g. luciferase reporter downstream of a FIH sequence.  
 
An important and currently unpublished finding (Randal Johnson, University of 
California, San Diego. Meeting report: Molecular, Cellular, Physiological and 
Pathogenic Responses to Hypoxia, Keystone Symposia, 2007) is that the global 
deletion of FIH in the mouse does not exhibit a phenotype. This is consistent with 
my own finding that FIH is likely to be inhibiting HIF-1alpha preferentially. The 
lack of detectable effects of knocking out FIH could therefore be as a result of the 
continuing activity of HIF-2alpha.  
 
It is probable that there is an enzymatic modification (e.g. phosphorylation) of 
HIF-2alpha that protects it from inactivation by FIH. Therefore, if the enzyme 
responsible could be identified this may provide an effective route to inactivating 
HIF-2alpha, which would potentially offer a therapeutic target in solid tumors.  
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The structure of the FIH enzyme has already been solved and there are 
prototype inhibitors implying it will be druggable (Banerji et al., 2005; McDonough 
et al., 2005). Raval et al. has also shown a reciprocal relationship between HIF-
1alpha and HIF-2alpha (Raval et al., 2005). Therefore an additional benefit of 
inhibiting FIH could be decreased HIF-2alpha activity (because of the increase in 
HIF-1alpha activity), as HIF-2alpha is said to be associated with increased 
tumour aggression and metastasis (Yoshimura et al., 2004).  
 
This study provides initial evidence of FIH as a therapeutic target in a subset of 
clear cell renal carcinomas, which would justify development of small molecule 
inhibitors.  
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Solutions used in protein procedures 
A list of solutions used for western immunoblotting and immunodetection. 
 
Lysis buffer 
 
• 8 M Urea 
• 1/10 vol glycerol  
• 1/20 vol 20% SDS 
• 1/200 vol 1 M DTT 
• 1/100 vol 1M Tris (pH 6.8) 
 
The above components were mixed together and stored at RT.  Prior to cell lysis, 
an appropriate amount of buffer was placed in a separate tube and 1/100 vol of a 
500µM stock of phenylmethylsulfonyl fluoride (PMSF), a protease inhibitor, was 
added. 
 
4x TrisCl/SDS (pH 8.8)  
 
• 1.5 M Tris-Cl  
• 0.4% SDS 
 
91g of Tris base was dissolved in 300ml dH2O and the pH adjusted to 8.8 using 
1M HCl.  dH2O was added to give a total volume of 500ml prior to filtering the 
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solution through a 0.45µm filter. 2g of SDS was then added and the buffer was 
stored at 4oC for up to 2 months. 
 
4x TrisCl/SDS (pH 6.8) 
 
• 0.5 M Tris-Cl  
• 0.4% SDS 
 
12.1g of Tris base was dissolved in 80 ml of dH2O. The pH was then adjusted to 
6.8 with 1M HCl dH2O was then added to give a total volume of 200ml. The 
solution was then filtered using a 0.45µm filter, prior to the addition of 0.8g of 
SDS.  The final solution was stored at 4oC for up to 2 months. 
 
4x SDS loading buffer 
 
• 12.5 ml 4x TrisCl/SDS (pH 6.8) 
• 10 ml glycerol 
• 2 g SDS 
• 1.55 g DTT 
 
The sample buffer was prepared by mixing the indicated volumes of 4x 
TrisCl/SDS (pH 6.8), glycerol, SDS and DTT. dH2O was added to give a total 
volume of 50 ml.  The buffer was aliquoted and stored at -20oC. 
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Electrophoresis running buffer 
 
• 25 mM TrisCl 
• 200 mM Glycine  
• 0.1% SDS 
 
Running buffer was prepared as a 5x stock solution and stored at 4oC. The 1x 
buffer was prepared by diluting the stock solution with dH2O as required.  
 
Transfer buffer 
 
• 10 mM Tris-Cl 
• 100 mM Glycine 
• 10% Methanol 
• 0.005% SDS 
 
A 10x solution of 1M glycine and 100mM Tris-Cl was prepared and stored at 4oC. 
1x transfer buffer was prepared as required by diluting the 10x stock solution with 
dH2O and adding 10% methanol and 0.005% SDS.  
 
Phosphate buffered saline (PBS) (pH 7.4) 
 
• 137 mM NaCl 
  187 
• 2.7 mM KCl 
• 4.3 mM Na2HPO4.7H2O 
• 1.4 mM KH2PO4 
 
A 10x stock solution of PBS was prepared and stored at RT.  1x PBS was 
prepared from the 10x stock solution by dilution with dH2O. The PBS was then 
adjusted to the correct pH using 1M HCl.  PBS-Tween (PBST) was prepared 
from a 1x PBS solution by adding Tween20 to a final concentration of 0.1%. 
 
Blocking solution 
 
• 5 g dried skimmed milk (Marvel, UK) 
• 1 g bovine serum albumin (BSA) 
 
Blocking solution was prepared by mixing the components listed above in 100 ml 
of PBST. 
 
 
 
 
 
  188 
 
 
 
 
References 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  189 
Reference List 
 
Alberghini,A., Recalcati,S., Tacchini,L., Santambrogio,P., Campanella,A., and 
Cairo,G. (2005). Loss of the von Hippel Lindau tumor suppressor disrupts iron 
homeostasis in renal carcinoma cells. J. Biol. Chem. 280, 30120-30128. 
Andree,H.A., Reutelingsperger,C.P., Hauptmann,R., Hemker,H.C., 
Hermens,W.T., and Willems,G.M. (1990). Binding of vascular anticoagulant 
alpha (VAC alpha) to planar phospholipid bilayers. J. Biol. Chem. 265, 4923-
4928. 
Appelhoff,R.J., Tian,Y.M., Raval,R.R., Turley,H., Harris,A.L., Pugh,C.W., 
Ratcliffe,P.J., and Gleadle,J.M. (2004). Differential function of the prolyl 
hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible 
factor. J. Biol. Chem. 279, 38458-38465. 
Aprelikova,O., Chandramouli,G.V., Wood,M., Vasselli,J.R., Riss,J., 
Maranchie,J.K., Linehan,W.M., and Barrett,J.C. (2004). Regulation of HIF prolyl 
hydroxylases by hypoxia-inducible factors. J. Cell Biochem. 92, 491-501. 
Arany,Z., Huang,L.E., Eckner,R., Bhattacharya,S., Jiang,C., Goldberg,M.A., 
Bunn,H.F., and Livingston,D.M. (1996). An essential role for p300/CBP in the 
cellular response to hypoxia. Proc. Natl. Acad. Sci. U. S. A 93, 12969-12973. 
Arnesen,T., Kong,X., Evjenth,R., Gromyko,D., Varhaug,J.E., Lin,Z., Sang,N., 
Caro,J., and Lillehaug,J.R. (2005). Interaction between HIF-1 alpha (ODD) and 
hARD1 does not induce acetylation and destabilization of HIF-1 alpha. FEBS 
Lett. 579, 6428-6432. 
Bae,S.K., Kim,S.R., Kim,J.G., Kim,J.Y., Koo,T.H., Jang,H.O., Yun,I., Yoo,M.A., 
and Bae,M.K. (2006). Hypoxic induction of human visfatin gene is directly 
mediated by hypoxia-inducible factor-1. FEBS Lett. 580, 4105-4113. 
Banerji,B., Conejo-Garcia,A., McNeill,L.A., McDonough,M.A., Buck,M.R., 
Hewitson,K.S., Oldham,N.J., and Schofield,C.J. (2005). The inhibition of factor 
inhibiting hypoxia-inducible factor (FIH) by beta-oxocarboxylic acids. Chem. 
Commun. (Camb. ) 5438-5440. 
Bazan,N.G., Palacios-Pelaez,R., and Lukiw,W.J. (2002). Hypoxia signaling to 
genes: significance in Alzheimer's disease. Mol. Neurobiol. 26, 283-298. 
Bernhardt,W.M., Campean,V., Kany,S., Jurgensen,J.S., Weidemann,A., 
Warnecke,C., Arend,M., Klaus,S., Gunzler,V., Amann,K., Willam,C., 
Wiesener,M.S., and Eckardt,K.U. (2006). Preconditional activation of hypoxia-
inducible factors ameliorates ischemic acute renal failure. J. Am. Soc. Nephrol. 
17, 1970-1978. 
  190 
Berra,E., Benizri,E., Ginouves,A., Volmat,V., Roux,D., and Pouyssegur,J. (2003). 
HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels 
of HIF-1alpha in normoxia. EMBO J. 22, 4082-4090. 
Bhattacharya,S., Michels,C.L., Leung,M.K., Arany,Z.P., Kung,A.L., and 
Livingston,D.M. (1999). Functional role of p35srj, a novel p300/CBP binding 
protein, during transactivation by HIF-1. Genes Dev. 13, 64-75. 
Bianchi,L., Tacchini,L., and Cairo,G. (1999). HIF-1-mediated activation of 
transferrin receptor gene transcription by iron chelation. Nucleic Acids Res. 27, 
4223-4227. 
Boulares,A.H., Yakovlev,A.G., Ivanova,V., Stoica,B.A., Wang,G., Iyer,S., and 
Smulson,M. (1999). Role of poly(ADP-ribose) polymerase (PARP) cleavage in 
apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in 
transfected cells. J. Biol. Chem. 274, 22932-22940. 
Brahimi-Horn,M.C. and Pouyssegur,J. (2007). Harnessing the hypoxia-inducible 
factor in cancer and ischemic disease. Biochem. Pharmacol. 73, 450-457. 
Bruick,R.K. (2000). Expression of the gene encoding the proapoptotic Nip3 
protein is induced by hypoxia. Proc. Natl. Acad. Sci. U. S. A 97, 9082-9087. 
Bruick,R.K. and McKnight,S.L. (2001). A conserved family of prolyl-4-
hydroxylases that modify HIF. Science 294, 1337-1340. 
Brusselmans,K., Compernolle,V., Tjwa,M., Wiesener,M.S., Maxwell,P.H., 
Collen,D., and Carmeliet,P. (2003). Heterozygous deficiency of hypoxia-inducible 
factor-2alpha protects mice against pulmonary hypertension and right ventricular 
dysfunction during prolonged hypoxia. J. Clin. Invest 111, 1519-1527. 
Carmeliet,P., Dor,Y., Herbert,J.M., Fukumura,D., Brusselmans,K., Dewerchin,M., 
Neeman,M., Bono,F., Abramovitch,R., Maxwell,P., Koch,C.J., Ratcliffe,P., 
Moons,L., Jain,R.K., Collen,D., and Keshert,E. (1998). Role of HIF-1alpha in 
hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 
394, 485-490. 
Chen,B., Lam,K.S., Wang,Y., Wu,D., Lam,M.C., Shen,J., Wong,L., Hoo,R.L., 
Zhang,J., and Xu,A. (2006). Hypoxia dysregulates the production of adiponectin 
and plasminogen activator inhibitor-1 independent of reactive oxygen species in 
adipocytes. Biochem. Biophys. Res. Commun. 341, 549-556. 
Chen,Y.H., Comeaux,L.M., Eyles,S.J., and Knapp,M.J. (2008). Auto-
hydroxylation of FIH-1: an Fe(ii), alpha-ketoglutarate-dependent human hypoxia 
sensor. Chem. Commun. (Camb. ) 4768-4770. 
  191 
Chomczynski,P. and Sacchi,N. (1987). Single-step method of RNA isolation by 
acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162, 
156-159. 
Cockman,M.E., Lancaster,D.E., Stolze,I.P., Hewitson,K.S., McDonough,M.A., 
Coleman,M.L., Coles,C.H., Yu,X., Hay,R.T., Ley,S.C., Pugh,C.W., Oldham,N.J., 
Masson,N., Schofield,C.J., and Ratcliffe,P.J. (2006). Posttranslational 
hydroxylation of ankyrin repeats in IkappaB proteins by the hypoxia-inducible 
factor (HIF) asparaginyl hydroxylase, factor inhibiting HIF (FIH). Proc. Natl. Acad. 
Sci. U. S. A 103, 14767-14772. 
Cockman,M.E., Masson,N., Mole,D.R., Jaakkola,P., Chang,G.W., Clifford,S.C., 
Maher,E.R., Pugh,C.W., Ratcliffe,P.J., and Maxwell,P.H. (2000). Hypoxia 
inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor 
suppressor protein. J. Biol. Chem. 275, 25733-25741. 
Coleman,M.L., McDonough,M.A., Hewitson,K.S., Coles,C., Mecinovic,J., 
Edelmann,M., Cook,K.M., Cockman,M.E., Lancaster,D.E., Kessler,B.M., 
Oldham,N.J., Ratcliffe,P.J., and Schofield,C.J. (2007). Asparaginyl hydroxylation 
of the Notch ankyrin repeat domain by factor inhibiting hypoxia-inducible factor. 
J. Biol. Chem. 282, 24027-24038. 
Compernolle,V., Brusselmans,K., Acker,T., Hoet,P., Tjwa,M., Beck,H., 
Plaisance,S., Dor,Y., Keshet,E., Lupu,F., Nemery,B., Dewerchin,M., Van,V.P., 
Plate,K., Moons,L., Collen,D., and Carmeliet,P. (2002). Loss of HIF-2alpha and 
inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF 
prevents fatal respiratory distress in premature mice. Nat. Med. 8, 702-710. 
Covello,K.L., Kehler,J., Yu,H., Gordan,J.D., Arsham,A.M., Hu,C.J., Labosky,P.A., 
Simon,M.C., and Keith,B. (2006). HIF-2alpha regulates Oct-4: effects of hypoxia 
on stem cell function, embryonic development, and tumor growth. Genes Dev. 
20, 557-570. 
Cramer,T., Yamanishi,Y., Clausen,B.E., Forster,I., Pawlinski,R., Mackman,N., 
Haase,V.H., Jaenisch,R., Corr,M., Nizet,V., Firestein,G.S., Gerber,H.P., 
Ferrara,N., and Johnson,R.S. (2003). HIF-1alpha is essential for myeloid cell-
mediated inflammation. Cell 112, 645-657. 
Csipo,I., Montel,A.H., Hobbs,J.A., Morse,P.A., and Brahmi,Z. (1998). Effect of 
Fas+ and Fas- target cells on the ability of NK cells to repeatedly fragment DNA 
and trigger lysis via the Fas lytic pathway. Apoptosis. 3, 105-114. 
Cummins,E.P., Berra,E., Comerford,K.M., Ginouves,A., Fitzgerald,K.T., 
Seeballuck,F., Godson,C., Nielsen,J.E., Moynagh,P., Pouyssegur,J., and 
Taylor,C.T. (2006). Prolyl hydroxylase-1 negatively regulates IkappaB kinase-
beta, giving insight into hypoxia-induced NFkappaB activity. Proc. Natl. Acad. 
Sci. U. S. A 103, 18154-18159. 
  192 
Dann,C.E., III, Bruick,R.K., and Deisenhofer,J. (2002). Structure of factor-
inhibiting hypoxia-inducible factor 1: An asparaginyl hydroxylase involved in the 
hypoxic response pathway. Proc. Natl. Acad. Sci. U. S. A 99, 15351-15356. 
Datta,K., Li,J., Bhattacharya,R., Gasparian,L., Wang,E., and Mukhopadhyay,D. 
(2004). Protein kinase C zeta transactivates hypoxia-inducible factor alpha by 
promoting its association with p300 in renal cancer. Cancer Res. 64, 456-462. 
Dawn,B. and Bolli,R. (2005). HO-1 induction by HIF-1: a new mechanism for 
delayed cardioprotection? Am. J. Physiol Heart Circ. Physiol 289, H522-H524. 
Dayan,F., Roux,D., Brahimi-Horn,M.C., Pouyssegur,J., and Mazure,N.M. (2006). 
The oxygen sensor factor-inhibiting hypoxia-inducible factor-1 controls 
expression of distinct genes through the bifunctional transcriptional character of 
hypoxia-inducible factor-1alpha. Cancer Res. 66, 3688-3698. 
Del,P.L., Castellanos,M.C., Temes,E., Martin-Puig,S., Cuevas,Y., Olmos,G., and 
Landazuri,M.O. (2003). The von Hippel Lindau/hypoxia-inducible factor (HIF) 
pathway regulates the transcription of the HIF-proline hydroxylase genes in 
response to low oxygen. J. Biol. Chem. 278, 48690-48695. 
Ding,K., Scortegagna,M., Seaman,R., Birch,D.G., and Garcia,J.A. (2005). Retinal 
disease in mice lacking hypoxia-inducible transcription factor-2alpha. Invest 
Ophthalmol. Vis. Sci. 46, 1010-1016. 
Dunn,C., O'Dowd,A., and Randall,R.E. (1999). Fine mapping of the binding sites 
of monoclonal antibodies raised against the Pk tag. J. Immunol. Methods 224, 
141-150. 
Eckhart,A.D., Yang,N., Xin,X., and Faber,J.E. (1997). Characterization of the 
alpha1B-adrenergic receptor gene promoter region and hypoxia regulatory 
elements in vascular smooth muscle. Proc. Natl. Acad. Sci. U. S. A 94, 9487-
9492. 
Eckle,T., Kohler,D., Lehmann,R., El,K.K., and Eltzschig,H.K. (2008). Hypoxia-
inducible factor-1 is central to cardioprotection: a new paradigm for ischemic 
preconditioning. Circulation 118, 166-175. 
Elbashir,S.M., Martinez,J., Patkaniowska,A., Lendeckel,W., and Tuschl,T. 
(2001). Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila 
melanogaster embryo lysate. EMBO J. 20, 6877-6888. 
Elkins,J.M., Hewitson,K.S., McNeill,L.A., Seibel,J.F., Schlemminger,I., 
Pugh,C.W., Ratcliffe,P.J., and Schofield,C.J. (2003). Structure of factor-inhibiting 
hypoxia-inducible factor (HIF) reveals mechanism of oxidative modification of 
HIF-1 alpha. J. Biol. Chem. 278, 1802-1806. 
  193 
Elvidge,G.P., Glenny,L., Appelhoff,R.J., Ratcliffe,P.J., Ragoussis,J., and 
Gleadle,J.M. (2006). Concordant regulation of gene expression by hypoxia and 
2-oxoglutarate-dependent dioxygenase inhibition: the role of HIF-1alpha, HIF-
2alpha, and other pathways. J. Biol. Chem. 281, 15215-15226. 
Ema,M., Hirota,K., Mimura,J., Abe,H., Yodoi,J., Sogawa,K., Poellinger,L., and 
Fujii-Kuriyama,Y. (1999). Molecular mechanisms of transcription activation by 
HLF and HIF1alpha in response to hypoxia: their stabilization and redox signal-
induced interaction with CBP/p300. EMBO J. 18, 1905-1914. 
Ema,M., Taya,S., Yokotani,N., Sogawa,K., Matsuda,Y., and Fujii-Kuriyama,Y. 
(1997). A novel bHLH-PAS factor with close sequence similarity to hypoxia-
inducible factor 1alpha regulates the VEGF expression and is potentially involved 
in lung and vascular development. Proc. Natl. Acad. Sci. U. S. A 94, 4273-4278. 
Epstein,A.C., Gleadle,J.M., McNeill,L.A., Hewitson,K.S., O'Rourke,J., Mole,D.R., 
Mukherji,M., Metzen,E., Wilson,M.I., Dhanda,A., Tian,Y.M., Masson,N., 
Hamilton,D.L., Jaakkola,P., Barstead,R., Hodgkin,J., Maxwell,P.H., Pugh,C.W., 
Schofield,C.J., and Ratcliffe,P.J. (2001). C. elegans EGL-9 and mammalian 
homologs define a family of dioxygenases that regulate HIF by prolyl 
hydroxylation. Cell 107, 43-54. 
Esteban,M.A., Tran,M.G., Harten,S.K., Hill,P., Castellanos,M.C., Chandra,A., 
Raval,R., O'brien,T.S., and Maxwell,P.H. (2006). Regulation of E-cadherin 
expression by VHL and hypoxia-inducible factor. Cancer Res. 66, 3567-3575. 
Feldser,D., Agani,F., Iyer,N.V., Pak,B., Ferreira,G., and Semenza,G.L. (1999). 
Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like 
growth factor 2. Cancer Res. 59, 3915-3918. 
Ferguson,J.E., III, Wu,Y., Smith,K., Charles,P., Powers,K., Wang,H., and 
Patterson,C. (2007). ASB4 is a hydroxylation substrate of FIH and promotes 
vascular differentiation via an oxygen-dependent mechanism. Mol. Cell Biol. 27, 
6407-6419. 
Fire,A., Xu,S., Montgomery,M.K., Kostas,S.A., Driver,S.E., and Mello,C.C. 
(1998). Potent and specific genetic interference by double-stranded RNA in 
Caenorhabditis elegans. Nature 391, 806-811. 
Freeburg,P.B. and Abrahamson,D.R. (2004). Divergent expression patterns for 
hypoxia-inducible factor-1beta and aryl hydrocarbon receptor nuclear transporter-
2 in developing kidney. J. Am. Soc. Nephrol. 15, 2569-2578. 
Freeburg,P.B., Robert,B., St,J.P., and Abrahamson,D.R. (2003). Podocyte 
expression of hypoxia-inducible factor (HIF)-1 and HIF-2 during glomerular 
development. J. Am. Soc. Nephrol. 14, 927-938. 
  194 
Freedman,S.J., Sun,Z.Y., Poy,F., Kung,A.L., Livingston,D.M., Wagner,G., and 
Eck,M.J. (2002). Structural basis for recruitment of CBP/p300 by hypoxia-
inducible factor-1 alpha. Proc. Natl. Acad. Sci. U. S. A 99, 5367-5372. 
Fukuba,H., Takahashi,T., Jin,H.G., Kohriyama,T., and Matsumoto,M. (2008). 
Abundance of aspargynyl-hydroxylase FIH is regulated by Siah-1 under normoxic 
conditions. Neurosci. Lett. 433, 209-214. 
Fukuba,H., Yamashita,H., Nagano,Y., Jin,H.G., Hiji,M., Ohtsuki,T., Takahashi,T., 
Kohriyama,T., and Matsumoto,M. (2007). Siah-1 facilitates ubiquitination and 
degradation of factor inhibiting HIF-1alpha (FIH). Biochem. Biophys. Res. 
Commun. 353, 324-329. 
Fukuda,R., Hirota,K., Fan,F., Jung,Y.D., Ellis,L.M., and Semenza,G.L. (2002). 
Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular 
endothelial growth factor expression, which is dependent on MAP kinase and 
phosphatidylinositol 3-kinase signaling in colon cancer cells. J. Biol. Chem. 277, 
38205-38211. 
Giaccia,A., Siim,B.G., and Johnson,R.S. (2003). HIF-1 as a target for drug 
development. Nat. Rev. Drug Discov. 2, 803-811. 
Ginouves,A., Ilc,K., Macias,N., Pouyssegur,J., and Berra,E. (2008). PHDs 
overactivation during chronic hypoxia "desensitizes" HIFalpha and protects cells 
from necrosis. Proc. Natl. Acad. Sci. U. S. A 105, 4745-4750. 
Gnarra,J.R. (1998). von Hippel-Lindau gene mutations in human and rodent 
renal tumors--association with clear cell phenotype. J. Natl. Cancer Inst. 90, 
1685-1687. 
Goodman,R.H. and Smolik,S. (2000). CBP/p300 in cell growth, transformation, 
and development. Genes Dev. 14, 1553-1577. 
Grabmaier,K., Weijert MC,A.d., Verhaegh,G.W., Schalken,J.A., and 
Oosterwijk,E. (2004). Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear 
cell renal cell carcinoma. Oncogene 23, 5624-5631. 
Graven,K.K., Yu,Q., Pan,D., Roncarati,J.S., and Farber,H.W. (1999). 
Identification of an oxygen responsive enhancer element in the glyceraldehyde-3-
phosphate dehydrogenase gene. Biochim. Biophys. Acta 1447, 208-218. 
Greijer,A.E. and van der,W.E. (2004). The role of hypoxia inducible factor 1 (HIF-
1) in hypoxia induced apoptosis. J. Clin. Pathol. 57, 1009-1014. 
Grosfeld,A., Andre,J., Hauguel-De,M.S., Berra,E., Pouyssegur,J., and Guerre-
Millo,M. (2002). Hypoxia-inducible factor 1 transactivates the human leptin gene 
promoter. J. Biol. Chem. 277, 42953-42957. 
  195 
Gunaratnam,L., Morley,M., Franovic,A., de,P.N., Mekhail,K., Parolin,D.A., 
Nakamura,E., Lorimer,I.A., and Lee,S. (2003). Hypoxia inducible factor activates 
the transforming growth factor-alpha/epidermal growth factor receptor growth 
stimulatory pathway in VHL(-/-) renal cell carcinoma cells. J. Biol. Chem. 278, 
44966-44974. 
Guo,K., Searfoss,G., Krolikowski,D., Pagnoni,M., Franks,C., Clark,K., Yu,K.T., 
Jaye,M., and Ivashchenko,Y. (2001). Hypoxia induces the expression of the pro-
apoptotic gene BNIP3. Cell Death. Differ. 8, 367-376. 
Gustafsson,M.V., Zheng,X., Pereira,T., Gradin,K., Jin,S., Lundkvist,J., Ruas,J.L., 
Poellinger,L., Lendahl,U., and Bondesson,M. (2005). Hypoxia requires notch 
signaling to maintain the undifferentiated cell state. Dev. Cell 9, 617-628. 
Haase,V.H. (2006). Hypoxia-inducible factors in the kidney. Am. J. Physiol Renal 
Physiol 291, F271-F281. 
Hagg,M. and Wennstrom,S. (2005). Activation of hypoxia-induced transcription in 
normoxia. Exp. Cell Res. 306, 180-191. 
Hammond,S.M., Bernstein,E., Beach,D., and Hannon,G.J. (2000). An RNA-
directed nuclease mediates post-transcriptional gene silencing in Drosophila 
cells. Nature 404, 293-296. 
Han,Y.H., Xia,L., Song,L.P., Zheng,Y., Chen,W.L., Zhang,L., Huang,Y., 
Chen,G.Q., and Wang,L.S. (2006). Comparative proteomic analysis of hypoxia-
treated and untreated human leukemic U937 cells. Proteomics. 6, 3262-3274. 
Harms,K.L. and Chen,X. (2005). The C terminus of p53 family proteins is a cell 
fate determinant. Mol. Cell Biol. 25, 2014-2030. 
Hewitson,K.S., Holmes,S.L., Ehrismann,D., Hardy,A.P., Chowdhury,R., 
Schofield,C.J., and McDonough,M.A. (2008). Evidence that two enzyme-derived 
histidine ligands are sufficient for iron binding and catalysis by factor inhibiting 
HIF (FIH). J. Biol. Chem. 283, 25971-25978. 
Hewitson,K.S., McNeill,L.A., Riordan,M.V., Tian,Y.M., Bullock,A.N., 
Welford,R.W., Elkins,J.M., Oldham,N.J., Bhattacharya,S., Gleadle,J.M., 
Ratcliffe,P.J., Pugh,C.W., and Schofield,C.J. (2002). Hypoxia-inducible factor 
(HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is 
related to the cupin structural family. J. Biol. Chem. 277, 26351-26355. 
Hill,P., Shukla,D., Tran,M.G., Aragones,J., Cook,H.T., Carmeliet,P., and 
Maxwell,P.H. (2008). Inhibition of hypoxia inducible factor hydroxylases protects 
against renal ischemia-reperfusion injury. J. Am. Soc. Nephrol. 19, 39-46. 
  196 
Hofbauer,K.H., Gess,B., Lohaus,C., Meyer,H.E., Katschinski,D., and Kurtz,A. 
(2003). Oxygen tension regulates the expression of a group of procollagen 
hydroxylases. Eur. J. Biochem. 270, 4515-4522. 
Holmquist-Mengelbier,L., Fredlund,E., Lofstedt,T., Noguera,R., Navarro,S., 
Nilsson,H., Pietras,A., Vallon-Christersson,J., Borg,A., Gradin,K., Poellinger,L., 
and Pahlman,S. (2006). Recruitment of HIF-1alpha and HIF-2alpha to common 
target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an 
aggressive phenotype. Cancer Cell 10, 413-423. 
Hong,K.H., Yoo,S.A., Kang,S.S., Choi,J.J., Kim,W.U., and Cho,C.S. (2006). 
Hypoxia induces expression of connective tissue growth factor in scleroderma 
skin fibroblasts. Clin. Exp. Immunol. 146, 362-370. 
Hu,C.J., Wang,L.Y., Chodosh,L.A., Keith,B., and Simon,M.C. (2003). Differential 
roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic 
gene regulation. Mol. Cell Biol. 23, 9361-9374. 
Iliopoulos,O., Kibel,A., Gray,S., and Kaelin,W.G., Jr. (1995). Tumour suppression 
by the human von Hippel-Lindau gene product. Nat. Med. 1, 822-826. 
Imazu,T., Shimizu,S., Tagami,S., Matsushima,M., Nakamura,Y., Miki,T., 
Okuyama,A., and Tsujimoto,Y. (1999). Bcl-2/E1B 19 kDa-interacting protein 3-
like protein (Bnip3L) interacts with bcl-2/Bcl-xL and induces apoptosis by altering 
mitochondrial membrane permeability. Oncogene 18, 4523-4529. 
Iwai,K. (1999). [Roles of the ubiquitin system in stress responses]. 
Tanpakushitsu Kakusan Koso 44, 759-765. 
Iwai,K., Drake,S.K., Wehr,N.B., Weissman,A.M., LaVaute,T., Minato,N., 
Klausner,R.D., Levine,R.L., and Rouault,T.A. (1998). Iron-dependent oxidation, 
ubiquitination, and degradation of iron regulatory protein 2: implications for 
degradation of oxidized proteins. Proc. Natl. Acad. Sci. U. S. A 95, 4924-4928. 
Jaakkola,P., Mole,D.R., Tian,Y.M., Wilson,M.I., Gielbert,J., Gaskell,S.J., 
Kriegsheim,A., Hebestreit,H.F., Mukherji,M., Schofield,C.J., Maxwell,P.H., 
Pugh,C.W., and Ratcliffe,P.J. (2001). Targeting of HIF-alpha to the von Hippel-
Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292, 
468-472. 
Jaskiewicz,L. and Filipowicz,W. (2008). Role of Dicer in posttranscriptional RNA 
silencing. Curr. Top. Microbiol. Immunol. 320, 77-97. 
Jelkmann,W. (1992). Erythropoietin: structure, control of production, and 
function. Physiol Rev. 72, 449-489. 
  197 
Jeong,J.W., Bae,M.K., Ahn,M.Y., Kim,S.H., Sohn,T.K., Bae,M.H., Yoo,M.A., 
Song,E.J., Lee,K.J., and Kim,K.W. (2002). Regulation and destabilization of HIF-
1alpha by ARD1-mediated acetylation. Cell 111, 709-720. 
Jiang,H., Guo,R., and Powell-Coffman,J.A. (2001). The Caenorhabditis elegans 
hif-1 gene encodes a bHLH-PAS protein that is required for adaptation to 
hypoxia. Proc. Natl. Acad. Sci. U. S. A 98, 7916-7921. 
Jiang,Y., Zhang,W., Kondo,K., Klco,J.M., St,M.T., Dufault,M.R., Madden,S.L., 
Kaelin,W.G., Jr., and Nacht,M. (2003). Gene expression profiling in a renal cell 
carcinoma cell line: dissecting VHL and hypoxia-dependent pathways. Mol. 
Cancer Res. 1, 453-462. 
Jurgensen,J.S., Rosenberger,C., Wiesener,M.S., Warnecke,C., Horstrup,J.H., 
Grafe,M., Philipp,S., Griethe,W., Maxwell,P.H., Frei,U., Bachmann,S., 
Willenbrock,R., and Eckardt,K.U. (2004). Persistent induction of HIF-1alpha and -
2alpha in cardiomyocytes and stromal cells of ischemic myocardium. FASEB J. 
18, 1415-1417. 
Kaelin,W.G., Jr. (2007). The von Hippel-Lindau tumor suppressor protein and 
clear cell renal carcinoma. Clin. Cancer Res. 13, 680s-684s. 
Kaelin,W.G., Jr. (2004). The von Hippel-Lindau tumor suppressor gene and 
kidney cancer. Clin. Cancer Res. 10, 6290S-6295S. 
Kakinuma,Y., Miyauchi,T., Yuki,K., Murakoshi,N., Goto,K., and Yamaguchi,I. 
(2001). Novel molecular mechanism of increased myocardial endothelin-1 
expression in the failing heart involving the transcriptional factor hypoxia-
inducible factor-1alpha induced for impaired myocardial energy metabolism. 
Circulation 103, 2387-2394. 
Kang,H.J., Kim,H.J., Kim,S.K., Barouki,R., Cho,C.H., Khanna,K.K., Rosen,E.M., 
and Bae,I. (2006). BRCA1 modulates xenobiotic stress-inducible gene 
expression by interacting with ARNT in human breast cancer cells. J. Biol. Chem. 
281, 14654-14662. 
Kim,K., Lee,Y.S., Harris,D., Nakahara,K., and Carthew,R.W. (2006). The RNAi 
pathway initiated by Dicer-2 in Drosophila. Cold Spring Harb. Symp. Quant. Biol. 
71, 39-44. 
Koike,T., Kimura,N., Miyazaki,K., Yabuta,T., Kumamoto,K., Takenoshita,S., 
Chen,J., Kobayashi,M., Hosokawa,M., Taniguchi,A., Kojima,T., Ishida,N., 
Kawakita,M., Yamamoto,H., Takematsu,H., Suzuki,A., Kozutsumi,Y., and 
Kannagi,R. (2004). Hypoxia induces adhesion molecules on cancer cells: A 
missing link between Warburg effect and induction of selectin-ligand 
carbohydrates. Proc. Natl. Acad. Sci. U. S. A 101, 8132-8137. 
  198 
Koivunen,P., Hirsila,M., Gunzler,V., Kivirikko,K.I., and Myllyharju,J. (2004). 
Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing 
pathway are distinct from those of its prolyl 4-hydroxylases. J. Biol. Chem. 279, 
9899-9904. 
Kondo,K. and Kaelin,W.G., Jr. (2001). The von Hippel-Lindau tumor suppressor 
gene. Exp. Cell Res. 264, 117-125. 
Koopman,G., Reutelingsperger,C.P., Kuijten,G.A., Keehnen,R.M., Pals,S.T., and 
van Oers,M.H. (1994). Annexin V for flow cytometric detection of 
phosphatidylserine expression on B cells undergoing apoptosis. Blood 84, 1415-
1420. 
Koshiji,M., Kageyama,Y., Pete,E.A., Horikawa,I., Barrett,J.C., and Huang,L.E. 
(2004). HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. 
EMBO J. 23, 1949-1956. 
Kotch,L.E., Iyer,N.V., Laughner,E., and Semenza,G.L. (1999). Defective 
vascularization of HIF-1alpha-null embryos is not associated with VEGF 
deficiency but with mesenchymal cell death. Dev. Biol. 209, 254-267. 
Koukourakis,M.I., Giatromanolaki,A., Polychronidis,A., Simopoulos,C., 
Gatter,K.C., Harris,A.L., and Sivridis,E. (2006). Endogenous markers of 
hypoxia/anaerobic metabolism and anemia in primary colorectal cancer. Cancer 
Sci. 97, 582-588. 
Krieg,M., Haas,R., Brauch,H., Acker,T., Flamme,I., and Plate,K.H. (2000). Up-
regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under 
normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor 
suppressor gene loss of function. Oncogene 19, 5435-5443. 
Lancaster,D.E., McNeill,L.A., McDonough,M.A., Aplin,R.T., Hewitson,K.S., 
Pugh,C.W., Ratcliffe,P.J., and Schofield,C.J. (2004). Disruption of dimerization 
and substrate phosphorylation inhibit factor inhibiting hypoxia-inducible factor 
(FIH) activity. Biochem. J. 383, 429-437. 
Lando,D., Peet,D.J., Pongratz,I., and Whitelaw,M.L. (2002). Mammalian two-
hybrid assay showing redox control of HIF-like factor. Methods Enzymol. 353, 3-
10. 
Latif,F., Tory,K., Gnarra,J., Yao,M., Duh,F.M., Orcutt,M.L., Stackhouse,T., 
Kuzmin,I., Modi,W., Geil,L., and . (1993). Identification of the von Hippel-Lindau 
disease tumor suppressor gene. Science 260, 1317-1320. 
Laughner,E., Taghavi,P., Chiles,K., Mahon,P.C., and Semenza,G.L. (2001). 
HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-
1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial 
growth factor expression. Mol. Cell Biol. 21, 3995-4004. 
  199 
LeCouter,J., Kowalski,J., Foster,J., Hass,P., Zhang,Z., llard-Telm,L., Frantz,G., 
Rangell,L., DeGuzman,L., Keller,G.A., Peale,F., Gurney,A., Hillan,K.J., and 
Ferrara,N. (2001). Identification of an angiogenic mitogen selective for endocrine 
gland endothelium. Nature 412, 877-884. 
Lee,C., Kim,S.J., Jeong,D.G., Lee,S.M., and Ryu,S.E. (2003). Structure of 
human FIH-1 reveals a unique active site pocket and interaction sites for HIF-1 
and von Hippel-Lindau. J. Biol. Chem. 278, 7558-7563. 
Lee,S.H., Wolf,P.L., Escudero,R., Deutsch,R., Jamieson,S.W., and 
Thistlethwaite,P.A. (2000). Early expression of angiogenesis factors in acute 
myocardial ischemia and infarction. N. Engl. J. Med. 342, 626-633. 
Li,J., Post,M., Volk,R., Gao,Y., Li,M., Metais,C., Sato,K., Tsai,J., Aird,W., 
Rosenberg,R.D., Hampton,T.G., Sellke,F., Carmeliet,P., and Simons,M. (2000). 
PR39, a peptide regulator of angiogenesis. Nat. Med. 6, 49-55. 
Li,J., Wang,E., Dutta,S., Lau,J.S., Jiang,S.W., Datta,K., and Mukhopadhyay,D. 
(2007). Protein kinase C-mediated modulation of FIH-1 expression by the 
homeodomain protein CDP/Cut/Cux. Mol. Cell Biol. 27, 7345-7353. 
Linke,S., Stojkoski,C., Kewley,R.J., Booker,G.W., Whitelaw,M.L., and Peet,D.J. 
(2004). Substrate requirements of the oxygen-sensing asparaginyl hydroxylase 
factor-inhibiting hypoxia-inducible factor. J. Biol. Chem. 279, 14391-14397. 
Lisy,K. and Peet,D.J. (2008). Turn me on: regulating HIF transcriptional activity. 
Cell Death. Differ. 15, 642-649. 
Liu,Y.L., Yu,J.M., Song,X.R., Wang,X.W., Xing,L.G., and Gao,B.B. (2006). 
Regulation of the chemokine receptor CXCR4 and metastasis by hypoxia-
inducible factor in non small cell lung cancer cell lines. Cancer Biol. Ther. 5, 
1320-1326. 
Louis,N.A., Hamilton,K.E., Canny,G., Shekels,L.L., Ho,S.B., and Colgan,S.P. 
(2006). Selective induction of mucin-3 by hypoxia in intestinal epithelia. J. Cell 
Biochem. 99, 1616-1627. 
Lu,F., Li,G., Cui,X., Liu,C., Wang,X.J., and Cao,X. (2008). Comparative analysis 
of JmjC domain-containing proteins reveals the potential histone demethylases in 
Arabidopsis and rice. J. Integr. Plant Biol. 50, 886-896. 
Ma,Y., Freitag,P., Zhou,J., Brune,B., Frede,S., and Fandrey,J. (2004). Thyroid 
hormone induces erythropoietin gene expression through augmented 
accumulation of hypoxia-inducible factor-1. Am. J. Physiol Regul. Integr. Comp 
Physiol 287, R600-R607. 
  200 
Mahon,P.C., Hirota,K., and Semenza,G.L. (2001). FIH-1: a novel protein that 
interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional 
activity. Genes Dev. 15, 2675-2686. 
Maltzman,W. and Czyzyk,L. (1984). UV irradiation stimulates levels of p53 
cellular tumor antigen in nontransformed mouse cells. Mol. Cell Biol. 4, 1689-
1694. 
Marxsen,J.H., Stengel,P., Doege,K., Heikkinen,P., Jokilehto,T., Wagner,T., 
Jelkmann,W., Jaakkola,P., and Metzen,E. (2004). Hypoxia-inducible factor-1 
(HIF-1) promotes its degradation by induction of HIF-alpha-prolyl-4-hydroxylases. 
Biochem. J. 381, 761-767. 
Masson,N., Willam,C., Maxwell,P.H., Pugh,C.W., and Ratcliffe,P.J. (2001). 
Independent function of two destruction domains in hypoxia-inducible factor-
alpha chains activated by prolyl hydroxylation. EMBO J. 20, 5197-5206. 
Mathupala,S.P., Rempel,A., and Pedersen,P.L. (2001). Glucose catabolism in 
cancer cells: identification and characterization of a marked activation response 
of the type II hexokinase gene to hypoxic conditions. J. Biol. Chem. 276, 43407-
43412. 
Maxwell,P.H., Dachs,G.U., Gleadle,J.M., Nicholls,L.G., Harris,A.L., Stratford,I.J., 
Hankinson,O., Pugh,C.W., and Ratcliffe,P.J. (1997). Hypoxia-inducible factor-1 
modulates gene expression in solid tumors and influences both angiogenesis 
and tumor growth. Proc. Natl. Acad. Sci. U. S. A 94, 8104-8109. 
Maxwell,P.H., Pugh,C.W., and Ratcliffe,P.J. (2001). Insights into the role of the 
von Hippel-Lindau gene product. A key player in hypoxic regulation. Exp. 
Nephrol. 9, 235-240. 
Maxwell,P.H., Wiesener,M.S., Chang,G.W., Clifford,S.C., Vaux,E.C., 
Cockman,M.E., Wykoff,C.C., Pugh,C.W., Maher,E.R., and Ratcliffe,P.J. (1999). 
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-
dependent proteolysis. Nature 399, 271-275. 
McDonough,M.A., Li,V., Flashman,E., Chowdhury,R., Mohr,C., Lienard,B.M., 
Zondlo,J., Oldham,N.J., Clifton,I.J., Lewis,J., McNeill,L.A., Kurzeja,R.J., 
Hewitson,K.S., Yang,E., Jordan,S., Syed,R.S., and Schofield,C.J. (2006). 
Cellular oxygen sensing: Crystal structure of hypoxia-inducible factor prolyl 
hydroxylase (PHD2). Proc. Natl. Acad. Sci. U. S. A 103, 9814-9819. 
McDonough,M.A., McNeill,L.A., Tilliet,M., Papamicael,C.A., Chen,Q.Y., 
Banerji,B., Hewitson,K.S., and Schofield,C.J. (2005). Selective inhibition of factor 
inhibiting hypoxia-inducible factor. J. Am. Chem. Soc. 127, 7680-7681. 
McMahon,S., Grondin,F., McDonald,P.P., Richard,D.E., and Dubois,C.M. (2005). 
Hypoxia-enhanced expression of the proprotein convertase furin is mediated by 
  201 
hypoxia-inducible factor-1: impact on the bioactivation of proproteins. J. Biol. 
Chem. 280, 6561-6569. 
McNeill,L.A., Hewitson,K.S., Claridge,T.D., Seibel,J.F., Horsfall,L.E., and 
Schofield,C.J. (2002). Hypoxia-inducible factor asparaginyl hydroxylase (FIH-1) 
catalyses hydroxylation at the beta-carbon of asparagine-803. Biochem. J. 367, 
571-575. 
Mellor,H.R. and Harris,A.L. (2007). The role of the hypoxia-inducible BH3-only 
proteins BNIP3 and BNIP3L in cancer. Cancer Metastasis Rev. 26, 553-566. 
Metzen,E., Berchner-Pfannschmidt,U., Stengel,P., Marxsen,J.H., Stolze,I., 
Klinger,M., Huang,W.Q., Wotzlaw,C., Hellwig-Burgel,T., Jelkmann,W., Acker,H., 
and Fandrey,J. (2003). Intracellular localisation of human HIF-1 alpha 
hydroxylases: implications for oxygen sensing. J. Cell Sci. 116, 1319-1326. 
Metzen,E., Stiehl,D.P., Doege,K., Marxsen,J.H., Hellwig-Burgel,T., and 
Jelkmann,W. (2005). Regulation of the prolyl hydroxylase domain protein 2 
(phd2/egln-1) gene: identification of a functional hypoxia-responsive element. 
Biochem. J. 387, 711-717. 
Min,J.H., Yang,H., Ivan,M., Gertler,F., Kaelin,W.G., Jr., and Pavletich,N.P. 
(2002). Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in 
signaling. Science 296, 1886-1889. 
Minchenko,A., Leshchinsky,I., Opentanova,I., Sang,N., Srinivas,V., Armstead,V., 
and Caro,J. (2002). Hypoxia-inducible factor-1-mediated expression of the 6-
phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) gene. Its 
possible role in the Warburg effect. J. Biol. Chem. 277, 6183-6187. 
Morita,M., Ohneda,O., Yamashita,T., Takahashi,S., Suzuki,N., Nakajima,O., 
Kawauchi,S., Ema,M., Shibahara,S., Udono,T., Tomita,K., Tamai,M., Sogawa,K., 
Yamamoto,M., and Fujii-Kuriyama,Y. (2003). HLF/HIF-2alpha is a key factor in 
retinopathy of prematurity in association with erythropoietin. EMBO J. 22, 1134-
1146. 
Morris,M.R., Maina,E., Morgan,N.V., Gentle,D., Astuti,D., Moch,H., Kishida,T., 
Yao,M., Schraml,P., Richards,F.M., Latif,F., and Maher,E.R. (2004). Molecular 
genetic analysis of FIH-1, FH, and SDHB candidate tumour suppressor genes in 
renal cell carcinoma. J. Clin. Pathol. 57, 706-711. 
Mosmann,T. (1983). Rapid colorimetric assay for cellular growth and survival: 
application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55-
63. 
Motzer,R.J., Bander,N.H., and Nanus,D.M. (1996). Renal-cell carcinoma. N. 
Engl. J. Med. 335, 865-875. 
  202 
Mukhopadhyay,C.K., Mazumder,B., and Fox,P.L. (2000). Role of hypoxia-
inducible factor-1 in transcriptional activation of ceruloplasmin by iron deficiency. 
J. Biol. Chem. 275, 21048-21054. 
Nishi,H., Nakada,T., Hokamura,M., Osakabe,Y., Itokazu,O., Huang,L.E., and 
Isaka,K. (2004). Hypoxia-inducible factor-1 transactivates transforming growth 
factor-beta3 in trophoblast. Endocrinology 145, 4113-4118. 
O'Rourke,J.F., Pugh,C.W., Bartlett,S.M., and Ratcliffe,P.J. (1996). Identification 
of hypoxically inducible mRNAs in HeLa cells using differential-display PCR. Role 
of hypoxia-inducible factor-1. Eur. J. Biochem. 241, 403-410. 
O'Rourke,J.F., Tian,Y.M., Ratcliffe,P.J., and Pugh,C.W. (1999). Oxygen-
regulated and transactivating domains in endothelial PAS protein 1: comparison 
with hypoxia-inducible factor-1alpha. J. Biol. Chem. 274, 2060-2071. 
Ockaili,R., Natarajan,R., Salloum,F., Fisher,B.J., Jones,D., Fowler,A.A., III, and 
Kukreja,R.C. (2005). HIF-1 activation attenuates postischemic myocardial injury: 
role for heme oxygenase-1 in modulating microvascular chemokine generation. 
Am. J. Physiol Heart Circ. Physiol 289, H542-H548. 
Ovcharenko,D., Jarvis,R., Hunicke-Smith,S., Kelnar,K., and Brown,D. (2005). 
High-throughput RNAi screening in vitro: from cell lines to primary cells. RNA. 11, 
985-993. 
Park,J.W., Chun,Y.S., and Kim,M.S. (2004). Hypoxia-inducible factor 1-related 
diseases and prospective therapeutic tools. J. Pharmacol. Sci. 94, 221-232. 
Parkin,D.M., Bray,F., Ferlay,J., and Pisani,P. (2005). Global cancer statistics, 
2002. CA Cancer J. Clin. 55, 74-108. 
Pescador,N., Cuevas,Y., Naranjo,S., Alcaide,M., Villar,D., Landazuri,M.O., and 
del,P.L. (2005). Identification of a functional hypoxia-responsive element that 
regulates the expression of the egl nine homologue 3 (egln3/phd3) gene. 
Biochem. J. 390, 189-197. 
Pfander,D., Cramer,T., Schipani,E., and Johnson,R.S. (2003). HIF-1alpha 
controls extracellular matrix synthesis by epiphyseal chondrocytes. J. Cell Sci. 
116, 1819-1826. 
Pillai,R.S., Bhattacharyya,S.N., and Filipowicz,W. (2007). Repression of protein 
synthesis by miRNAs: how many mechanisms? Trends Cell Biol. 17, 118-126. 
Preall,J.B. and Sontheimer,E.J. (2005). RNAi: RISC gets loaded. Cell 123, 543-
545. 
Raval,R.R., Lau,K.W., Tran,M.G., Sowter,H.M., Mandriota,S.J., Li,J.L., 
Pugh,C.W., Maxwell,P.H., Harris,A.L., and Ratcliffe,P.J. (2005). Contrasting 
  203 
properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-
associated renal cell carcinoma. Mol. Cell Biol. 25, 5675-5686. 
Ravi,R., Mookerjee,B., Bhujwalla,Z.M., Sutter,C.H., Artemov,D., Zeng,Q., 
Dillehay,L.E., Madan,A., Semenza,G.L., and Bedi,A. (2000). Regulation of tumor 
angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. 
Genes Dev. 14, 34-44. 
Riccardi,C. and Nicoletti,I. (2006). Analysis of apoptosis by propidium iodide 
staining and flow cytometry. Nat. Protoc. 1, 1458-1461. 
Richard,D.E., Berra,E., Gothie,E., Roux,D., and Pouyssegur,J. (1999). p42/p44 
mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha 
(HIF-1alpha) and enhance the transcriptional activity of HIF-1. J. Biol. Chem. 
274, 32631-32637. 
Rosenberger,C., Rosen,S., Shina,A., Frei,U., Eckardt,K.U., Flippin,L.A., 
Arend,M., Klaus,S.J., and Heyman,S.N. (2008). Activation of hypoxia inducible 
factors (HIF) ameliorates hypoxic distal tubular injury in the isolated perfused rat 
kidney. Nephrol. Dial. Transplant. 
Ryan,H.E., Lo,J., and Johnson,R.S. (1998). HIF-1 alpha is required for solid 
tumor formation and embryonic vascularization. EMBO J. 17, 3005-3015. 
Safran,M. and Kaelin,W.G., Jr. (2003). HIF hydroxylation and the mammalian 
oxygen-sensing pathway. J. Clin. Invest 111, 779-783. 
Sang,N., Stiehl,D.P., Bohensky,J., Leshchinsky,I., Srinivas,V., and Caro,J. 
(2003). MAPK signaling up-regulates the activity of hypoxia-inducible factors by 
its effects on p300. J. Biol. Chem. 278, 14013-14019. 
Saze,H., Shiraishi,A., Miura,A., and Kakutani,T. (2008). Control of genic DNA 
methylation by a jmjC domain-containing protein in Arabidopsis thaliana. Science 
319, 462-465. 
Schofield,C.J. and Ratcliffe,P.J. (2004). Oxygen sensing by HIF hydroxylases. 
Nat. Rev. Mol. Cell Biol. 5, 343-354. 
Schofield,C.J. and Zhang,Z. (1999). Structural and mechanistic studies on 2-
oxoglutarate-dependent oxygenases and related enzymes. Curr. Opin. Struct. 
Biol. 9, 722-731. 
Schultz,A., Lavie,L., Hochberg,I., Beyar,R., Stone,T., Skorecki,K., Lavie,P., 
Roguin,A., and Levy,A.P. (1999). Interindividual heterogeneity in the hypoxic 
regulation of VEGF: significance for the development of the coronary artery 
collateral circulation. Circulation 100, 547-552. 
  204 
Scortegagna,M., Ding,K., Oktay,Y., Gaur,A., Thurmond,F., Yan,L.J., Marck,B.T., 
Matsumoto,A.M., Shelton,J.M., Richardson,J.A., Bennett,M.J., and Garcia,J.A. 
(2003). Multiple organ pathology, metabolic abnormalities and impaired 
homeostasis of reactive oxygen species in Epas1-/- mice. Nat. Genet. 35, 331-
340. 
Semenza,G.L., Agani,F., Iyer,N., Kotch,L., Laughner,E., Leung,S., and Yu,A. 
(1999). Regulation of cardiovascular development and physiology by hypoxia-
inducible factor 1. Ann. N. Y. Acad. Sci. 874, 262-268. 
Semenza,G.L., Jiang,B.H., Leung,S.W., Passantino,R., Concordet,J.P., Maire,P., 
and Giallongo,A. (1996). Hypoxia response elements in the aldolase A, enolase 
1, and lactate dehydrogenase A gene promoters contain essential binding sites 
for hypoxia-inducible factor 1. J. Biol. Chem. 271, 32529-32537. 
Semenza,G.L., Roth,P.H., Fang,H.M., and Wang,G.L. (1994). Transcriptional 
regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J. 
Biol. Chem. 269, 23757-23763. 
Semenza,G.L. and Wang,G.L. (1992). A nuclear factor induced by hypoxia via de 
novo protein synthesis binds to the human erythropoietin gene enhancer at a site 
required for transcriptional activation. Mol. Cell Biol. 12, 5447-5454. 
Shah,R., Hurley,C.K., and Posch,P.E. (2006). A molecular mechanism for the 
differential regulation of TGF-beta1 expression due to the common SNP -509C-T 
(c. -1347C > T). Hum. Genet. 120, 461-469. 
Simon,M.C. (2006). Coming up for air: HIF-1 and mitochondrial oxygen 
consumption. Cell Metab 3, 150-151. 
Siolas,D., Lerner,C., Burchard,J., Ge,W., Linsley,P.S., Paddison,P.J., 
Hannon,G.J., and Cleary,M.A. (2005). Synthetic shRNAs as potent RNAi 
triggers. Nat. Biotechnol. 23, 227-231. 
Soilleux,E.J., Turley,H., Tian,Y.M., Pugh,C.W., Gatter,K.C., and Harris,A.L. 
(2005). Use of novel monoclonal antibodies to determine the expression and 
distribution of the hypoxia regulatory factors PHD-1, PHD-2, PHD-3 and FIH in 
normal and neoplastic human tissues. Histopathology 47, 602-610. 
Sowter,H.M., Ratcliffe,P.J., Watson,P., Greenberg,A.H., and Harris,A.L. (2001). 
HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 
and NIX in human tumors. Cancer Res. 61, 6669-6673. 
Span,L.F., Pennings,A.H., Vierwinden,G., Boezeman,J.B., Raymakers,R.A., and 
de,W.T. (2002). The dynamic process of apoptosis analyzed by flow cytometry 
using Annexin-V/propidium iodide and a modified in situ end labeling technique. 
Cytometry 47, 24-31. 
  205 
Stewart,S.A., Dykxhoorn,D.M., Palliser,D., Mizuno,H., Yu,E.Y., An,D.S., 
Sabatini,D.M., Chen,I.S., Hahn,W.C., Sharp,P.A., Weinberg,R.A., and 
Novina,C.D. (2003). Lentivirus-delivered stable gene silencing by RNAi in 
primary cells. RNA. 9, 493-501. 
Stickle,N.H., Cheng,L.S., Watson,I.R., Alon,N., Malkin,D., Irwin,M.S., and Ohh,M. 
(2005). Expression of p53 in renal carcinoma cells is independent of pVHL. 
Mutat. Res. 578, 23-32. 
Stiehl,D.P., Jelkmann,W., Wenger,R.H., and Hellwig-Burgel,T. (2002). Normoxic 
induction of the hypoxia-inducible factor 1alpha by insulin and interleukin-1beta 
involves the phosphatidylinositol 3-kinase pathway. FEBS Lett. 512, 157-162. 
Stolze,I.P., Tian,Y.M., Appelhoff,R.J., Turley,H., Wykoff,C.C., Gleadle,J.M., and 
Ratcliffe,P.J. (2004). Genetic analysis of the role of the asparaginyl hydroxylase 
factor inhibiting hypoxia-inducible factor (HIF) in regulating HIF transcriptional 
target genes. J. Biol. Chem. 279, 42719-42725. 
Synnestvedt,K., Furuta,G.T., Comerford,K.M., Louis,N., Karhausen,J., 
Eltzschig,H.K., Hansen,K.R., Thompson,L.F., and Colgan,S.P. (2002). Ecto-5'-
nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates 
permeability changes in intestinal epithelia. J. Clin. Invest 110, 993-1002. 
Taylor,M.S. (2001). Characterization and comparative analysis of the EGLN gene 
family. Gene 275, 125-132. 
THOMLINSON,R.H. and GRAY,L.H. (1955). The histological structure of some 
human lung cancers and the possible implications for radiotherapy. Br. J. Cancer 
9, 539-549. 
Tian,H., Hammer,R.E., Matsumoto,A.M., Russell,D.W., and McKnight,S.L. 
(1998). The hypoxia-responsive transcription factor EPAS1 is essential for 
catecholamine homeostasis and protection against heart failure during embryonic 
development. Genes Dev. 12, 3320-3324. 
Vande,V.C., Cizeau,J., Dubik,D., Alimonti,J., Brown,T., Israels,S., Hakem,R., and 
Greenberg,A.H. (2000). BNIP3 and genetic control of necrosis-like cell death 
through the mitochondrial permeability transition pore. Mol. Cell Biol. 20, 5454-
5468. 
Verheul,H.M., Salumbides,B., Van,E.K., Hammers,H., Qian,D.Z., Sanni,T., 
Atadja,P., and Pili,R. (2008). Combination Strategy Targeting the Hypoxia 
Inducible Factor-1{alpha} with Mammalian Target of Rapamycin and Histone 
Deacetylase Inhibitors. Clin. Cancer Res. 14, 3589-3597. 
Volm,M. and Koomagi,R. (2000). Hypoxia-inducible factor (HIF-1) and its 
relationship to apoptosis and proliferation in lung cancer. Anticancer Res. 20, 
1527-1533. 
  206 
Wang,G.L., Jiang,B.H., Rue,E.A., and Semenza,G.L. (1995). Hypoxia-inducible 
factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 
tension. Proc. Natl. Acad. Sci. U. S. A 92, 5510-5514. 
Wang,L., Liu,N., Yao,L., Li,F., Zhang,J., Deng,Y., Liu,J., Ji,S., Yang,A., Han,H., 
Zhang,Y., Zhang,J., Han,W., and Liu,X. (2008). NDRG2 is a new HIF-1 target 
gene necessary for hypoxia-induced apoptosis in A549 cells. Cell Physiol 
Biochem. 21, 239-250. 
Warnecke,C., Zaborowska,Z., Kurreck,J., Erdmann,V.A., Frei,U., Wiesener,M., 
and Eckardt,K.U. (2004). Differentiating the functional role of hypoxia-inducible 
factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: 
erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells. FASEB J. 
18, 1462-1464. 
Wenger,R.H., Stiehl,D.P., and Camenisch,G. (2005). Integration of oxygen 
signaling at the consensus HRE. Sci. STKE. 2005, re12. 
Wilhide,M.E. and Jones,W.K. (2006). Potential therapeutic gene for the treatment 
of ischemic disease: Ad2/hypoxia-inducible factor-1alpha (HIF-1)/VP16 enhances 
B-type natriuretic peptide gene expression via a HIF-1-responsive element. Mol. 
Pharmacol. 69, 1773-1778. 
Wykoff,C.C., Beasley,N.J., Watson,P.H., Turner,K.J., Pastorek,J., Sibtain,A., 
Wilson,G.D., Turley,H., Talks,K.L., Maxwell,P.H., Pugh,C.W., Ratcliffe,P.J., and 
Harris,A.L. (2000). Hypoxia-inducible expression of tumor-associated carbonic 
anhydrases. Cancer Res. 60, 7075-7083. 
Yan,Q., Bartz,S., Mao,M., Li,L., and Kaelin,W.G., Jr. (2007). The hypoxia-
inducible factor 2alpha N-terminal and C-terminal transactivation domains 
cooperate to promote renal tumorigenesis in vivo. Mol. Cell Biol. 27, 2092-2102. 
Yao,L., Zhang,J., and Liu,X. (2008). NDRG2: a Myc-repressed gene involved in 
cancer and cell stress. Acta Biochim. Biophys. Sin. (Shanghai) 40, 625-635. 
Yoshimura,H., Dhar,D.K., Kohno,H., Kubota,H., Fujii,T., Ueda,S., Kinugasa,S., 
Tachibana,M., and Nagasue,N. (2004). Prognostic impact of hypoxia-inducible 
factors 1alpha and 2alpha in colorectal cancer patients: correlation with tumor 
angiogenesis and cyclooxygenase-2 expression. Clin. Cancer Res. 10, 8554-
8560. 
Yu,A.Y., Shimoda,L.A., Iyer,N.V., Huso,D.L., Sun,X., McWilliams,R., Beaty,T., 
Sham,J.S., Wiener,C.M., Sylvester,J.T., and Semenza,G.L. (1999). Impaired 
physiological responses to chronic hypoxia in mice partially deficient for hypoxia-
inducible factor 1alpha. J. Clin. Invest 103, 691-696. 
Yu,R.M., Chen,E.X., Kong,R.Y., Ng,P.K., Mok,H.O., and Au,D.W. (2006). 
Hypoxia induces telomerase reverse transcriptase (TERT) gene expression in 
  207 
non-tumor fish tissues in vivo: the marine medaka (Oryzias melastigma) model. 
BMC. Mol. Biol. 7, 27. 
Zelzer,E., Levy,Y., Kahana,C., Shilo,B.Z., Rubinstein,M., and Cohen,B. (1998). 
Insulin induces transcription of target genes through the hypoxia-inducible factor 
HIF-1alpha/ARNT. EMBO J. 17, 5085-5094. 
Zhang,J.H. and Xu,M. (2000). DNA fragmentation in apoptosis. Cell Res. 10, 
205-211. 
Zhang,W., Petrovic,J.M., Callaghan,D., Jones,A., Cui,H., Howlett,C., and 
Stanimirovic,D. (2006). Evidence that hypoxia-inducible factor-1 (HIF-1) mediates 
transcriptional activation of interleukin-1beta (IL-1beta) in astrocyte cultures. J. 
Neuroimmunol. 174, 63-73. 
Zheng,X., Linke,S., Dias,J.M., Zheng,X., Gradin,K., Wallis,T.P., Hamilton,B.R., 
Gustafsson,M., Ruas,J.L., Wilkins,S., Bilton,R.L., Brismar,K., Whitelaw,M.L., 
Pereira,T., Gorman,J.J., Ericson,J., Peet,D.J., Lendahl,U., and Poellinger,L. 
(2008). Interaction with factor inhibiting HIF-1 defines an additional mode of 
cross-coupling between the Notch and hypoxia signaling pathways. Proc. Natl. 
Acad. Sci. U. S. A 105, 3368-3373. 
Zhivotosky,B. and Orrenius,S. (2001). Assessment of apoptosis and necrosis by 
DNA fragmentation and morphological criteria. Curr. Protoc. Cell Biol. Chapter 
18, Unit. 
 
 
